<?xml version="1.0" encoding="UTF-8" ?>
<!DOCTYPE PubmedArticleSet>
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">35778693</PMID>
      <DateCompleted>
        <Year>2023</Year>
        <Month>02</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>02</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2407</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC cancer</Title>
          <ISOAbbreviation>BMC Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Kayadiol exerted anticancer effects through p53-mediated ferroptosis in NKTCL cells.</ArticleTitle>
        <Pagination>
          <StartPage>724</StartPage>
          <MedlinePgn>724</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">724</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-022-09825-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Extranodal natural killer/T cell lymphoma (NKTCL) is a highly aggressive type of non-Hodgkin lymphoma that facing the treatment challenges. Natural compounds are important sources for drug development because of their diverse biological and chemical properties, among which terpenoids have strong anticancer activities.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The human NK/T cell lymphoma cell line YT and peripheral blood lymphocytes isolated from NKTCL patients were treated with different concentrations of kayadiol. Then, the following experiments were performed: CCK-8 assay for cell viability, reactive oxygen species (ROS) and glutathione (GSH) assay and co-treatment with NAC, reduced GSH, or ferrostatin-1 for ferroptosis, the proteome profiling for elucidating signaling pathways, and western blot for the expression of p53, SCL7A11, and GPX4. siRNA and CRISPR/Cas9 plasmid for p53 knockout was designed and transfected into YT cells to evaluate the causal role of p53 in kayadiol-induced ferroptosis. The synergistic effect was evaluated by CCK8 assay after co-treatment of kayadiol with L-asparaginase or cisplatin.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In this study, we found that kayadiol, a diterpenoid extracted from Torreya nucifera, exerted significant killing effect on NKTCL cells without killing the healthy lymphocytes. Subsequently, we observed that kayadiol treatment triggered significant ferroptosis events, including ROS accumulation and GSH depletion. ROS scavenger NAC, GSH, and ferroptosis inhibitor ferrostatin-1 (Fer-1) reversed kayadiol-induced cell death in NKTCL cells. Furthermore, kayadiol decreased the expression of SLC7A11 and GPX4, the negative regulatory proteins for ferroptosis. We then demonstrated that p53 was the key mediator of kayadiol-induced ferroptosis by SLC7A11/GPX4 axis through p53 knockout experiments. In addition, kayadiol exerted a synergistic effect with L-asparaginase and cisplatin in NKTCL cells.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Taken together, our results suggested that the natural product kayadiol exerted anticancer effects through p53-mediated ferroptosis in NK/T cell lymphoma cells. Hence, it can serve as an effective alternative in the treatment of NK/T cell lymphoma, especially for patients exhibiting chemoresistance.</AbstractText>
          <CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Cuiying</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, The Fourth Hospital of Hebei Medical University, NO.169, TianShan Street, Shijiazhuang, Hebei, 050035, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Research Center and Tumor Research Institute, The Fourth Hospital of Hebei Medical University, NO.12, Jiankang Road, Shijiazhuang, Hebei, 050011, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hebei Medical University, Shijiazhuang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chengzhao</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>College of Basic Medicine, Hebei Medical University, Shijiazhuang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Haisheng</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, The Fourth Hospital of Hebei Medical University, NO.169, TianShan Street, Shijiazhuang, Hebei, 050035, People's Republic of China. liuhs78299@outlook.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shan</LastName>
            <ForeName>Baoen</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Research Center and Tumor Research Institute, The Fourth Hospital of Hebei Medical University, NO.12, Jiankang Road, Shijiazhuang, Hebei, 050011, People's Republic of China. baoenshan6@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hebei Medical University, Shijiazhuang, China. baoenshan6@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>20220162</GrantID>
            <Agency>the Funding of Health Commission of Hebei Province</Agency>
          </Grant>
          <Grant>
            <GrantID>20220162</GrantID>
            <Agency>the Funding of Health Commission of Hebei Province</Agency>
          </Grant>
          <Grant>
            <GrantID>20220162</GrantID>
            <Agency>the Funding of Health Commission of Hebei Province</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>07</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>BMC Cancer</MedlineTA>
        <NlmUniqueID>100967800</NlmUniqueID>
        <ISSNLinking>1471-2407</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 3.5.1.1</RegistryNumber>
          <NameOfSubstance UI="D001215">Asparaginase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004224">Diterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000723744">kayadiol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001215" MajorTopicYN="N">Asparaginase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004224" MajorTopicYN="Y">Diterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016399" MajorTopicYN="Y">Lymphoma, T-Cell</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">Kayadiol</Keyword>
        <Keyword MajorTopicYN="N">NKTCL</Keyword>
        <Keyword MajorTopicYN="N">p53</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>6</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>23</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35778693</ArticleId>
        <ArticleId IdType="pmc">PMC9250166</ArticleId>
        <ArticleId IdType="doi">10.1186/s12885-022-09825-5</ArticleId>
        <ArticleId IdType="pii">10.1186/s12885-022-09825-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wang L, Wang JW. Extranodal natural-killer T-cell lymphoma: experience from China. Lancet Haematol. 2020;7(6):e441. doi: 10.1016/S2352-3026(20)30103-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2352-3026(20)30103-4</ArticleId>
            <ArticleId IdType="pubmed">32470431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Fu BB, Gale RP, Liang Y. NK-/T-cell lymphomas. Leukemia. 2021;35(9):2460&#x2013;2468. doi: 10.1038/s41375-021-01313-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41375-021-01313-2</ArticleId>
            <ArticleId IdType="pmc">PMC8410593</ArticleId>
            <ArticleId IdType="pubmed">34117356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodrigues T, Reker D, Schneider P, Schneider G. Counting on natural products for drug design. Nat Chem. 2016;8(6):531&#x2013;541. doi: 10.1038/nchem.2479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchem.2479</ArticleId>
            <ArticleId IdType="pubmed">27219696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Baba C, Baassiri A, Kiriako G, Dia B, Fadlallah S, Moodad S, Darwiche N. Terpenoids' anti-cancer effects: focus on autophagy. Apoptosis. 2021;26(9&#x2013;10):491&#x2013;511. doi: 10.1007/s10495-021-01684-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10495-021-01684-y</ArticleId>
            <ArticleId IdType="pubmed">34269920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen SP, Dong M, Kita K, Shi QW, Cong B, Guo WZ, Sugaya S, Sugita K, Suzuki N. Anti-proliferative and apoptosis-inducible activity of labdane and abietane diterpenoids from the pulp of Torreya nucifera in HeLa cells. Mol Med Rep. 2010;3(4):673&#x2013;678. doi: 10.3892/mmr_00000315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr_00000315</ArticleId>
            <ArticleId IdType="pubmed">21472297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Li J, Kang R, Klionsky DJ. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054&#x2013;2081. doi: 10.1080/15548627.2020.1810918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2020.1810918</ArticleId>
            <ArticleId IdType="pmc">PMC8496712</ArticleId>
            <ArticleId IdType="pubmed">32804006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1&#x2013;2):317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic Biol Med. 2020;152:175&#x2013;185. doi: 10.1016/j.freeradbiomed.2020.02.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.02.027</ArticleId>
            <ArticleId IdType="pubmed">32165281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dancik V, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10(1):1617. doi: 10.1038/s41467-019-09277-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-09277-9</ArticleId>
            <ArticleId IdType="pmc">PMC6453886</ArticleId>
            <ArticleId IdType="pubmed">30962421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266&#x2013;282. doi: 10.1038/s41580-020-00324-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41580-020-00324-8</ArticleId>
            <ArticleId IdType="pmc">PMC8142022</ArticleId>
            <ArticleId IdType="pubmed">33495651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440&#x2013;6. doi: 10.1158/0008-5472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472</ArticleId>
            <ArticleId IdType="pubmed">20068163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48(W1):W488&#x2013;W493. doi: 10.1093/nar/gkaa216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkaa216</ArticleId>
            <ArticleId IdType="pmc">PMC7319457</ArticleId>
            <ArticleId IdType="pubmed">32246720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Gu W. p53 in ferroptosis regulation: the new weapon for the old guardian. Cell Death Differ. 2022 doi: 10.1038/s41418-022-00943-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-022-00943-y</ArticleId>
            <ArticleId IdType="pmc">PMC9091200</ArticleId>
            <ArticleId IdType="pubmed">35087226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato M, Kusumi R, Hamashima S, Kobayashi S, Sasaki S, Komiyama Y, Izumikawa T, Conrad M, Bannai S, Sato H. The ferroptosis inducer erastin irreversibly inhibits system xc- and synergizes with cisplatin to increase cisplatin's cytotoxicity in cancer cells. Sci Rep. 2018 doi: 10.1038/s41598-018-19213-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-19213-4</ArticleId>
            <ArticleId IdType="pmc">PMC5772355</ArticleId>
            <ArticleId IdType="pubmed">29343855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roh JL, Kim EH, Jang H, Shin D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 2017;11:254&#x2013;62.&#xa0;10.1016/j.redox.2016.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5198738</ArticleId>
            <ArticleId IdType="pubmed">28012440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demain AL. From natural products discovery to commercialization: a success story. J Ind Microbiol Biotechnol. 2006 doi: 10.1007/s10295-005-0076-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10295-005-0076-x</ArticleId>
            <ArticleId IdType="pubmed">16402247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gershenzon J, Dudareva N. The function of terpene natural products in the natural world. Nat Chem Biol. 2007;3(7):408&#x2013;414. doi: 10.1038/nchembio.2007.5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2007.5</ArticleId>
            <ArticleId IdType="pubmed">17576428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang YH, Mao JW, Tan XL. Research progress on the source, production, and anti-cancer mechanisms of paclitaxel. Chin J Nat Med. 2020;18(12):890&#x2013;897. doi: 10.1016/S1875-5364(20)60032-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1875-5364(20)60032-2</ArticleId>
            <ArticleId IdType="pubmed">33357719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abu Samaan TM, Samec M, Liskova A, Kubatka P, Busselberg D. Paclitaxel's mechanistic and clinical effects on breast cancer. Biomolecules. 2019;9(12):789. doi: 10.3390/biom9120789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom9120789</ArticleId>
            <ArticleId IdType="pmc">PMC6995578</ArticleId>
            <ArticleId IdType="pubmed">31783552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei G, Zhang Y, Hong T, Zhang X, Liu X, Mao C, Yan Y, Koppula P, Cheng W, Sood AK, et al. Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene. 2021;40(20):3533&#x2013;3547. doi: 10.1038/s41388-021-01790-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-021-01790-w</ArticleId>
            <ArticleId IdType="pmc">PMC8141034</ArticleId>
            <ArticleId IdType="pubmed">33927351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, Gu W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57&#x2013;62. doi: 10.1038/nature14344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14344</ArticleId>
            <ArticleId IdType="pmc">PMC4455927</ArticleId>
            <ArticleId IdType="pubmed">25799988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599&#x2013;620. doi: 10.1007/s13238-020-00789-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13238-020-00789-5</ArticleId>
            <ArticleId IdType="pmc">PMC8310547</ArticleId>
            <ArticleId IdType="pubmed">33000412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FriedmannAngeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180&#x2013;1191. doi: 10.1038/ncb3064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3064</ArticleId>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui X, Zhang R, Liu S, Duan T, Zhai L, Zhang M, Han X, Xiang Y, Huang X, Lin H, et al. RSL3 drives Ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. Front Pharmacol. 2018;9:1371. doi: 10.3389/fphar.2018.01371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2018.01371</ArticleId>
            <ArticleId IdType="pmc">PMC6262051</ArticleId>
            <ArticleId IdType="pubmed">30524291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aozasa K, Takakuwa T, Hongyo T, Yang WI. Nasal NK/T-cell lymphoma: epidemiology and pathogenesis. Int J Hematol. 2008;87(2):110&#x2013;117. doi: 10.1007/s12185-008-0021-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12185-008-0021-7</ArticleId>
            <ArticleId IdType="pmc">PMC2276242</ArticleId>
            <ArticleId IdType="pubmed">18256789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S, Park H, Kang S, Kim S, Hwang J, Lee S, Kwak S, Park K, Yoo H, Kim WS, et al. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget. 2015;6(19):17764&#x2013;76. doi: 10.18632/oncotarget.3776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.3776</ArticleId>
            <ArticleId IdType="pmc">PMC4627344</ArticleId>
            <ArticleId IdType="pubmed">25980440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, Gu Z, Yan Z, Zhao X, Xie Y, Zhang Z, Pan C, Hu Y, Cai C, Dong Y, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet. 2015;47(9):1061&#x2013;6. doi: 10.1038/ng.3358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3358</ArticleId>
            <ArticleId IdType="pubmed">26192917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bi XW, Jiang WQ, Zhang WW, Huang JJ, Xia Y, Wang Y, Sun P, Li ZM. Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy. Ann Hematol. 2015;94(7):1175&#x2013;1184. doi: 10.1007/s00277-015-2336-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00277-015-2336-9</ArticleId>
            <ArticleId IdType="pubmed">25687842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu J, Li T, Yang Y, Jiang L, Wang W, Fu L, Zhu Y, Hao Y. Activatable nanomedicine for overcoming hypoxia-induced resistance to chemotherapy and inhibiting tumor growth by inducing collaborative apoptosis and ferroptosis in solid tumors. Biomaterials. 2021;268:120537. doi: 10.1016/j.biomaterials.2020.120537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2020.120537</ArticleId>
            <ArticleId IdType="pubmed">33260096</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35197507</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Endothelial cell ferroptosis mediates monocrotaline-induced pulmonary hypertension in rats by modulating NLRP3 inflammasome activation.</ArticleTitle>
        <Pagination>
          <StartPage>3056</StartPage>
          <MedlinePgn>3056</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">3056</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-06848-7</ELocationID>
        <Abstract>
          <AbstractText>Inflammation triggers pulmonary vascular remodelling. Ferroptosis, a nonapoptotic form of cell death that is triggered by iron-dependent lipid peroxidation and contributes to the pathogenesis of several inflammation-related diseases, but its role in pulmonary hypertension (PH) has not been studied. We examined endothelial cell ferroptosis in PH and the potential mechanisms. Pulmonary artery endothelial cells (PAECs) and lung tissues from monocrotaline (MCT)-induced PH rats were analysed for ferroptosis markers, including lipid peroxidation, the labile iron pool (LIP) and the protein expression of glutathione peroxidase 4 (GPX4), ferritin heavy chain 1 (FTH1) and NADPH oxidase-4 (NOX4). The effects of the ferroptosis inhibitor ferrostatin-1 (Fer-1) on endothelial cell ferroptosis and pulmonary vascular remodelling in MCT-induced rats were studied in vitro and in vivo. Ferroptosis was observed in PAECs from MCT-induced PH rats in vitro and in vivo and was characterized by a decline in cell viability accompanied by increases in the LIP and lipid peroxidation, the downregulation of GPX4 and FTH1 expression and the upregulation of NOX4 expression. High-mobility group box 1 (HMGB1)/Toll-like receptor 4 (TLR4)/NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome signalling was measured by western blotting. These changes were significantly blocked by Fer-1 administration in vitro and in vivo. These results suggest that Fer-1 plays a role in inhibiting ferroptosis-mediated PAEC loss during the progression of PH. The ferroptosis-induced inflammatory response depended on the activation of HMGB1/TLR4 signalling, which activated the NLRP3 inflammasome in vivo. We are the first to suggest that pulmonary artery endothelial ferroptosis triggers inflammatory responses via the HMGB1/TLR4/NLRP3 inflammasome signalling pathway in MCT-induced rats. Treating PH with a ferroptosis inhibitor and exploring new treatments based on ferroptosis regulation might be promising therapeutic strategies for PH.</AbstractText>
          <CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Shan-Shan</ForeName>
            <Initials>SS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, First Affiliated Hospital of Guangxi Medical University, 6 Shuang yong Road, Nanning, 530021, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, First Affiliated Hospital of Guangxi Medical University, 6 Shuang yong Road, Nanning, 530021, People's Republic of China. 190662044@qq.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Echocardiography of Cardiovascular Disease Institute, First Affiliated Hospital of Guangxi Medical University, 6 Shuang yong Road, Nanning, 530021, People's Republic of China. 190662044@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Sheng-Lan</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, First Affiliated Hospital of Guangxi Medical University, 6 Shuang yong Road, Nanning, 530021, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jia-Quan</ForeName>
            <Initials>JQ</Initials>
            <AffiliationInfo>
              <Affiliation>Experimental Centre of Guangxi Medical University, Nanning, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Ying-Chuan</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Juan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, First Affiliated Hospital of Guangxi Medical University, 6 Shuang yong Road, Nanning, 530021, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Dan-Dan</ForeName>
            <Initials>DD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, First Affiliated Hospital of Guangxi Medical University, 6 Shuang yong Road, Nanning, 530021, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lan</LastName>
            <ForeName>Wei-Fang</ForeName>
            <Initials>WF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, First Affiliated Hospital of Guangxi Medical University, 6 Shuang yong Road, Nanning, 530021, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001427">Bacterial Toxins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003514">Cyclohexylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C104200">Hbp1 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C573346">Nlrp3 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010655">Phenylenediamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495347">Tlr4 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C067044">cytolethal distending toxin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C573944">ferrostatin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>73077K8HYV</RegistryNumber>
          <NameOfSubstance UI="D016686">Monocrotaline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001427" MajorTopicYN="N">Bacterial Toxins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003514" MajorTopicYN="N">Cyclohexylamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
          <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016686" MajorTopicYN="N">Monocrotaline</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010655" MajorTopicYN="N">Phenylenediamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35197507</ArticleId>
        <ArticleId IdType="pmc">PMC8866506</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-022-06848-7</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-022-06848-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hoeper MM, et al. Pulmonary Hypertension. Dtsch Arztebl Int. 2017;114:73&#x2013;84. doi: 10.3238/arztebl.2017.0073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3238/arztebl.2017.0073</ArticleId>
            <ArticleId IdType="pmc">PMC5331483</ArticleId>
            <ArticleId IdType="pubmed">28241922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guignabert C, et al. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. Chest. 2015;147:529&#x2013;537. doi: 10.1378/chest.14-0862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.14-0862</ArticleId>
            <ArticleId IdType="pubmed">25644906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: Pathogenesis and clinical management. BMJ. 2018;360:j5492. doi: 10.1136/bmj.j5492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.j5492</ArticleId>
            <ArticleId IdType="pmc">PMC6889979</ArticleId>
            <ArticleId IdType="pubmed">29540357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lajoie AC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: A meta-analysis. Lancet Respir. Med. 2016;4:291&#x2013;305. doi: 10.1016/S2213-2600(16)00027-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(16)00027-8</ArticleId>
            <ArticleId IdType="pubmed">26935844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369&#x2013;379. doi: 10.1038/cdd.2015.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.158</ArticleId>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, et al. The emerging role of ferroptosis in inflammation. Biomed. Pharmacother. 2020;127:110108. doi: 10.1016/j.biopha.2020.110108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2020.110108</ArticleId>
            <ArticleId IdType="pubmed">32234642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen Q, Liu J, Kang R, Zhou B, Tang D. The release and activity of HMGB1 in ferroptosis. Biochem. Biophys. Res. Commun. 2019;510:278&#x2013;283. doi: 10.1016/j.bbrc.2019.01.090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.01.090</ArticleId>
            <ArticleId IdType="pubmed">30686534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarhan M, von Massenhausen A, Hugo C, Oberbauer R, Linkermann A. Immunological consequences of kidney cell death. Cell Death Dis. 2018;9:114. doi: 10.1038/s41419-017-0057-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-017-0057-9</ArticleId>
            <ArticleId IdType="pmc">PMC5833784</ArticleId>
            <ArticleId IdType="pubmed">29371597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tonnus W, et al. The clinical relevance of necroinflammation-highlighting the importance of acute kidney injury and the adrenal glands. Cell Death Differ. 2019;26:68&#x2013;82. doi: 10.1038/s41418-018-0193-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-018-0193-5</ArticleId>
            <ArticleId IdType="pmc">PMC6294800</ArticleId>
            <ArticleId IdType="pubmed">30224638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, et al. Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation. J. Clin. Invest. 2019;129:2293&#x2013;2304. doi: 10.1172/JCI126428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI126428</ArticleId>
            <ArticleId IdType="pmc">PMC6546457</ArticleId>
            <ArticleId IdType="pubmed">30830879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siques P, Brito J, Pena E. Reactive oxygen species and pulmonary vasculature during hypobaric hypoxia. Front Physiol. 2018;9:865. doi: 10.3389/fphys.2018.00865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2018.00865</ArticleId>
            <ArticleId IdType="pmc">PMC6052911</ArticleId>
            <ArticleId IdType="pubmed">30050455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knock GA. NADPH oxidase in the vasculature: Expression, regulation and signalling pathways; role in normal cardiovascular physiology and its dysregulation in hypertension. Free Radic. Biol. Med. 2019;145:385&#x2013;427. doi: 10.1016/j.freeradbiomed.2019.09.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2019.09.029</ArticleId>
            <ArticleId IdType="pubmed">31585207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Incalza MA, et al. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul. Pharmacol. 2018;100:1&#x2013;19. doi: 10.1016/j.vph.2017.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vph.2017.05.005</ArticleId>
            <ArticleId IdType="pubmed">28579545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, et al. Effect of endothelial progenitor cell-derived extracellular vesicles on endothelial cell ferroptosis and atherosclerotic vascular endothelial injury. Cell Death Discov. 2021;7:235. doi: 10.1038/s41420-021-00610-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41420-021-00610-0</ArticleId>
            <ArticleId IdType="pmc">PMC8423825</ArticleId>
            <ArticleId IdType="pubmed">34493702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, et al. The protective effects of MSC-EXO against pulmonary hypertension through regulating Wnt5a/BMP signalling pathway. J. Cell Mol. Med. 2020;24:13938&#x2013;13948. doi: 10.1111/jcmm.16002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.16002</ArticleId>
            <ArticleId IdType="pmc">PMC7754064</ArticleId>
            <ArticleId IdType="pubmed">33090702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol. Cell Oncol. 2015;2:e1054549. doi: 10.1080/23723556.2015.1054549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/23723556.2015.1054549</ArticleId>
            <ArticleId IdType="pmc">PMC4905356</ArticleId>
            <ArticleId IdType="pubmed">27308510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu M, et al. Immunogenic Cell Death Induction by Ionizing Radiation. Front Immunol. 2021;12:705361. doi: 10.3389/fimmu.2021.705361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.705361</ArticleId>
            <ArticleId IdType="pmc">PMC8417736</ArticleId>
            <ArticleId IdType="pubmed">34489957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pellegrini L, et al. HMGB1 and repair: focus on the heart. Pharmacol. Ther. 2019;196:160&#x2013;182. doi: 10.1016/j.pharmthera.2018.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2018.12.005</ArticleId>
            <ArticleId IdType="pubmed">30529040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paudel YN, et al. HMGB1: A common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction. Front Neurosci. 2018;12:628. doi: 10.3389/fnins.2018.00628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2018.00628</ArticleId>
            <ArticleId IdType="pmc">PMC6142787</ArticleId>
            <ArticleId IdType="pubmed">30271319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aldabbous L, et al. Neutrophil extracellular traps promote angiogenesis: Evidence from vascular pathology in pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 2016;36:2078&#x2013;2087. doi: 10.1161/ATVBAHA.116.307634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/ATVBAHA.116.307634</ArticleId>
            <ArticleId IdType="pubmed">27470511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia D, et al. RAGE-mediated extracellular matrix proteins accumulation exacerbates HySu-induced pulmonary hypertension. Cardiovasc. Res. 2017;113:586&#x2013;597. doi: 10.1093/cvr/cvx051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cvr/cvx051</ArticleId>
            <ArticleId IdType="pubmed">28407046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai M, et al. HMGB1 is mechanistically essential in the development of experimental pulmonary hypertension. Am. J. Physiol. Cell Physiol. 2019;316:C175&#x2013;C185. doi: 10.1152/ajpcell.00148.2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpcell.00148.2018</ArticleId>
            <ArticleId IdType="pubmed">30517029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasqua T, Pagliaro P, Rocca C, Angelone T, Penna C. Role of NLRP-3 inflammasome in hypertension: A potential therapeutic target. Curr. Pharm. Biotechnol. 2018;19:708&#x2013;714. doi: 10.2174/1389201019666180808162011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1389201019666180808162011</ArticleId>
            <ArticleId IdType="pubmed">30091406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S, Suh GY, Ryter SW, Choi AM. Regulation and function of the nucleotide binding domain leucine-rich repeat-containing receptor, pyrin domain-containing-3 inflammasome in lung disease. Am. J. Respir. Cell Mol. Biol. 2016;54:151&#x2013;160. doi: 10.1165/rcmb.2015-0231TR.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2015-0231TR</ArticleId>
            <ArticleId IdType="pmc">PMC4821045</ArticleId>
            <ArticleId IdType="pubmed">26418144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cero FT, et al. Absence of the inflammasome adaptor ASC reduces hypoxia-induced pulmonary hypertension in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2015;309:L378&#x2013;387. doi: 10.1152/ajplung.00342.2014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajplung.00342.2014</ArticleId>
            <ArticleId IdType="pubmed">26071556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng Y, et al. Activation of Nicotinic Acetylcholine &#x3b1;7 receptor attenuates progression of monocrotaline-induced pulmonary hypertension in rats by downregulating the NLRP3 inflammasome. Front. Pharmacol. 2019 doi: 10.3389/fphar.2019.00128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2019.00128</ArticleId>
            <ArticleId IdType="pmc">PMC6399137</ArticleId>
            <ArticleId IdType="pubmed">30863307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill NS, Gillespie MN, McMurtry IF. Fifty years of monocrotaline-induced pulmonary hypertension: What Has It Meant to the Field? Chest. 2017;152:1106&#x2013;1108. doi: 10.1016/j.chest.2017.10.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chest.2017.10.007</ArticleId>
            <ArticleId IdType="pubmed">29223258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomez-Arroyo JG, et al. The monocrotaline model of pulmonary hypertension in perspective. Am. J. Physiol. Lung Cell Mol. Physiol. 2012;302:L363&#x2013;369. doi: 10.1152/ajplung.00212.2011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajplung.00212.2011</ArticleId>
            <ArticleId IdType="pubmed">21964406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zimmer A, et al. The progression of pulmonary arterial hypertension induced by monocrotaline is characterized by lung nitrosative and oxidative stress, and impaired pulmonary artery reactivity. Eur. J. Pharmacol. 2021;891:173699. doi: 10.1016/j.ejphar.2020.173699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2020.173699</ArticleId>
            <ArticleId IdType="pubmed">33160936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, et al. S-Nitroso-L-Cysteine Ameliorated Pulmonary Hypertension in the MCT-Induced Rats through Anti-ROS and Anti-Inflammatory Pathways. Oxid. Med. Cell Longev. 2021;2021:6621232. doi: 10.1155/2021/6621232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2021/6621232</ArticleId>
            <ArticleId IdType="pmc">PMC7861928</ArticleId>
            <ArticleId IdType="pubmed">33574976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O, et al. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death. ACS Cent. Sci. 2017;3:232&#x2013;243. doi: 10.1021/acscentsci.7b00028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acscentsci.7b00028</ArticleId>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miotto G, et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2020;28:101328. doi: 10.1016/j.redox.2019.101328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2019.101328</ArticleId>
            <ArticleId IdType="pmc">PMC6812032</ArticleId>
            <ArticleId IdType="pubmed">31574461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Zheng Y, Wang C, Liu Y. Glutathione depletion induces ferroptosis, autophagy, and premature cell senescence in retinal pigment epithelial cells. Cell Death Dis. 2018;9:753. doi: 10.1038/s41419-018-0794-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-0794-4</ArticleId>
            <ArticleId IdType="pmc">PMC6037763</ArticleId>
            <ArticleId IdType="pubmed">29988039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie BS, et al. Inhibition of ferroptosis attenuates tissue damage and improves long-term outcomes after traumatic brain injury in mice. CNS Neurosci. Ther. 2019;25:465&#x2013;475. doi: 10.1111/cns.13069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cns.13069</ArticleId>
            <ArticleId IdType="pmc">PMC6488926</ArticleId>
            <ArticleId IdType="pubmed">30264934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, et al. Glutathione peroxidase 4 participates in secondary brain injury through mediating ferroptosis in a rat model of intracerebral hemorrhage. Brain Res. 2018;1701:112&#x2013;125. doi: 10.1016/j.brainres.2018.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2018.09.012</ArticleId>
            <ArticleId IdType="pubmed">30205109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng Y, et al. Altered mTOR and Beclin-1 mediated autophagic activation during right ventricular remodeling in monocrotaline-induced pulmonary hypertension. Respir. Res. 2017;18:53. doi: 10.1186/s12931-017-0536-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12931-017-0536-7</ArticleId>
            <ArticleId IdType="pmc">PMC5366117</ArticleId>
            <ArticleId IdType="pubmed">28340591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamezaki F, et al. Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 2008;177:219&#x2013;226. doi: 10.1164/rccm.200702-264OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.200702-264OC</ArticleId>
            <ArticleId IdType="pubmed">17962640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Homma N, et al. Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am. J. Physiol. Lung Cell Mol. Physiol. 2008;295:L71&#x2013;78. doi: 10.1152/ajplung.90251.2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajplung.90251.2008</ArticleId>
            <ArticleId IdType="pmc">PMC2494797</ArticleId>
            <ArticleId IdType="pubmed">18469113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaji-Kegan K, et al. Hypoxia-induced mitogenic factor (FIZZ1/RELMalpha) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 2014;306:L1090&#x2013;1103. doi: 10.1152/ajplung.00279.2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajplung.00279.2013</ArticleId>
            <ArticleId IdType="pmc">PMC4060011</ArticleId>
            <ArticleId IdType="pubmed">24793164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuniga MC, White SL, Zhou W. Design and utilization of macrophage and vascular smooth muscle cell co-culture systems in atherosclerotic cardiovascular disease investigation. Vasc. Med. 2014;19:394&#x2013;406. doi: 10.1177/1358863X14550542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1358863X14550542</ArticleId>
            <ArticleId IdType="pubmed">25204605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu B, et al. Puerarin protects against heart failure induced by pressure overload through mitigation of ferroptosis. Biochem. Biophys. Res. Commun. 2018;497:233&#x2013;240. doi: 10.1016/j.bbrc.2018.02.061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2018.02.061</ArticleId>
            <ArticleId IdType="pubmed">29427658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol. Life Sci. 2016;73:2195&#x2013;2209. doi: 10.1007/s00018-016-2194-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-016-2194-1</ArticleId>
            <ArticleId IdType="pmc">PMC4887533</ArticleId>
            <ArticleId IdType="pubmed">27048822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao S, et al. Cysteine Dioxygenase 1 Mediates Erastin-induced ferroptosis in human gastric cancer cells. Neoplasia. 2017;19:1022&#x2013;1032. doi: 10.1016/j.neo.2017.10.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neo.2017.10.005</ArticleId>
            <ArticleId IdType="pmc">PMC5686465</ArticleId>
            <ArticleId IdType="pubmed">29144989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, et al. Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury. Cell Death Differ. 2020;27:2635&#x2013;2650. doi: 10.1038/s41418-020-0528-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-020-0528-x</ArticleId>
            <ArticleId IdType="pmc">PMC7429834</ArticleId>
            <ArticleId IdType="pubmed">32203170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao X-Y, Zhou H-H, Jin W-L. Ferroptosis induction in pentylenetetrazole kindling and pilocarpine-induced epileptic seizures in Mice. Front Neurosci-Switz. 2019 doi: 10.3389/fnins.2019.00721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2019.00721</ArticleId>
            <ArticleId IdType="pmc">PMC6652743</ArticleId>
            <ArticleId IdType="pubmed">31379480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anthonymuthu TS, et al. Resolving the paradox of ferroptotic cell death: Ferrostatin-1 binds to 15LOX/PEBP1 complex, suppresses generation of peroxidized ETE-PE, and protects against ferroptosis. Redox Biol. 2021;38:101744. doi: 10.1016/j.redox.2020.101744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2020.101744</ArticleId>
            <ArticleId IdType="pmc">PMC7596334</ArticleId>
            <ArticleId IdType="pubmed">33126055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864&#x2013;868. doi: 10.1038/nature05859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05859</ArticleId>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng Y, et al. Interferon regulatory factor 7 inhibits rat vascular smooth muscle cell proliferation and inflammation in monocrotaline-induced pulmonary hypertension. Life Sci. 2021;264:118709. doi: 10.1016/j.lfs.2020.118709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2020.118709</ArticleId>
            <ArticleId IdType="pubmed">33152351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ. Res. 2014;115:165&#x2013;175. doi: 10.1161/CIRCRESAHA.113.301141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.113.301141</ArticleId>
            <ArticleId IdType="pmc">PMC4097142</ArticleId>
            <ArticleId IdType="pubmed">24951765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efimova I, et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J. Immunother. Cancer. 2020 doi: 10.1136/jitc-2020-001369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-001369</ArticleId>
            <ArticleId IdType="pmc">PMC7668384</ArticleId>
            <ArticleId IdType="pubmed">33188036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, et al. HMGB1 participates in LPSinduced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2, TLR4, and RAGE/NFkappaB signaling pathways. Int. J. Mol. Med. 2020;45:61&#x2013;80. doi: 10.3892/ijmm.2019.4402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2019.4402</ArticleId>
            <ArticleId IdType="pmc">PMC6889921</ArticleId>
            <ArticleId IdType="pubmed">31746367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu R, et al. Inhibition of HMGB1 improves necrotizing enterocolitis by inhibiting NLRP3 via TLR4 and NF-kappaB signaling pathways. J. Cell Physiol. 2019;234:13431&#x2013;13438. doi: 10.1002/jcp.28022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.28022</ArticleId>
            <ArticleId IdType="pubmed">30618088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sutendra G, et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFalpha contributes to the pathogenesis of pulmonary arterial hypertension. J. Mol. Med. (Berl) 2011;89:771&#x2013;783. doi: 10.1007/s00109-011-0762-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00109-011-0762-2</ArticleId>
            <ArticleId IdType="pubmed">21809123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He S, et al. GLI1-mediated pulmonary artery smooth muscle cell pyroptosis contributes to hypoxia-induced pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 2020;318:L472&#x2013;L482. doi: 10.1152/ajplung.00405.2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajplung.00405.2019</ArticleId>
            <ArticleId IdType="pubmed">31868509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai T, Li MX, Liu YF, Qiao ZT, Wang ZW. Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell. Free Radical Bio. Med. 2020;160:92&#x2013;102. doi: 10.1016/j.freeradbiomed.2020.07.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.07.026</ArticleId>
            <ArticleId IdType="pubmed">32768568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acker SN, et al. Altered pulmonary artery endothelial-smooth muscle cell interactions in experimental congenital diaphragmatic hernia. Pediatr. Res. 2015;77:511&#x2013;519. doi: 10.1038/pr.2015.13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/pr.2015.13</ArticleId>
            <ArticleId IdType="pmc">PMC4363155</ArticleId>
            <ArticleId IdType="pubmed">25580737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, et al. TGF-beta1 attenuates mitochondrial bioenergetics in pulmonary arterial endothelial cells via the disruption of carnitine homeostasis. Redox. Biol. 2020;36:101593. doi: 10.1016/j.redox.2020.101593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2020.101593</ArticleId>
            <ArticleId IdType="pmc">PMC7303661</ArticleId>
            <ArticleId IdType="pubmed">32554303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarhan M, Land WG, Tonnus W, Hugo CP, Linkermann A. Origin and consequences of necroinflammation. Physiol. Rev. 2018;98:727&#x2013;780. doi: 10.1152/physrev.00041.2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.00041.2016</ArticleId>
            <ArticleId IdType="pubmed">29465288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang YY, et al. Elevated serum HMGB1 in pulmonary arterial hypertension secondary to congenital heart disease. Vascul. Pharmacol. 2016;85:66&#x2013;72. doi: 10.1016/j.vph.2016.08.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vph.2016.08.009</ArticleId>
            <ArticleId IdType="pubmed">27568461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li WJ, et al. HMGB1 affects the development of pulmonary arterial hypertension via RAGE. Eur. Rev. Med. Pharmacol. Sci. 2017;21:3950&#x2013;3958.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28975966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Wang Z, Liu Z, Du K, Lu X. Protective effects of dexazoxane on rat ferroptosis in doxorubicin-induced cardiomyopathy through regulating HMGB1. Front Cardiovasc. Med. 2021;8:685434. doi: 10.3389/fcvm.2021.685434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcvm.2021.685434</ArticleId>
            <ArticleId IdType="pmc">PMC8318065</ArticleId>
            <ArticleId IdType="pubmed">34336950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vats K, et al. Keratinocyte death by ferroptosis initiates skin inflammation after UVB exposure. Redox Biol. 2021;47:102143. doi: 10.1016/j.redox.2021.102143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2021.102143</ArticleId>
            <ArticleId IdType="pmc">PMC8487085</ArticleId>
            <ArticleId IdType="pubmed">34592565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villegas LR, et al. Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome. Antioxid. Redox. Signal. 2013;18:1753&#x2013;1764. doi: 10.1089/ars.2012.4799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2012.4799</ArticleId>
            <ArticleId IdType="pmc">PMC3619229</ArticleId>
            <ArticleId IdType="pubmed">23240585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai Y, et al. M2 macrophage-derived exosomes carry microRNA-148a to alleviate myocardial ischemia/reperfusion injury via inhibiting TXNIP and the TLR4/NF-kappaB/NLRP3 inflammasome signaling pathway. J. Mol. Cell. Cardiol. 2020;142:65&#x2013;79. doi: 10.1016/j.yjmcc.2020.02.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yjmcc.2020.02.007</ArticleId>
            <ArticleId IdType="pubmed">32087217</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34991659</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1756-8722</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of hematology &amp; oncology</Title>
          <ISOAbbreviation>J Hematol Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk.</ArticleTitle>
        <Pagination>
          <StartPage>2</StartPage>
          <MedlinePgn>2</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13045-021-01223-x</ELocationID>
        <Abstract>
          <AbstractText>Tumor-associated macrophages (TAMs) are major components of the tumor microenvironment (TME) which are closely associated with the tumor malignant progression. However, the regulatory mechanisms by which TAMs influence the progression of triple-negative breast cancer (TNBC) remain unclear. Here, we report that hepatic leukemia factor (HLF) acts as a novel oncoprotein in TNBC. We found that HLF was regulated by transforming growth factor-beta1 (TGF-β1) that is secreted by TAMs. Then, HLF transactivated gamma-glutamyltransferase 1 (GGT1) to promote the ferroptosis resistance, thus driving TNBC cell proliferation, metastasis and cisplatin resistance. Reciprocally, IL-6 produced by TNBC cells activated the JAK2/STAT3 axis to induce TGF-β1 secretion by TAMs, thus constituted a feed-forward circuit. The accuracy of TNBC patient prognosis could be improved by employing a combination of HLF and GGT1 values. Thus, our findings document that the interactive dialogue between TNBC cells and TAMs promotes sustained activation of HLF in tumor cells through the IL-6-TGF-β1 axis. Subsequently, HLF promotes the ferroptosis resistance in TNBC cells via GGT1 and ultimately facilitates the malignant tumor progression. Our study provides a potential target for the treatment of TNBC.</AbstractText>
          <CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Li</LastName>
            <ForeName>Hengyu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast and Thyroid Surgery, Changhai Hospital, Naval Military Medical University, 230 Changhai Road, Shanghai, 200433, China. lhy@smmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Yang</LastName>
            <ForeName>Pinghua</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatic Surgery, Third Affiliated Hospital of Naval Military Medical University, Shanghai, 200438, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>JingHan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatic Surgery, Third Affiliated Hospital of Naval Military Medical University, Shanghai, 200438, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Hepatobiliary Surgery, East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatic Surgery, Third Affiliated Hospital of Naval Military Medical University, Shanghai, 200438, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Qianyun</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology Surgery, Changhai Hospital, Naval Military Medical University, Shanghai, 200433, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Yingjie</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, 200433, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Yani</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast and Thyroid Surgery, Changhai Hospital, Naval Military Medical University, 230 Changhai Road, Shanghai, 200433, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, 110001, China. than1984@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiang</LastName>
            <ForeName>Daimin</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-1386-8082</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, No. 25, Lane 2200, Xietu Road, Shanghai, 200127, China. xdm20079@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Hematol Oncol</MedlineTA>
        <NlmUniqueID>101468937</NlmUniqueID>
        <ISSNLinking>1756-8722</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050976">Basic-Leucine Zipper Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C490671">HLF protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050976" MajorTopicYN="N">Basic-Leucine Zipper Transcription Factors</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000084582" MajorTopicYN="N">Tumor-Associated Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">GGT1</Keyword>
        <Keyword MajorTopicYN="N">TGF-&#x3b2;1/SMAD3/HLF/IL-6/JAK2/STAT3 pathway</Keyword>
        <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Tumor-associated macrophages</Keyword>
      </KeywordList>
      <CoiStatement>No potential competing interest was disclosed.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>47</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34991659</ArticleId>
        <ArticleId IdType="pmc">PMC8740349</ArticleId>
        <ArticleId IdType="doi">10.1186/s13045-021-01223-x</ArticleId>
        <ArticleId IdType="pii">10.1186/s13045-021-01223-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Su S, Liu Q, Chen J, Chen J, Chen F, He C, Huang D, Wu W, Lin L, Huang W, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell. 2014;25:605&#x2013;620. doi: 10.1016/j.ccr.2014.03.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2014.03.021</ArticleId>
            <ArticleId IdType="pubmed">24823638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, Liu Q, Dou R, Xiong B. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18:64. doi: 10.1186/s12943-019-0976-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-019-0976-4</ArticleId>
            <ArticleId IdType="pmc">PMC6441214</ArticleId>
            <ArticleId IdType="pubmed">30927925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin Y, Yao S, Hu Y, Feng Y, Li M, Bian Z, Zhang J, Qin Y, Qi X, Zhou L, et al. The immune-microenvironment confers chemoresistance of colorectal cancer through macrophage-derived IL6. Clin Cancer Res. 2017;23:7375&#x2013;7387. doi: 10.1158/1078-0432.CCR-17-1283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-1283</ArticleId>
            <ArticleId IdType="pubmed">28928161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Luo G, Zhang K, Cao J, Huang C, Jiang T, Liu B, Su L, Qiu Z. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kgamma to promote pancreatic cancer metastasis. Cancer Res. 2018;78:4586&#x2013;4598. doi: 10.1158/0008-5472.CAN-17-3841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-3841</ArticleId>
            <ArticleId IdType="pubmed">29880482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiang D, Sun W, Ning B, Zhou T, Li X, Zhong W, Cheng Z, Xia M, Wang X, Deng X, et al. The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut. 2018;67:1704&#x2013;1715. doi: 10.1136/gutjnl-2016-313392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2016-313392</ArticleId>
            <ArticleId IdType="pubmed">28754776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiang D, Sun W, Zhou T, Zhang C, Cheng Z, Li S, Jiang W, Wang R, Fu G, Cui X, et al. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance. Gut. 2019;68:1858&#x2013;1871. doi: 10.1136/gutjnl-2018-317440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2018-317440</ArticleId>
            <ArticleId IdType="pubmed">31118247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bansal A, Sanchez DJ, Nimgaonkar V, Sanchez D, Riscal R, Skuli N, Simon MC. Gamma-glutamyltransferase 1 promotes clear cell renal cell carcinoma initiation and progression. Mol Cancer Res. 2019;17:1881&#x2013;1892. doi: 10.1158/1541-7786.MCR-18-1204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-18-1204</ArticleId>
            <ArticleId IdType="pmc">PMC6726546</ArticleId>
            <ArticleId IdType="pubmed">31151999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Swanda RV, Nie L, Liu X, Wang C, Lee H, Lei G, Mao C, Koppula P, Cheng W, et al. mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat Commun. 2021;12:1589. doi: 10.1038/s41467-021-21841-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-21841-w</ArticleId>
            <ArticleId IdType="pmc">PMC7952727</ArticleId>
            <ArticleId IdType="pubmed">33707434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawakami K, Fujita Y, Matsuda Y, Arai T, Horie K, Kameyama K, Kato T, Masunaga K, Kasuya Y, Tanaka M, et al. Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer. BMC Cancer. 2017;17:316. doi: 10.1186/s12885-017-3301-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-017-3301-x</ArticleId>
            <ArticleId IdType="pmc">PMC5420129</ArticleId>
            <ArticleId IdType="pubmed">28476099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weng YS, Tseng HY, Chen YA, Shen PC, Al Haq AT, Chen LM, Tung YC, Hsu HL. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer. 2019;18:42. doi: 10.1186/s12943-019-0988-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-019-0988-0</ArticleId>
            <ArticleId IdType="pmc">PMC6421700</ArticleId>
            <ArticleId IdType="pubmed">30885232</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34985903</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-5126</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>144</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Chemical Society</Title>
          <ISOAbbreviation>J Am Chem Soc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>787</StartPage>
          <EndPage>797</EndPage>
          <MedlinePgn>787-797</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/jacs.1c09753</ELocationID>
        <Abstract>
          <AbstractText>Tumor-derived exosome can suppress dendritic cells (DCs) and T cells functions. Excessive secretion of exosomal programmed death-ligand 1 (PD-L1) results in therapeutic resistance to PD-1/PD-L1 immunotherapy and clinical failure. Restored T cells by antiexosomal PD-L1 tactic can intensify ferroptosis of tumor cells and vice versa. Diminishing exosomal suppression and establishing a nexus of antiexosomal PD-L1 and ferroptosis may rescue the discouraging antitumor immunity. Here, we engineered phototheranostic metal-phenolic networks (PFG MPNs) by an assembly of semiconductor polymers encapsulating ferroptosis inducer (Fe[3+]) and exosome inhibitor (GW4869). The PFG MPNs elicited superior near-infrared II fluorescence/photoacoustic imaging tracking performance for a precise photothermal therapy (PTT). PTT-augmented immunogenic cell death relieved exosomal silencing on DC maturation. GW4869 mediated PD-L1 based exosomal inhibition revitalized T cells and enhanced the ferroptosis. This novel synergy of PTT with antiexosomal PD-L1 enhanced ferroptosis evoked potent antitumor immunity in B16F10 tumors and immunological memory against metastatic tumors in lymph nodes.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Lisi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Flexible Electronics (KLOFE) and Institute of Advanced Materials (IAM), Nanjing Tech University (NanjingTech), Nanjing 210009, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Guohao</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Mengze</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Wenxi</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Bei</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zhan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Zhen</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0003-3061-6263</Identifier>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Quli</ForeName>
            <Initials>Q</Initials>
            <Identifier Source="ORCID">0000-0002-9387-0165</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory for Organic Electronics and Information Displays and Institute of Advanced Materials (IAM), Jiangsu National Synergetic Innovation Center for Advanced Materials (SICAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Yunlu</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-4023-7320</Identifier>
            <AffiliationInfo>
              <Affiliation>Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Am Chem Soc</MedlineTA>
        <NlmUniqueID>7503056</NlmUniqueID>
        <ISSNLinking>0002-7863</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001597">Benzylidene Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005290">Ferric Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C468773">GW 4869</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000073396">Metal-Organic Frameworks</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>339NCG44TV</RegistryNumber>
          <NameOfSubstance UI="D019800">Phenol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
          <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001597" MajorTopicYN="N">Benzylidene Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005290" MajorTopicYN="N">Ferric Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079527" MajorTopicYN="N">Immunogenic Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="N">Melanoma, Experimental</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073396" MajorTopicYN="N">Metal-Organic Frameworks</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019800" MajorTopicYN="N">Phenol</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061088" MajorTopicYN="N">Photoacoustic Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068936" MajorTopicYN="N">Theranostic Nanomedicine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>17</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34985903</ArticleId>
        <ArticleId IdType="doi">10.1021/jacs.1c09753</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34811833</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2184</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>55</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell proliferation</Title>
          <ISOAbbreviation>Cell Prolif</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway.</ArticleTitle>
        <Pagination>
          <StartPage>e13158</StartPage>
          <MedlinePgn>e13158</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e13158</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cpr.13158</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Evidences demonstrate that sorafenib alleviates liver fibrosis via inhibiting HSC activation and ECM accumulation. The underlying mechanism remains unclear. Ferroptosis, a novel programmed cell death, regulates diverse physiological/pathological processes. In this study, we aim to investigate the functional role of HSC ferroptosis in the anti-fibrotic effect of sorafenib.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The effects of sorafenib on HSC ferroptosis and ECM expression were assessed in mouse model of liver fibrosis induced by CCl4 . In vitro, Fer-1 and DFO were used to block ferroptosis and then explored the anti-fibrotic effect of sorafenib by detecting &#x3b1;-SMA, COL1&#x3b1;1 and fibronectin proteins. Finally, HIF-1&#x3b1; siRNA, plasmid and stabilizers were applied to assess related signalling pathway.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Sorafenib attenuated liver injury and ECM accumulation in CCl4 -induced fibrotic livers, accompanied by reduction of SLC7A11 and GPX4 proteins. In sorafenib-treated HSC-T6 cells, ferroptotic events (depletion of SLC7A11, GPX4 and GSH; accumulation iron, ROS and MDA) were discovered. Intriguingly, these ferroptotic events were not appeared in hepatocytes or macrophages. Sorafenib-elicited HSC ferroptosis and ECM reduction were abrogated by Fer-1 and DFO. Additionally, both HIF-1&#x3b1; and SLC7A11 proteins were reduced in sorafenib-treated HSC-T6 cells. SLC7A11 was positively regulated by HIF-1&#x3b1;, inactivation of HIF-1&#x3b1;/SLC7A11 pathway was required for sorafenib-induced HSC ferroptosis, and elevation of HIF-1&#x3b1; could inhibit ferroptosis, ultimately limited the anti-fibrotic effect.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Sorafenib triggers HSC ferroptosis via HIF-1&#x3b1;/SLC7A11&#xa0;signalling, which in turn attenuates liver injury and fibrosis.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 The Authors. Cell Proliferation published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Siyu</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Can</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The Second People's Hospital of Hefei, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Guofang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lijun</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jiahao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Lingling</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Shiyi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-4600-0156</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>81600498</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>82004010</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2019xkj084</GrantID>
            <Agency>Anhui Medical University</Agency>
          </Grant>
          <Grant>
            <GrantID>2020xkj187</GrantID>
            <Agency>Anhui Medical University</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Prolif</MedlineTA>
        <NlmUniqueID>9105195</NlmUniqueID>
        <ISSNLinking>0960-7722</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C558396">Acta2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000199">Actins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027182">Amino Acid Transport System y+</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024042">Collagen Type I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497443">Hif1a protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C492255">Slc7a11 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9ZOQ3TZI87</RegistryNumber>
          <NameOfSubstance UI="D000077157">Sorafenib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027182" MajorTopicYN="N">Amino Acid Transport System y+</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024042" MajorTopicYN="N">Collagen Type I</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055166" MajorTopicYN="N">Hepatic Stellate Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022781" MajorTopicYN="N">Hepatocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051795" MajorTopicYN="N">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055550" MajorTopicYN="N">Protein Stability</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077157" MajorTopicYN="N">Sorafenib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">HIF-1&#x3b1;/SLC7A11</Keyword>
        <Keyword MajorTopicYN="N">HSCs</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">liver fibrosis</Keyword>
        <Keyword MajorTopicYN="N">sorafenib</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>51</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34811833</ArticleId>
        <ArticleId IdType="pmc">PMC8780895</ArticleId>
        <ArticleId IdType="doi">10.1111/cpr.13158</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151&#x2010;171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30266282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campana L, Iredale JP. Regression of Liver Fibrosis. Semin Liver Dis. 2017;37(1):1&#x2010;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28201843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman SL, Rockey DC, McGuire RF, Maher JJ, Boyles JK, Yamasaki G. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology. 1992;15(2):234&#x2010;243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1735526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397&#x2010;411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28487545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang L, Zhan S, Huang C, et al. TRPM7 channel regulates PDGF&#x2010;BB&#x2010;induced proliferation of hepatic stellate cells via PI3K and ERK pathways. Toxicol Appl Pharmacol. 2013;272(3):713&#x2010;725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23958495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai S, Wu L, Yuan S, et al. Carvacrol alleviates liver fibrosis by inhibiting TRPM7 and modulating the MAPK signaling pathway. Eur J Pharmacol. 2021;898: 173982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33647257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang YR, Bu FT, Yang Y, et al. LEFTY2 alleviates hepatic stellate cell activation and liver fibrosis by regulating the TGF&#x2010;beta1/Smad3 pathway. Mol Immunol. 2020;126:31&#x2010;39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32745796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273&#x2010;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369&#x2010;379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Guo M, Li Y, et al. RNA&#x2010;binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells. Autophagy. 2020;16(8):1482&#x2010;1505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7469536</ArticleId>
            <ArticleId IdType="pubmed">31679460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Yao Z, Wang L, et al. Activation of ferritinophagy is required for the RNA&#x2010;binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells. Autophagy. 2018;14(12):2083&#x2010;2103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6984765</ArticleId>
            <ArticleId IdType="pubmed">30081711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Zhang Z, Li M, et al. P53&#x2010;dependent induction of ferroptosis is required for artemether to alleviate carbon tetrachloride&#x2010;induced liver fibrosis and hepatic stellate cell activation. IUBMB Life. 2019;71(1):45&#x2010;56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30321484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong Z, Liu R, Cheng Y. Artesunate alleviates liver fibrosis by regulating ferroptosis signaling pathway. Biomed Pharmacother. 2019;109:2043&#x2010;2053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30551460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol. 2010;53(1):132&#x2010;144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20447716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong F, Chou H, Fiel MI, et al. Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo. Dig Dis Sci. 2012;58(1):257&#x2010;264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3543488</ArticleId>
            <ArticleId IdType="pubmed">22918681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X, Zhu S, Chen P, et al. AMPK&#x2010;mediated BECN1 phosphorylation promotes ferroptosis by directly blocking system Xc(&#x2010;) activity. Curr Biol. 2018;28(15):2388&#x2010;2399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6081251</ArticleId>
            <ArticleId IdType="pubmed">30057310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, An P, Xie E, et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology. 2017;66(2):449&#x2010;465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5573904</ArticleId>
            <ArticleId IdType="pubmed">28195347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corpechot C, Barbu V, Wendum D, et al. Hypoxia&#x2010;induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002;35(5):1010&#x2010;1021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11981751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moon JO, Welch TP, Gonzalez FJ, et al. Reduced liver fibrosis in hypoxia&#x2010;inducible factor&#x2010;1alpha&#x2010;deficient mice. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G582&#x2010;592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2660171</ArticleId>
            <ArticleId IdType="pubmed">19136383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han J, He Y, Zhao H, Xu X. Hypoxia inducible factor&#x2010;1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN/p65 signaling pathway. J Cell Biochem. 2019;120(9):14735&#x2010;14744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31009107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu M, Zheng YL, Xie XY, et al. Sorafenib blocks the HIF&#x2010;1alpha/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells. DNA Cell Biol. 2014;33(5):275&#x2010;281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24611881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang M, Chen P, Liu J, et al. Clockophagy is a novel selective autophagy process favoring ferroptosis. Sci Adv. 2019;5(7):eaaw2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6656546</ArticleId>
            <ArticleId IdType="pubmed">31355331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ananth S, Babu E, Veeranan&#x2010;Karmegam R, Bozard Baldowski BR, Boettger T, Martin PM. Induction of the cystine/glutamate exchanger SLC7A11 in retinal pigment epithelial cells by the antipsoriatic drug monomethylfumarate. Invest Ophthalmol Vis Sci. 2013;54(3):1592&#x2010;1602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23404113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh CH, Lin YJ, Chen WL, et al. HIF&#x2010;1alpha triggers long&#x2010;lasting glutamate excitotoxicity via system xc(&#x2010;) in cerebral ischaemia&#x2010;reperfusion. J Pathol. 2017;241(3):337&#x2010;349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27801527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sims B, Clarke M, Francillion L, Kindred E, Hopkins ES, Sontheimer H. Hypoxic preconditioning involves system Xc&#x2010; regulation in mouse neural stem cells. Stem Cell Res. 2012;8(2):285&#x2010;291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22056639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Wei C, Cai S, et al. TRPM7 modulates macrophage polarization by STAT1/STAT6 pathways in RAW264.7 cells. Biochem Biophys Res Commun. 2020;533(4):692&#x2010;697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33153718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng YR, Ma HD, Tsuneyama K, et al. STAT3&#x2010;mediated attenuation of CCl4&#x2010;induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. J Autoimmun. 2013;46:25&#x2010;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23948302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trefts E, Gannon M, Wasserman DH, et al. The liver. Curr Biol. 2017;27(21):R1147&#x2010;R1151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5897118</ArticleId>
            <ArticleId IdType="pubmed">29112863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue H, Chen D, Zhong YK, et al. Deferoxamine ameliorates hepatosteatosis via several mechanisms in ob/ob mice. Ann N Y Acad Sci. 2016;1375(1):52&#x2010;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27447538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su TH, Shiau CW, Jao P, et al. Sorafenib and its derivative SC&#x2010;1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proc Natl Acad Sci U S A. 2015;112(23):7243&#x2010;7248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4466718</ArticleId>
            <ArticleId IdType="pubmed">26039995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez&#x2010;Hernandez MA, de la Cruz&#x2010;Ojeda P, Gallego P, et al. Dose&#x2010;dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells. Biochem Pharmacol. 2020;176: 113902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32156660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong H, Xiao M, Zarkovic K, et al. Mitochondrial control of apoptosis through modulation of cardiolipin oxidation in hepatocellular carcinoma: A novel link between oxidative stress and cancer. Free Radic Biol Med. 2017;102:67&#x2010;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27838437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlson BA, Tobe R, Yefremova E, et al. Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration. Redox Biol. 2016;9:22&#x2010;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4900515</ArticleId>
            <ArticleId IdType="pubmed">27262435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180&#x2010;1191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang ES, Lee J, Homma T, et al. xCT deficiency aggravates acetaminophen&#x2010;induced hepatotoxicity under inhibition of the transsulfuration pathway. Free Radic Res. 2017;51(1):80&#x2010;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28081640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang AW, Wangensteen KJ, Wang YJ, et al. TRAP&#x2010;seq identifies cystine/glutamate antiporter as a driver of recovery from liver injury. J Clin Invest. 2018;128(6):2297&#x2010;2309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5983312</ArticleId>
            <ArticleId IdType="pubmed">29517978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du K, Oh SH, Dutta RK, et al. Inhibiting xCT/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells but exacerbates chronic liver injury. Liver Int. 2021;41(9):2214&#x2013;2227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8594404</ArticleId>
            <ArticleId IdType="pubmed">33991158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron&#x2010;dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060&#x2010;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegmund SV, Seki E, Osawa Y, Uchinami H, Cravatt BF, Schwabe RF. Fatty acid amide hydrolase determines anandamide&#x2010;induced cell death in the liver. J Biol Chem. 2006;281(15):10431&#x2010;10438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16418162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang P, Geng J, Gao J, et al. Macrophage achieves self&#x2010;protection against oxidative stress&#x2010;induced ageing through the Mst&#x2010;Nrf2 axis. Nat Commun. 2019;10(1):755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6376064</ArticleId>
            <ArticleId IdType="pubmed">30765703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Xuefeng Y, Shandong W. COX&#x2010;2 in liver fibrosis. Clin Chim Acta. 2020;506:196&#x2010;203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32184095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goss JA, Mangino MJ, Flye MW. Prostaglandin E2 production during hepatic regeneration downregulates Kupffer cell IL&#x2010;6 production. Ann Surg. 1992;215(6):553&#x2010;559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1242501</ArticleId>
            <ArticleId IdType="pubmed">1632677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu L, Yang F, Wang L, et al. Identification the ferroptosis&#x2010;related gene signature in patients with esophageal adenocarcinoma. Cancer Cell Int. 2021;21(1):124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7891153</ArticleId>
            <ArticleId IdType="pubmed">33602233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada N, Karasawa T, Kimura H, et al. Ferroptosis driven by radical oxidation of n&#x2010;6 polyunsaturated fatty acids mediates acetaminophen&#x2010;induced acute liver failure. Cell Death Dis. 2020;11(2):144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7039960</ArticleId>
            <ArticleId IdType="pubmed">32094346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Guo M, Shen M, et al. The BRD7&#x2010;P53&#x2010;SLC25A28 axis regulates ferroptosis in hepatic stellate cells. Redox Biol. 2020;36: 101619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7330619</ArticleId>
            <ArticleId IdType="pubmed">32863216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampilvanjil A, Karasawa T, Yamada N, et al. Cigarette smoke extract induces ferroptosis in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2020;318(3):H508&#x2010;H518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31975626</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34717678</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1742-2094</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neuroinflammation</Title>
          <ISOAbbreviation>J Neuroinflammation</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Microglia and macrophage exhibit attenuated inflammatory response and ferroptosis resistance after RSL3 stimulation via increasing Nrf2 expression.</ArticleTitle>
        <Pagination>
          <StartPage>249</StartPage>
          <MedlinePgn>249</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">249</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12974-021-02231-x</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Many neurological diseases involve neuroinflammation, during which overproduction of cytokines by immune cells, especially microglia, can aggregate neuronal death. Ferroptosis is a recently discovered cell metabolism-related form of cell death and RSL3 is a well-known inducer of cell ferroptosis. Here, we aimed to investigate the effects of RSL3 in neuroinflammation and sensitivity of different type of microglia and macrophage to ferroptosis.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Here, we used quantitative RT-PCR analysis and ELISA analysis to analyze the production of proinflammatory cytokine production of microglia and macrophages after lipopolysaccharides (LPS) stimulation. We used CCK8, LDH, and flow cytometry analysis to evaluate the sensitivity of different microglia and macrophages to RSL3-induced ferroptosis. Western blot was used to test the activation of inflammatory signaling pathway and knockdown efficiency. SiRNA-mediated interference was conducted to knockdown GPX4 or Nrf2 in BV2 microglia. Intraperitoneal injection of LPS was performed to evaluate systemic inflammation and neuroinflammation severity in in vivo conditions.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that ferroptosis inducer RSL3 inhibited lipopolysaccharides (LPS)-induced inflammation of microglia and peritoneal macrophages (PMs) in a cell ferroptosis-independent manner, whereas cell ferroptosis-conditioned medium significantly triggered inflammation of microglia and PMs. Different type of microglia and macrophages showed varied sensitivity to RSL3-induced ferroptosis. Mechanistically, RSL3 induced Nrf2 protein expression to inhibit RNA Polymerase II recruitment to transcription start site of proinflammatory cytokine genes to repress cytokine transcription, and protect cells from ferroptosis. Furthermore, simultaneously injection of RSL3 and Fer-1 ameliorated LPS-induced neuroinflammation in in vivo conditions.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data revealed the proinflammatory role of ferroptosis in microglia and macrophages, identified RSL3 as a novel inhibitor of LPS-induced inflammation, and uncovered the molecular regulation of microglia and macrophage sensitivity to ferroptosis. Thus, targeting ferroptosis in diseases by using RSL3 should consider both the pro-ferroptosis effect and the anti-inflammation effect to achieve optimal outcome.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroregeneration &amp; Neurorehabilitation, Department of Pathophysiology, Qingdao University, Ningxia Road 308, Qingdao, 266071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zhaolong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>The Affiliated Hospital of Qingdao University, Jiangsu Road 16, Qingdao, 266000, Shandong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroregeneration &amp; Neurorehabilitation, Department of Pathophysiology, Qingdao University, Ningxia Road 308, Qingdao, 266071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Zhiyuan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>The Affiliated Hospital of Qingdao University, Jiangsu Road 16, Qingdao, 266000, Shandong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>The Affiliated Hospital of Qingdao University, Jiangsu Road 16, Qingdao, 266000, Shandong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Xiangyu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>The Affiliated Hospital of Qingdao University, Jiangsu Road 16, Qingdao, 266000, Shandong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kong</LastName>
            <ForeName>Xiangyi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroregeneration &amp; Neurorehabilitation, Department of Pathophysiology, Qingdao University, Ningxia Road 308, Qingdao, 266071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Jinyang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroregeneration &amp; Neurorehabilitation, Department of Pathophysiology, Qingdao University, Ningxia Road 308, Qingdao, 266071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Xujin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroregeneration &amp; Neurorehabilitation, Department of Pathophysiology, Qingdao University, Ningxia Road 308, Qingdao, 266071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wen</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Center, Qingdao University, Qingdao, 266071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Feifei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medicine, Qingdao University, Ningxia Road 308, Qingdao, 266071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Shengli</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medicine, Qingdao University, Ningxia Road 308, Qingdao, 266071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Jiangdong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroregeneration &amp; Neurorehabilitation, Department of Pathophysiology, Qingdao University, Ningxia Road 308, Qingdao, 266071, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <Identifier Source="ORCID">0000-0001-6014-1620</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroregeneration &amp; Neurorehabilitation, Department of Pathophysiology, Qingdao University, Ningxia Road 308, Qingdao, 266071, China. qiwan1@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>31900634</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>82071385</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2019YFC0120000; 2018YFC1312300</GrantID>
            <Agency>National Key R&amp;D Program of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2019JZZY021010</GrantID>
            <Agency>the Key Research and Development Project of Shandong</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Neuroinflammation</MedlineTA>
        <NlmUniqueID>101222974</NlmUniqueID>
        <ISSNLinking>1742-2094</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002243">Carbolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495636">Nfe2l2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C587550">RSL3 compound</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067996" MajorTopicYN="N">RAW 264.7 Cells</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">LPS</Keyword>
        <Keyword MajorTopicYN="N">Macrophage</Keyword>
        <Keyword MajorTopicYN="N">Microglia</Keyword>
        <Keyword MajorTopicYN="N">Neuroinflammation</Keyword>
        <Keyword MajorTopicYN="N">RSL3</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>20</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34717678</ArticleId>
        <ArticleId IdType="pmc">PMC8557003</ArticleId>
        <ArticleId IdType="doi">10.1186/s12974-021-02231-x</ArticleId>
        <ArticleId IdType="pii">10.1186/s12974-021-02231-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783&#x2013;801. doi: 10.1016/j.cell.2006.02.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.02.015</ArticleId>
            <ArticleId IdType="pubmed">16497588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao TS. Innate immunity and inflammation. Cell Mol Immunol. 2017;14(1):1&#x2013;3. doi: 10.1038/cmi.2016.45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cmi.2016.45</ArticleId>
            <ArticleId IdType="pmc">PMC5214945</ArticleId>
            <ArticleId IdType="pubmed">27545072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003:21335&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12524386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373&#x2013;384. doi: 10.1038/ni.1863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1863</ArticleId>
            <ArticleId IdType="pubmed">20404851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Degan D, Ornello R, Tiseo C, Carolei A, Sacco S, Pistoia F. The role of inflammation in neurological disorders. Curr Pharm Des. 2018;24(14):1485&#x2013;1501. doi: 10.2174/1381612824666180327170632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1381612824666180327170632</ArticleId>
            <ArticleId IdType="pubmed">29589534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao X. Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat Rev Immunol. 2016;16(1):35&#x2013;50. doi: 10.1038/nri.2015.8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2015.8</ArticleId>
            <ArticleId IdType="pubmed">26711677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805&#x2013;820. doi: 10.1016/j.cell.2010.01.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.01.022</ArticleId>
            <ArticleId IdType="pubmed">20303872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng J, Conrad M. The metabolic underpinnings of ferroptosis. Cell Metab. 2020;32(6):920&#x2013;937. doi: 10.1016/j.cmet.2020.10.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2020.10.011</ArticleId>
            <ArticleId IdType="pubmed">33217331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gasc&#xf3;n S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1-2):317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234&#x2013;245. doi: 10.1016/j.chembiol.2008.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2008.02.010</ArticleId>
            <ArticleId IdType="pmc">PMC2683762</ArticleId>
            <ArticleId IdType="pubmed">18355723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369&#x2013;379. doi: 10.1038/cdd.2015.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.158</ArticleId>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26(3):165&#x2013;176. doi: 10.1016/j.tcb.2015.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2015.10.014</ArticleId>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Jiang G, Zhang P, Fan J. Programmed cell death and its role in inflammation. Mil Med Res. 2015;212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4455968</ArticleId>
            <ArticleId IdType="pubmed">26045969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol. 2008:399&#x2013;126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3094097</ArticleId>
            <ArticleId IdType="pubmed">18039143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7(2):99&#x2013;109. doi: 10.1038/nrmicro2070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrmicro2070</ArticleId>
            <ArticleId IdType="pmc">PMC2910423</ArticleId>
            <ArticleId IdType="pubmed">19148178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han C, Liu Y, Dai R, Ismail N, Su W, Li B. Ferroptosis and its potential role in human diseases. Front Pharmacol. 2020;11239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7090218</ArticleId>
            <ArticleId IdType="pubmed">32256352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren JX, Sun X, Yan XL, Guo ZN, Yang Y. Ferroptosis in neurological diseases. Front Cell Neurosci. 2020;14218.</Citation>
        </Reference>
        <Reference>
          <Citation>Cui Y, Zhang Y, Zhao X, Shao L, Liu G, Sun C, Xu R, Zhang Z. ACSL4 exacerbates ischemic stroke by promoting ferroptosis-induced brain injury and neuroinflammation. Brain Behav Immun. 2021;93:312&#x2013;321. doi: 10.1016/j.bbi.2021.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2021.01.003</ArticleId>
            <ArticleId IdType="pubmed">33444733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19(7):405&#x2013;414. doi: 10.1038/s41568-019-0149-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-019-0149-1</ArticleId>
            <ArticleId IdType="pubmed">31101865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown CW, Mercurio AM. Ferroptosis resistance mediated by exosomal release of iron. Mol Cell Oncol. 2020;7(3):1730144. doi: 10.1080/23723556.2020.1730144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/23723556.2020.1730144</ArticleId>
            <ArticleId IdType="pmc">PMC7199748</ArticleId>
            <ArticleId IdType="pubmed">32391424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown CW, Amante JJ, Chhoy P, Elaimy AL, Liu H, Zhu LJ, Baer CE, Dixon SJ, Mercurio AM. Prominin2 drives ferroptosis resistance by stimulating iron export. Dev Cell. 2019;51(5):575&#x2013;586. doi: 10.1016/j.devcel.2019.10.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2019.10.007</ArticleId>
            <ArticleId IdType="pmc">PMC8316835</ArticleId>
            <ArticleId IdType="pubmed">31735663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, Prokisch H, Tr&#xfc;mbach D, Mao G, Qu F, Bayir H, F&#xfc;llekrug J, Scheel CH, Wurst W, Schick JA, Kagan VE, Angeli JPF, Conrad M. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91&#x2013;98. doi: 10.1038/nchembio.2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2239</ArticleId>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown CW, Amante JJ, Goel HL, Mercurio AM. The alpha6beta4 integrin promotes resistance to ferroptosis. J Cell Biol. 2017;216(12):4287&#x2013;4297. doi: 10.1083/jcb.201701136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201701136</ArticleId>
            <ArticleId IdType="pmc">PMC5716272</ArticleId>
            <ArticleId IdType="pubmed">28972104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, Tang D. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63(1):173&#x2013;184. doi: 10.1002/hep.28251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28251</ArticleId>
            <ArticleId IdType="pmc">PMC4688087</ArticleId>
            <ArticleId IdType="pubmed">26403645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 2019;23101107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6859567</ArticleId>
            <ArticleId IdType="pubmed">30692038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapralov AA, Yang Q, Dar HH, Tyurina YY, Anthonymuthu TS, Kim R, St. Croix CM, Mikulska-Ruminska K, Liu B, Shrivastava IH, Tyurin VA, Ting HC, Wu YL, Gao Y, Shurin GV, Artyukhova MA, Ponomareva LA, Timashev PS, Domingues RM, Stoyanovsky DA, Greenberger JS, Mallampalli RK, Bahar I, Gabrilovich DI, Bay&#x131;r H, Kagan VE. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat Chem Biol. 2020;16(3):278&#x2013;290. doi: 10.1038/s41589-019-0462-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41589-019-0462-8</ArticleId>
            <ArticleId IdType="pmc">PMC7233108</ArticleId>
            <ArticleId IdType="pubmed">32080625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu S, Liu X, Bao Y, Zhu X, Han C, Zhang P, Zhang X, Li W, Cao X. Constitutive MHC class I molecules negatively regulate TLR-triggered inflammatory responses via the Fps-SHP-2 pathway. Nat Immunol. 2012;13(6):551&#x2013;559. doi: 10.1038/ni.2283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2283</ArticleId>
            <ArticleId IdType="pubmed">22522491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia M, Liu J, Wu X, Liu S, Li G, Han C, Song L, Li Z, Wang Q, Wang J, Xu T, Cao X. Histone methyltransferase Ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme A20. Immunity. 2013;39(3):470&#x2013;481. doi: 10.1016/j.immuni.2013.08.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2013.08.016</ArticleId>
            <ArticleId IdType="pubmed">24012418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Zhu X, Chen X, Liu H, Xu Y, Chu Y, et al. The mediator subunit Med23 contributes to controlling T-cell activation and prevents autoimmunity. Nat Commun. 2014;55225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25301163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui Y, Zhang Y, Zhao X, Shao L, Liu G, Sun C, et al. ACSL4 exacerbates ischemic stroke by promoting ferroptosis-induced brain injury and neuroinflammation. Brain Behav Immun. 2021:93312&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33444733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Wang Q, Zhao X, Shao L, Liu G, Zheng X, Xie L, Zhang Y, Sun C, Xu R. YTHDC1 mitigates ischemic stroke by promoting Akt phosphorylation through destabilizing PTEN mRNA. Cell Death Dis. 2020;11(11):977. doi: 10.1038/s41419-020-03186-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-03186-2</ArticleId>
            <ArticleId IdType="pmc">PMC7666223</ArticleId>
            <ArticleId IdType="pubmed">33188203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Cui Y, Feng H, Liu H, Liu X. TGF-beta signaling controls Foxp3 methylation and T reg cell differentiation by modulating Uhrf1 activity. J Exp Med. 2019;216(12):2819&#x2013;2837. doi: 10.1084/jem.20190550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20190550</ArticleId>
            <ArticleId IdType="pmc">PMC6888975</ArticleId>
            <ArticleId IdType="pubmed">31515281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu H, Jiang Y, Xu X, Su X, Liu Y, Ma Y, Zhao Y, Shen Z, Huang B, Cao X. Inducible degradation of lncRNA Sros1 promotes IFN-gamma-mediated activation of innate immune responses by stabilizing Stat1 mRNA. Nat Immunol. 2019;20(12):1621&#x2013;1630. doi: 10.1038/s41590-019-0542-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-019-0542-7</ArticleId>
            <ArticleId IdType="pubmed">31740800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry VH, Teeling J. Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol. 2013;35(5):601&#x2013;612. doi: 10.1007/s00281-013-0382-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-013-0382-8</ArticleId>
            <ArticleId IdType="pmc">PMC3742955</ArticleId>
            <ArticleId IdType="pubmed">23732506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, III, Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Hayashi M, Sekine H, et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun. 2016;711624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4879264</ArticleId>
            <ArticleId IdType="pubmed">27211851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu W, Wang H, Li S, Liu Q, Sha H. The anti-inflammatory and anti-oxidant mechanisms of the Keap1/Nrf2/ARE signaling pathway in chronic diseases. Aging Dis. 2019;10(3):637&#x2013;651. doi: 10.14336/AD.2018.0513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14336/AD.2018.0513</ArticleId>
            <ArticleId IdType="pmc">PMC6538222</ArticleId>
            <ArticleId IdType="pubmed">31165007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voet S, Mc Guire C, Hagemeyer N, Martens A, Schroeder A, Wieghofer P, Daems C, Staszewski O, Vande Walle L, Jordao MJC, Sze M, Vikkula HK, Demeestere D, van Imschoot G, Scott CL, Hoste E, Gon&#xe7;alves A, Guilliams M, Lippens S, Libert C, Vandenbroucke RE, Kim KW, Jung S, Callaerts-Vegh Z, Callaerts P, de Wit J, Lamkanfi M, Prinz M, van Loo G. A20 critically controls microglia activation and inhibits inflammasome-dependent neuroinflammation. Nat Commun. 2018;9(1):2036. doi: 10.1038/s41467-018-04376-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-04376-5</ArticleId>
            <ArticleId IdType="pmc">PMC5964249</ArticleId>
            <ArticleId IdType="pubmed">29789522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci. 2019;20(1):19&#x2013;33. doi: 10.1038/s41583-018-0093-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41583-018-0093-1</ArticleId>
            <ArticleId IdType="pmc">PMC6342007</ArticleId>
            <ArticleId IdType="pubmed">30467385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, Taylor N, Fourgeaud L, Bhattacharya A. The role of microglial P2X7: modulation of cell death and cytokine release. J Neuroinflammation. 2017;14(1):135. doi: 10.1186/s12974-017-0904-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-017-0904-8</ArticleId>
            <ArticleId IdType="pmc">PMC5513370</ArticleId>
            <ArticleId IdType="pubmed">28716092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proneth B, Conrad M. Ferroptosis and necroinflammation, a yet poorly explored link. Cell Death Differ. 2019;26(1):14&#x2013;24. doi: 10.1038/s41418-018-0173-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-018-0173-9</ArticleId>
            <ArticleId IdType="pmc">PMC6294786</ArticleId>
            <ArticleId IdType="pubmed">30082768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Hambright WS, Na R, Ran Q. Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J Biol Chem. 2015;290(47):28097&#x2013;28106. doi: 10.1074/jbc.M115.680090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M115.680090</ArticleId>
            <ArticleId IdType="pmc">PMC4653669</ArticleId>
            <ArticleId IdType="pubmed">26400084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hambright WS, Fonseca RS, Chen L, Na R, Ran Q. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 2017:128&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5312549</ArticleId>
            <ArticleId IdType="pubmed">28212525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81&#x2013;90. doi: 10.1038/nchembio.2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2238</ArticleId>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seiler A, Schneider M, Forster H, Roth S, Wirth EK, Culmsee C, et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 2008;8(3):237&#x2013;248. doi: 10.1016/j.cmet.2008.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2008.07.005</ArticleId>
            <ArticleId IdType="pubmed">18762024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Sanchez D, Ruiz-Andres O, Poveda J, Carrasco S, Cannata-Ortiz P, Sanchez-Nino MD, et al. Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI. J Am Soc Nephrol. 2017;28(1):218&#x2013;229. doi: 10.1681/ASN.2015121376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2015121376</ArticleId>
            <ArticleId IdType="pmc">PMC5198282</ArticleId>
            <ArticleId IdType="pubmed">27352622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Chen P, Zhai B, Zhang M, Xiang Y, Fang J, et al. The emerging role of ferroptosis in inflammation. Biomed Pharmacother. 2020;127110108.</Citation>
        </Reference>
        <Reference>
          <Citation>Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res. 1990;49(2):186&#x2013;196. doi: 10.1016/0022-4804(90)90260-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-4804(90)90260-9</ArticleId>
            <ArticleId IdType="pubmed">2199735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh BM, Lee SJ, Park GL, Hwang YS, Lim J, Park ES, et al. Erastin inhibits septic shock and inflammatory gene expression via suppression of the NF-kappaB pathway. J Clin Med 2019;8(12).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6947339</ArticleId>
            <ArticleId IdType="pubmed">31847346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang C, Zhang X, Yang M, Dong X. Recent progress in ferroptosis inducers for cancer therapy. Adv Mater. 2019;31(51):e1904197. doi: 10.1002/adma.201904197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201904197</ArticleId>
            <ArticleId IdType="pubmed">31595562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27&#x2013;41. doi: 10.1016/j.immuni.2019.06.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2019.06.025</ArticleId>
            <ArticleId IdType="pmc">PMC6831096</ArticleId>
            <ArticleId IdType="pubmed">31315034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, Bassik MC, Nomura DK, Dixon SJ, Olzmann JA. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688&#x2013;692. doi: 10.1038/s41586-019-1705-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1705-2</ArticleId>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Z, Wirth AK, Chen D, Wruck CJ, Rauh M, Buchfelder M, Savaskan N. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis. 2017;6(8):e371. doi: 10.1038/oncsis.2017.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/oncsis.2017.65</ArticleId>
            <ArticleId IdType="pmc">PMC5608917</ArticleId>
            <ArticleId IdType="pubmed">28805788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis. 2017;1863(2):585&#x2013;597. doi: 10.1016/j.bbadis.2016.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2016.11.005</ArticleId>
            <ArticleId IdType="pubmed">27825853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, Rosenberg PA, Lo DC, Weinberg JM, Linkermann A, Stockwell BR. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc. 2014;136(12):4551&#x2013;4556. doi: 10.1021/ja411006a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ja411006a</ArticleId>
            <ArticleId IdType="pmc">PMC3985476</ArticleId>
            <ArticleId IdType="pubmed">24592866</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34593794</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-1723</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature communications</Title>
          <ISOAbbreviation>Nat Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>5733</StartPage>
          <MedlinePgn>5733</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">5733</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-021-25990-w</ELocationID>
        <Abstract>
          <AbstractText>In addition to increasing the expression of programmed death-ligand 1 (PD-L1), tumor cells can also secrete exosomal PD-L1 to suppress T cell activity. Emerging evidence has revealed that exosomal PD-L1 resists immune checkpoint blockade, and may contribute to resistance to therapy. In this scenario, suppressing the secretion of tumor-derived exosomes may aid therapy. Here, we develop an assembly of exosome inhibitor (GW4869) and ferroptosis inducer (Fe[3+]) via amphiphilic hyaluronic acid. Cooperation between the two active components in the constructed nanounit induces an anti-tumor immunoresponse to B16F10 melanoma cells and stimulates cytotoxic T lymphocytes and immunological memory. The nanounit enhances the response to PD-L1 checkpoint blockade and may represent a therapeutic strategy for enhancing the response to this therapy.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Guohao</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Xie</LastName>
            <ForeName>Lisi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Li</LastName>
            <ForeName>Bei</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Wenxi</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zhan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Ye</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Yunlu</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-4023-7320</Identifier>
            <AffiliationInfo>
              <Affiliation>Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China. yldai@um.edu.mo.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China. yldai@um.edu.mo.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, 999078, China. yldai@um.edu.mo.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Commun</MedlineTA>
        <NlmUniqueID>101528555</NlmUniqueID>
        <ISSNLinking>2041-1723</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001597">Benzylidene Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C498919">Cd274 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C468773">GW 4869</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9004-61-9</RegistryNumber>
          <NameOfSubstance UI="D006820">Hyaluronic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001597" MajorTopicYN="N">Benzylidene Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
          <QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006820" MajorTopicYN="N">Hyaluronic Acid</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="N">Melanoma, Experimental</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34593794</ArticleId>
        <ArticleId IdType="pmc">PMC8484261</ArticleId>
        <ArticleId IdType="doi">10.1038/s41467-021-25990-w</ArticleId>
        <ArticleId IdType="pii">10.1038/s41467-021-25990-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450&#x2013;461. doi: 10.1016/j.ccell.2015.03.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2015.03.001</ArticleId>
            <ArticleId IdType="pmc">PMC4400238</ArticleId>
            <ArticleId IdType="pubmed">25858804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hui E, et al. T cell costimulatory receptor CD28 is a primary target for PD-1&#x2013;mediated inhibition. Science. 2017;355:1428. doi: 10.1126/science.aaf1292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaf1292</ArticleId>
            <ArticleId IdType="pmc">PMC6286077</ArticleId>
            <ArticleId IdType="pubmed">28280247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Niel G, D&#x2019;Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 2018;19:213&#x2013;228. doi: 10.1038/nrm.2017.125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm.2017.125</ArticleId>
            <ArticleId IdType="pubmed">29339798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poggio M, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177:414&#x2013;427. doi: 10.1016/j.cell.2019.02.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2019.02.016</ArticleId>
            <ArticleId IdType="pmc">PMC6499401</ArticleId>
            <ArticleId IdType="pubmed">30951669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, Mellman I. Elements of cancer immunity and the cancer&#x2013;immune set point. Nature. 2017;541:321&#x2013;330. doi: 10.1038/nature21349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature21349</ArticleId>
            <ArticleId IdType="pubmed">28102259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, et al. 1D coordination polymer nanofibers for low-temperature photothermal therapy. Adv. Mater. 2017;29:1703588. doi: 10.1002/adma.201703588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201703588</ArticleId>
            <ArticleId IdType="pubmed">28833643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu. Rev. Med. 2014;65:185&#x2013;202. doi: 10.1146/annurev-med-092012-112807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-med-092012-112807</ArticleId>
            <ArticleId IdType="pubmed">24188664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;274. doi: 10.1038/s41586-019-1170-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efimova I, et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J. Immunother. Cancer. 2020;8:2020&#x2013;001369. doi: 10.1136/jitc-2020-001369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-001369</ArticleId>
            <ArticleId IdType="pmc">PMC7668384</ArticleId>
            <ArticleId IdType="pubmed">33188036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen Q, Liu J, Kang R, Zhou B, Tang D. The release and activity of HMGB1 in ferroptosis. Biochem Biophys. Res Commun. 2019;510:278&#x2013;283. doi: 10.1016/j.bbrc.2019.01.090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2019.01.090</ArticleId>
            <ArticleId IdType="pubmed">30686534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luberto C, et al. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J. Biol. Chem. 2002;277:41128&#x2013;41139. doi: 10.1074/jbc.M206747200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M206747200</ArticleId>
            <ArticleId IdType="pubmed">12154098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson JL, et al. Identification of neutrophil exocytosis inhibitors (Nexinhibs), small molecule inhibitors of neutrophil exocytosis and inflammation: DRUGGABILITY OF THE SMALL GTPase Rab27a. J. Biol. Chem. 2016;291:25965&#x2013;25982. doi: 10.1074/jbc.M116.741884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M116.741884</ArticleId>
            <ArticleId IdType="pmc">PMC5207069</ArticleId>
            <ArticleId IdType="pubmed">27702998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer. 2004;4:528&#x2013;539. doi: 10.1038/nrc1391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1391</ArticleId>
            <ArticleId IdType="pubmed">15229478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eliaz RE, Szoka FC., Jr Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001;61:2592&#x2013;2601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11289136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ying WW, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol. Cancer Ther. 2012;11:475&#x2013;484. doi: 10.1158/1535-7163.MCT-11-0755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-11-0755</ArticleId>
            <ArticleId IdType="pubmed">22144665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, et al. Activatable hyaluronic acid nanoparticle as a theranostic agent for optical/photoacoustic image-guided photothermal therapy. ACS Nano. 2014;8:12250&#x2013;12258. doi: 10.1021/nn506130t.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/nn506130t</ArticleId>
            <ArticleId IdType="pubmed">25402600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao S, et al. Oxygen-generating hybrid nanoparticles to enhance fluorescent/photoacoustic/ultrasound imaging guided tumor photodynamic therapy. Biomaterials. 2017;112:324&#x2013;335. doi: 10.1016/j.biomaterials.2016.10.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2016.10.030</ArticleId>
            <ArticleId IdType="pubmed">27776285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, et al. Exosomes mediate the cell-to-cell transmission of IFN-&#x3b1;-induced antiviral activity. Nat. Immunol. 2013;14:793&#x2013;803. doi: 10.1038/ni.2647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2647</ArticleId>
            <ArticleId IdType="pubmed">23832071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X, et al. Advances in engineering cells for cancer immunotherapy. Theranostics. 2019;9:7889&#x2013;7905. doi: 10.7150/thno.38583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.38583</ArticleId>
            <ArticleId IdType="pmc">PMC6831467</ArticleId>
            <ArticleId IdType="pubmed">31695806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31:107&#x2013;125. doi: 10.1038/s41422-020-00441-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-020-00441-1</ArticleId>
            <ArticleId IdType="pmc">PMC8026611</ArticleId>
            <ArticleId IdType="pubmed">33268902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu DS, et al. Inhibiting the system xC&#x2212;/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat. Commun. 2017;8:14844. doi: 10.1038/ncomms14844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms14844</ArticleId>
            <ArticleId IdType="pmc">PMC5379068</ArticleId>
            <ArticleId IdType="pubmed">28348409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688&#x2013;692. doi: 10.1038/s41586-019-1705-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1705-2</ArticleId>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57&#x2013;62. doi: 10.1038/nature14344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14344</ArticleId>
            <ArticleId IdType="pmc">PMC4455927</ArticleId>
            <ArticleId IdType="pubmed">25799988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golstein P, Griffiths GM. An early history of T cell-mediated cytotoxicity. Nat. Rev. Immunol. 2018;18:527&#x2013;535. doi: 10.1038/s41577-018-0009-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-018-0009-3</ArticleId>
            <ArticleId IdType="pubmed">29662120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braum&#xfc;ller H, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494:361&#x2013;365. doi: 10.1038/nature11824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11824</ArticleId>
            <ArticleId IdType="pubmed">23376950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382&#x2013;386. doi: 10.1038/s41586-018-0392-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-018-0392-8</ArticleId>
            <ArticleId IdType="pmc">PMC6095740</ArticleId>
            <ArticleId IdType="pubmed">30089911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theodoraki M-N, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. Clin. Cancer Res. 2018;24:896&#x2013;905. doi: 10.1158/1078-0432.CCR-17-2664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-2664</ArticleId>
            <ArticleId IdType="pmc">PMC6126905</ArticleId>
            <ArticleId IdType="pubmed">29233903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu P, et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc. Natl Acad. Sci. USA. 2012;109:6187&#x2013;6192. doi: 10.1073/pnas.1203479109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1203479109</ArticleId>
            <ArticleId IdType="pmc">PMC3341063</ArticleId>
            <ArticleId IdType="pubmed">22474386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crescitelli R, et al. Subpopulations of extracellular vesicles from human metastatic melanoma tissue identified by quantitative proteomics after optimized isolation. J. Extracell. Vesicles. 2020;9:1722433. doi: 10.1080/20013078.2020.1722433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/20013078.2020.1722433</ArticleId>
            <ArticleId IdType="pmc">PMC7034452</ArticleId>
            <ArticleId IdType="pubmed">32128073</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34396451</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1791-3004</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular medicine reports</Title>
          <ISOAbbreviation>Mol Med Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Erastin‑induced ferroptosis causes physiological and pathological changes in healthy tissues of mice.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">713</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/mmr.2021.12352</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is a non‑apoptotic form of cell death that relies on iron and lipid peroxidation, which is associated with multiple pathological processes in several diseases. Erastin is a small molecule capable of initiating ferroptotic cell death in cancer cells, which has shown great potential for cancer therapy. However, the physiological and pathological role of erastin‑induced ferroptosis on healthy tissues has not been well characterized. The present study intraperitoneally injected erastin into healthy mice to detect the metabolic changes of several tissues of mice. Erastin injection induced typical characteristics of ferroptosis with higher level of serum iron and malondialdehyde and lower level of glutathione and glutathione peroxidase 4 protein. Erastin injection enhanced iron deposition in the brain, duodenum, kidney and spleen of mice. Erastin‑induced ferroptosis altered the blood index values, causing mild cerebral infarction of brain and enlarged glomerular volume of kidney. It also promoted the growth of duodenal epithelium with thicker, longer and denser villi in erastin‑treated mice. The findings provided evidence that erastin induced ferroptosis and caused pathological changes in healthy tissues of mice. This suggested that the anti‑tumor drug erastin was somewhat toxic to healthy tissues.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Feed and Nutrition of Zhejiang Province, College of Animal Science, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Ben</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Feed and Nutrition of Zhejiang Province, College of Animal Science, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiong</LastName>
            <ForeName>Qingqing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Feed and Nutrition of Zhejiang Province, College of Animal Science, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Yunfei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolism, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Huahua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Feed and Nutrition of Zhejiang Province, College of Animal Science, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Greece</Country>
        <MedlineTA>Mol Med Rep</MedlineTA>
        <NlmUniqueID>101475259</NlmUniqueID>
        <ISSNLinking>1791-2997</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4Y8F71G49Q</RegistryNumber>
          <NameOfSubstance UI="D008315">Malondialdehyde</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008315" MajorTopicYN="N">Malondialdehyde</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">erastin</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">iron deposition</Keyword>
        <Keyword MajorTopicYN="N">lipid peroxidation</Keyword>
        <Keyword MajorTopicYN="N">morphology changes</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34396451</ArticleId>
        <ArticleId IdType="pmc">PMC8383038</ArticleId>
        <ArticleId IdType="doi">10.3892/mmr.2021.12352</ArticleId>
        <ArticleId IdType="pii">713</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29:347&#x2013;364. doi: 10.1038/s41422-019-0164-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-019-0164-5</ArticleId>
            <ArticleId IdType="pmc">PMC6796845</ArticleId>
            <ArticleId IdType="pubmed">30948788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D. Ferroptosis: Process and function. Cell Death Differ. 2016;23:369&#x2013;379. doi: 10.1038/cdd.2015.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.158</ArticleId>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia Y, Sun X, Luo Y, Stary CM. Ferroptosis contributes to isoflurane neurotoxicity. Front Mol Neurosci. 2019;11:486. doi: 10.3389/fnmol.2018.00486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2018.00486</ArticleId>
            <ArticleId IdType="pmc">PMC6333734</ArticleId>
            <ArticleId IdType="pubmed">30687003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belavgeni A, Meyer C, Stumpf J, Hugo C, Linkermann A. Ferroptosis and necroptosis in the kidneys. Cell Chem Biol. 2020;27:448&#x2013;462. doi: 10.1016/j.chembiol.2020.03.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2020.03.016</ArticleId>
            <ArticleId IdType="pubmed">32302582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada N, Karasawa T, Kimura H, Watanabe S, Komada T, Kamata R, Sampilvanjil A, Ito J, Nakagawa K, Kuwata H, et al. Ferroptosis driven by radical oxidation of n-6 polyunsaturated fatty acids mediates acetaminophen-induced acute liver failure. Cell Death Dis. 2020;11:144. doi: 10.1038/s41419-020-2334-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-2334-2</ArticleId>
            <ArticleId IdType="pmc">PMC7039960</ArticleId>
            <ArticleId IdType="pubmed">32094346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Feng D, Wang Z, Zhao Y, Sun R, Tian D, Liu D, Zhang F, Ning S, Yao J, Tian X. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ. 2019;26:2284&#x2013;2299. doi: 10.1038/s41418-019-0299-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-019-0299-4</ArticleId>
            <ArticleId IdType="pmc">PMC6889315</ArticleId>
            <ArticleId IdType="pubmed">30737476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3:285&#x2013;296. doi: 10.1016/S1535-6108(03)00050-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1535-6108(03)00050-3</ArticleId>
            <ArticleId IdType="pubmed">12676586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bridges RJ, Natale NR, Patel SA. System xc&#x2212; cystine/glutamate antiporter: An update on molecular pharmacology and roles within the CNS. Br J Pharmacol. 2012;165:20&#x2013;34. doi: 10.1111/j.1476-5381.2011.01480.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.2011.01480.x</ArticleId>
            <ArticleId IdType="pmc">PMC3252963</ArticleId>
            <ArticleId IdType="pubmed">21564084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics. 2019;19:e1800311. doi: 10.1002/pmic.201800311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pmic.201800311</ArticleId>
            <ArticleId IdType="pubmed">30888116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu T, Ding W, Ji X, Ao X, Liu Y, Yu W, Wang J. Molecular mechanisms of ferroptosis and its role in cancer therapy. J Cell Mol Med. 2019;23:4900&#x2013;4912. doi: 10.1111/jcmm.14511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.14511</ArticleId>
            <ArticleId IdType="pmc">PMC6653007</ArticleId>
            <ArticleId IdType="pubmed">31232522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Li Y, Zhang R, Wang F, Wang T, Jiao Y. The role of erastin in ferroptosis and its prospects in cancer therapy. Onco Targets Ther. 2020;13:5429&#x2013;5441. doi: 10.2147/OTT.S254995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S254995</ArticleId>
            <ArticleId IdType="pmc">PMC7295539</ArticleId>
            <ArticleId IdType="pubmed">32606760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huo H, Zhou Z, Qin J, Liu W, Wang B, Gu Y. Erastin disrupts mitochondrial permeability transition pore (mPTP) and induces apoptotic death of colorectal cancer cells. PLoS One. 2016;11:e0154605. doi: 10.1371/journal.pone.0154605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0154605</ArticleId>
            <ArticleId IdType="pmc">PMC4865238</ArticleId>
            <ArticleId IdType="pubmed">27171435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402&#x2013;408. doi: 10.1006/meth.2001.1262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId>
            <ArticleId IdType="pubmed">11846609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hambright WS, Fonseca RS, Chen L, Na R, Ran Q. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 2017;12:8&#x2013;17. doi: 10.1016/j.redox.2017.01.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2017.01.021</ArticleId>
            <ArticleId IdType="pmc">PMC5312549</ArticleId>
            <ArticleId IdType="pubmed">28212525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui M, Jiang X, Chen J, Yang H, Zhu Y. Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway. Biomed Pharmacother. 2018;106:125&#x2013;133. doi: 10.1016/j.biopha.2018.06.060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.06.060</ArticleId>
            <ArticleId IdType="pubmed">29957462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang X, Wang H, Han D, Xie E, Yang X, Wei J, Gu S, Gao F, Zhu N, Yin X, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci USA. 2019;116:2672&#x2013;2680. doi: 10.1073/pnas.1821022116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1821022116</ArticleId>
            <ArticleId IdType="pmc">PMC6377499</ArticleId>
            <ArticleId IdType="pubmed">30692261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imai H, Matsuoka M, Kumagai T, Sakamoto T, Koumura T. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis. Curr Top Microbiol Immunol. 2017;403:143&#x2013;170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28204974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youssef LA, Rebbaa A, Pampou S, Weisberg SP, Stockwell BR, Hod EA, Spitalnik SL. Increased erythrophagocytosis induces ferroptosis in red pulp macrophages in a mouse model of transfusion. Blood. 2018;131:2581&#x2013;2593. doi: 10.1182/blood-2017-12-822619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2017-12-822619</ArticleId>
            <ArticleId IdType="pmc">PMC5992863</ArticleId>
            <ArticleId IdType="pubmed">29666112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>NaveenKumar SK, SharathBabu BN, Hemshekhar M, Kemparaju K, Girish KS, Mugesh G. The role of reactive oxygen species and ferroptosis in heme-mediated activation of human platelets. ACS Chem Biol. 2018;13:1996&#x2013;2002. doi: 10.1021/acschembio.8b00458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.8b00458</ArticleId>
            <ArticleId IdType="pubmed">29869870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, He T, Yu K, Lu Q, Alkasir R, Guo G, Xue Y. Markers of iron status are associated with risk of hyperuricemia among Chinese adults: Nationwide population-based study. Nutrients. 2018;10:191. doi: 10.3390/nu10020191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu10020191</ArticleId>
            <ArticleId IdType="pmc">PMC5852767</ArticleId>
            <ArticleId IdType="pubmed">29425155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuo QZ, Lei P, Jackman KA, Li XL, Xiong H, Li XL, Liuyang ZY, Roisman L, Zhang ST, Ayton S, et al. Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. Mol Psychiatry. 2017;22:1520&#x2013;1530. doi: 10.1038/mp.2017.171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mp.2017.171</ArticleId>
            <ArticleId IdType="pubmed">28886009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanninen MM, Haapasalo J, Haapasalo H, Fleming RE, Britton RS, Bacon BR, Parkkila S. Expression of iron-related genes in human brain and brain tumors. BMC Neurosci. 2009;10:36. doi: 10.1186/1471-2202-10-36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2202-10-36</ArticleId>
            <ArticleId IdType="pmc">PMC2679039</ArticleId>
            <ArticleId IdType="pubmed">19386095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu M, Tao J, Yang Y, Tan S, Liu H, Jiang J, Zheng F, Wu B. Ferroptosis involves in intestinal epithelial cell death in ulcerative colitis. Cell Death Dis. 2020;11:86. doi: 10.1038/s41419-020-2299-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-2299-1</ArticleId>
            <ArticleId IdType="pmc">PMC6997394</ArticleId>
            <ArticleId IdType="pubmed">32015337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sim&#xf5;es F, Ousingsawat J, Wanitchakool P, Fonseca A, Cabrita I, Benedetto R, Schreiber R, Kunzelmann K. CFTR supports cell death through ROS-dependent activation of TMEM16F (anoctamin 6) Pflugers Arch. 2018;470:305&#x2013;314. doi: 10.1007/s00424-017-2065-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00424-017-2065-0</ArticleId>
            <ArticleId IdType="pubmed">28875346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schnabel D, Salas-Vidal E, Narv&#xe1;ez V, S&#xe1;nchez-Carbente Mdel R, Hern&#xe1;ndez-Garc&#xed;a D, Cuervo R, Covarrubias L. Expression and regulation of antioxidant enzymes in the developing limb support a function of ROS in interdigital cell death. Dev Biol. 2006;291:291&#x2013;299. doi: 10.1016/j.ydbio.2005.12.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ydbio.2005.12.023</ArticleId>
            <ArticleId IdType="pubmed">16445905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pu Y, Li S, Xiong H, Zhang X, Wang Y, Du H. Iron promotes intestinal development in neonatal piglets. Nutrients. 2018;10:726. doi: 10.3390/nu10060726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu10060726</ArticleId>
            <ArticleId IdType="pmc">PMC6024698</ArticleId>
            <ArticleId IdType="pubmed">29874829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SJ, Cho SS, Kim KM, Yang JH, Kim JH, Jeong EH, Yang JW, Han CY, Ku SK, Cho IJ, Ki SH. Protective effect of sestrin2 against iron overload and ferroptosis-induced liver injury. Toxicol Appl Pharmacol. 2019;379:114665. doi: 10.1016/j.taap.2019.114665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2019.114665</ArticleId>
            <ArticleId IdType="pubmed">31323261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong Z, Liu R, Cheng Y. Artesunate alleviates liver fibrosis by regulating ferroptosis signaling pathway. Biomed Pharmacother. 2019;109:2043&#x2013;2053. doi: 10.1016/j.biopha.2018.11.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.11.030</ArticleId>
            <ArticleId IdType="pubmed">30551460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsurusaki S, Tsuchiya Y, Koumura T, Nakasone M, Sakamoto T, Matsuoka M, Imai H, Yuet-Yin Kok C, Okochi H, Nakano H, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis. 2019;10:449. doi: 10.1038/s41419-019-1678-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-1678-y</ArticleId>
            <ArticleId IdType="pmc">PMC6579767</ArticleId>
            <ArticleId IdType="pubmed">31209199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li T, Liu X, Jiang L, Manfredi J, Zha S, Gu W. Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging. Oncotarget. 2016;7:11838&#x2013;11849. doi: 10.18632/oncotarget.7864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.7864</ArticleId>
            <ArticleId IdType="pmc">PMC4914251</ArticleId>
            <ArticleId IdType="pubmed">26943586</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34093872</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1838-7640</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>14</Issue>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Theranostics</Title>
          <ISOAbbreviation>Theranostics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>7072</StartPage>
          <EndPage>7091</EndPage>
          <MedlinePgn>7072-7091</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.57803</ELocationID>
        <Abstract>
          <AbstractText>Simultaneous targeting of both the tumor microenvironment and cancer cells by a single nanomedicine has not been reported to date. Here, we report the dual properties of zero-valent-iron nanoparticle (ZVI-NP) to induce cancer-specific cytotoxicity and anti-cancer immunity. Methods: Cancer-specific cytotoxicity induced by ZVI-NP was determined by MTT assay. Mitochondria functional assay, immunofluorescence staining, Western blot, RT-qPCR, and ChIP-qPCR assays were used to dissect the mechanism underlying ZVI-NP-induced ferroptotic cancer cell death. The therapeutic potential of ZVI-NP was evaluated in immunocompetent mice and humanized mice. Immune cell profiles of allografts and ex vivo cultured immune cells were examined by flow cytometry analysis, RT-qPCR assay, and immunofluorescence. Results: ZVI-NP caused mitochondria dysfunction, intracellular oxidative stress, and lipid peroxidation, leading to ferroptotic death of lung cancer cells. Degradation of NRF2 by GSK3/β-TrCP through AMPK/mTOR activation was enhanced in such cancer-specific ferroptosis. In addition, ZVI-NP attenuated self-renewal ability of cancer and downregulated angiogenesis-related genes. Importantly, ZVI-NP augmented anti-tumor immunity by shifting pro-tumor M2 macrophages to anti-tumor M1, decreasing the population of regulatory T cells, downregulating PD-1 and CTLA4 in CD8[+] T cells to potentiate their cytolytic activity against cancer cells, while attenuating PD-L1 expression in cancer cells in vitro and in tumor-bearing immunocompetent mice. In particular, ZVI-NPs preferentially accumulated in tumor and lung tissues, leading to prominent suppression of tumor growth and metastasis. Conclusions: This dual-functional nanomedicine established an effective strategy to synergistically induce ferroptotic cancer cell death and reprogram the immunosuppressive microenvironment, which highlights the potential of ZVI-NP as an advanced integrated anti-cancer strategy.</AbstractText>
          <CopyrightInformation>&#xa9; The author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hsieh</LastName>
            <ForeName>Chih-Hsiung</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsieh</LastName>
            <ForeName>Hung-Chia</ForeName>
            <Initials>HC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shih</LastName>
            <ForeName>Fu-Shiuan</ForeName>
            <Initials>FS</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Oral Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Pei-Wen</ForeName>
            <Initials>PW</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Oral Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Li-Xing</ForeName>
            <Initials>LX</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Oral Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shieh</LastName>
            <ForeName>Dar-Bin</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Oral Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Basic Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Applied Nanomedicine, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Micro/Nano Science and Technology, Advanced Optoelectronic Technology Center, Innovation Center for Advanced Medical Device Technology, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yi-Ching</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Basic Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>Theranostics</MedlineTA>
        <NlmUniqueID>101552395</NlmUniqueID>
        <ISSNLinking>1838-7640</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495636">Nfe2l2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.-</RegistryNumber>
          <NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.26</RegistryNumber>
          <NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.3</RegistryNumber>
          <NameOfSubstance UI="D000091162">AMP-Activated Protein Kinase Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000091162" MajorTopicYN="N">AMP-Activated Protein Kinase Kinases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064591" MajorTopicYN="N">Allografts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047369" MajorTopicYN="N">Chromatin Immunoprecipitation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053768" MajorTopicYN="N">Metal Nanoparticles</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">NRF2</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">lung cancer</Keyword>
        <Keyword MajorTopicYN="N">nanoparticle</Keyword>
        <Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34093872</ArticleId>
        <ArticleId IdType="pmc">PMC8171079</ArticleId>
        <ArticleId IdType="doi">10.7150/thno.57803</ArticleId>
        <ArticleId IdType="pii">thnov11p7072</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zou Y, Wang X, Khan A, Wang P, Liu Y, Alsaedi A. et al. Environmental remediation and application of nanoscale zero-valent iron and its composites for the removal of heavy metal ions: a review. Environ Sci Technol. 2016;50:7290&#x2013;304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27331413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nam S, Tratnyek PG. Reduction of azo dyes with zero-valent iron. Water Res. 2000;34:1837&#x2013;45.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang LX, Wu YN, Wang PW, Huang KJ, Su WC, Shieh DB. Silver-coated zero-valent iron nanoparticles enhance cancer therapy in mice through lysosome-dependent dual programed cell death pathways: triggering simultaneous apoptosis and autophagy only in cancerous cells. J Mater Chem B. 2020;8:4122&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32267258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyamoto T, Takahashi S, Ito H, Inagaki H, Noishiki Y. Tissue biocompatibility of cellulose and its derivatives. J Biomed Mater Res. 1989;23:125&#x2013;33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2708402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang KJ, Wei YH, Chiu YC, Wu SR, Shieh DB. Assessment of zero-valent iron-based nanotherapeutics for ferroptosis induction and resensitization strategy in cancer cells. Biomater Sci. 2019;7:1311&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30734774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X. et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29:347&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6796845</ArticleId>
            <ArticleId IdType="pubmed">30948788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Stockwell BR. The hallmarks of ferroptosis. Annu Rev Cancer Biol. 2019;3:35&#x2013;54.</Citation>
        </Reference>
        <Reference>
          <Citation>Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: a clinician's perspective. Semin Oncol. 2014;41(Suppl 2):S1&#x2013;S16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24576654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163&#x2013;73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29433850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443&#x2013;54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3544539</ArticleId>
            <ArticleId IdType="pubmed">22658127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7391259</ArticleId>
            <ArticleId IdType="pubmed">29567705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4400238</ArticleId>
            <ArticleId IdType="pubmed">25858804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Xia J, Ma Q, Zhu W, Gao Z, Han S. et al. Tumor microenvironment-triggered nanosystems as dual-relief tumor hypoxia immunomodulators for enhanced phototherapy. Theranostics. 2020;10:9132&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7415819</ArticleId>
            <ArticleId IdType="pubmed">32802183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu PC, Hsiao HT, Lin YC, Shieh DB, Liu YC. The analgesia efficiency of ultrasmall magnetic iron oxide nanoparticles in mice chronic inflammatory pain model. Nanomedicine. 2017;13:1975&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28539274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Zhang Z, Xue Y, Wang G, Cheng Y, Pan Y. et al. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I: C) promote melanoma regression. Theranostics. 2018;8:6307&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6299704</ArticleId>
            <ArticleId IdType="pubmed">30613299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian X, Shi Z, Qi H, Zhao M, Huang K, Han D. et al. A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors. Theranostics. 2019;9:7616&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6831455</ArticleId>
            <ArticleId IdType="pubmed">31695790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmid D, Park CG, Hartl CA, Subedi N, Cartwright AN, Puerto RB. et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun. 2017;8:1747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5700944</ArticleId>
            <ArticleId IdType="pubmed">29170511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joseph MM, Ramya AN, Vijayan VM, Nair JB, Bastian BT, Pillai RK. et al. Targeted theranostic nano vehicle endorsed with self-destruction and immunostimulatory features to circumvent drug resistance and wipe-out tumor reinitiating cancer stem cells. Small. 2020;16:e2003309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32797715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis MD, de Leenheer E, Fishman S, Siew LK, Gross G, Wong FS. A reproducible method for the expansion of mouse CD8+ T lymphocytes. J Immunol Methods. 2015;417:134&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4352898</ArticleId>
            <ArticleId IdType="pubmed">25602136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu X, Tao L, Rivera A, Williamson S, Song XT, Ahmed N. et al. A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS One. 2010;5:e11867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2912327</ArticleId>
            <ArticleId IdType="pubmed">20686618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H, Guo P, Xie X, Wang Y, Chen G. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med. 2017;21:648&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5345622</ArticleId>
            <ArticleId IdType="pubmed">27860262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10:9&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24346035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada S. Iron-induced tissue damage and cancer: the role of reactive oxygen species-free radicals. Pathol Int. 1996;46:311&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8809878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014;39:199&#x2013;218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24647116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH. et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I. et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31634899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD. et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13:76&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC316370</ArticleId>
            <ArticleId IdType="pubmed">9887101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol. 2011;31:1121&#x2013;33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3067901</ArticleId>
            <ArticleId IdType="pubmed">21245377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO. et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006;3:e420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1584412</ArticleId>
            <ArticleId IdType="pubmed">17020408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taguchi K, Shimada M, Fujii S, Sumi D, Pan X, Yamano S. et al. Redox cycling of 9,10-phenanthraquinone to cause oxidative stress is terminated through its monoglucuronide conjugation in human pulmonary epithelial A549 cells. Free Radic Biol Med. 2008;44:1645&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18294972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He L, Gomes AP, Wang X, Yoon SO, Lee G, Nagiec MJ. et al. mTORC1 promotes metabolic reprogramming by the suppression of GSK3-dependent Foxk1 phosphorylation. Mol Cell. 2018;70:949&#x2013;60. e4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6591025</ArticleId>
            <ArticleId IdType="pubmed">29861159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Qian G, Zhang QQ, Yao Y, Wang D, Chen ZG. et al. mTORC2 suppresses GSK3-dependent Snail degradation to positively regulate cancer cell invasion and metastasis. Cancer Res. 2019;79:3725&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31142514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koo J, Yue P, Gal AA, Khuri FR, Sun SY. Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth. Cancer Res. 2014;74:2555&#x2013;68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4029841</ArticleId>
            <ArticleId IdType="pubmed">24626091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Q, Zhao Y, Guo J, Zhao S, Fei C, Xiao C. et al. Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway. Cell Death Dis. 2018;9:515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5938711</ArticleId>
            <ArticleId IdType="pubmed">29725013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitamura H, Motohashi H. NRF2 addiction in cancer cells. Cancer Sci. 2018;109:900&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5891176</ArticleId>
            <ArticleId IdType="pubmed">29450944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammad A, Namani A, Elshaer M, Wang XJ, Tang X. "NRF2 addiction" in lung cancer cells and its impact on cancer therapy. Cancer Lett. 2019;467:40&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31574294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Recalcati S, Locati M, Marini A, Santambrogio P, Zaninotto F, De Pizzol M. et al. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol. 2010;40:824&#x2013;35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20039303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa da Silva M, Breckwoldt MO, Vinchi F, Correia MP, Stojanovic A, Thielmann CM. et al. Iron induces anti-tumor activity in tumor-associated macrophages. Front Immunol. 2017;8:1479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5682327</ArticleId>
            <ArticleId IdType="pubmed">29167669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perica K, Tu A, Richter A, Bieler JG, Edidin M, Schneck JP. Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity. ACS Nano. 2014;8:2252&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4004316</ArticleId>
            <ArticleId IdType="pubmed">24564881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Yin W, Zhu L, Li J, Yao Y, Chen F. et al. Iron drives T helper cell pathogenicity by promoting RNA-binding protein PCBP1-mediated proinflammatory cytokine production. Immunity. 2018;49:80&#x2013;92. e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29958803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arensman MD, Yang XS, Leahy DM, Toral-Barza L, Mileski M, Rosfjord EC. et al. Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity. Proc Natl Acad Sci U S A. 2019;116:9533&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6511047</ArticleId>
            <ArticleId IdType="pubmed">31019077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lan G, Ni K, Xu Z, Veroneau SS, Song Y, Lin W. Nanoscale metal-organic framework overcomes hypoxia for photodynamic therapy primed cancer immunotherapy. J Am Chem Soc. 2018;140:5670&#x2013;3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533908</ArticleId>
            <ArticleId IdType="pubmed">29665677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi C, Liu T, Guo Z, Zhuang R, Zhang X, Chen X. Reprogramming tumor-associated macrophages by nanoparticle-based reactive oxygen species photogeneration. Nano Lett. 2018;18:7330&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30339753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dingjan I, Verboogen DR, Paardekooper LM, Revelo NH, Sittig SP, Visser LJ. et al. Lipid peroxidation causes endosomal antigen release for cross-presentation. Sci Rep. 2016;6:22064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4764948</ArticleId>
            <ArticleId IdType="pubmed">26907999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen Q, Liu J, Kang R, Zhou B, Tang D. The release and activity of HMGB1 in ferroptosis. Biochem Biophys Res Commun. 2019;510:278&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30686534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proneth B, Conrad M. Ferroptosis and necroinflammation, a yet poorly explored link. Cell Death Differ. 2019;26:14&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6294786</ArticleId>
            <ArticleId IdType="pubmed">30082768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida M, Minagawa S, Araya J, Sakamoto T, Hara H, Tsubouchi K. et al. Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis. Nat Commun. 2019;10:3145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6637122</ArticleId>
            <ArticleId IdType="pubmed">31316058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efimova I, Catanzaro E, Van der Meeren L, Turubanova VD, Hammad H, Mishchenko TA, Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer. 2020. 8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7668384</ArticleId>
            <ArticleId IdType="pubmed">33188036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L. et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9:1673&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6891128</ArticleId>
            <ArticleId IdType="pubmed">31554642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK. et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pham BTT, Colvin EK, Pham NTH, Kim BJ, Fuller ES, Moon EA. et al. Biodistribution and clearance of stable superparamagnetic maghemite iron oxide nanoparticles in mice following intraperitoneal administration. Int J Mol Sci. 2018;19:205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5796154</ArticleId>
            <ArticleId IdType="pubmed">29320407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Wang R, Li J, Ding L, Wang X, Shi X. et al. Facile synthesis of lactobionic acid-targeted iron oxide nanoparticles with ultrahigh relaxivity for targeted MR imaging of an orthotopic model of human hepatocellular carcinoma. Part Part Syst Charact. 2017;34:1600113.</Citation>
        </Reference>
        <Reference>
          <Citation>Gobbo OL, Wetterling F, Vaes P, Teughels S, Markos F, Edge D. et al. Biodistribution and pharmacokinetic studies of SPION using particle electron paramagnetic resonance, MRI and ICP-MS. Nanomedicine (Lond) 2015;10:1751&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26080697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumoto Y, Nichols JW, Toh K, Nomoto T, Cabral H, Miura Y. et al. Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat Nanotechnol. 2016;11:533&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26878143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang LX, Wu YN, Wang PW, Su WC, Shieh DB. Iron release profile of silica-modified zero-valent iron NPs and their implication in cancer therapy. Int J Mol Sci. 2019. 20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6770483</ArticleId>
            <ArticleId IdType="pubmed">31487938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sujai PT, Joseph MM, Saranya G, Nair JB, Murali VP, Maiti KK. Surface charge modulates the internalization vs. penetration of gold nanoparticles: comprehensive scrutiny on monolayer cancer cells, multicellular spheroids and solid tumors by SERS modality. Nanoscale. 2020;12:6971&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32202584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu G, Gao J, Ai H, Chen X. Applications and potential toxicity of magnetic iron oxide nanoparticles. Small. 2013;9:1533&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23019129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28985214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D. et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91:1071&#x2013;121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3258432</ArticleId>
            <ArticleId IdType="pubmed">21742796</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34062295</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-8769</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>152</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>World neurosurgery</Title>
          <ISOAbbreviation>World Neurosurg</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptosis Suppressive Genes Correlate with Immunosuppression in Glioblastoma.</ArticleTitle>
        <Pagination>
          <StartPage>e436</StartPage>
          <EndPage>e448</EndPage>
          <MedlinePgn>e436-e448</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.wneu.2021.05.098</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1878-8750(21)00793-2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Glioblastoma (GBM) is the most lethal primary tumor in the central nervous system. Ferroptosis is a type of programmed iron-dependent cell death. In the present study, we aimed to identify prognostic ferroptosis-related genes and their role in tumor immunity.</AbstractText>
          <AbstractText Label="METHODS">We used differential and survival analysis and The Cancer Genome Atlas (TCGA) GBM RNA sequencing data. We also used systematic bioinformatic methods.</AbstractText>
          <AbstractText Label="RESULTS">Using differential and survival analysis, we found that a ferroptosis suppressor was predominant within ferroptosis-related genes in TCGA GBM RNA sequencing data. By integrating TCGA and gene expression omnibus GBM cohorts, 12 dysregulated ferroptosis suppressors were detected. Among the suppressors, CD44, heat shock protein family B (small) member 1 (HSPB1), and solute carrier family 40 member 1 (SLC40A1) were relevant to overall survival. Using systematic bioinformatic methods, we observed that ferroptosis suppressor expression correlated with immunosuppression, which could be attributed to T-cell exhaustion and cytotoxic T-lymphocyte evasion. Finally, we observed that a potential ferroptosis-inducing drug, acetaminophen, interacted with CD44, HSPB1, and SLC40A1.</AbstractText>
          <AbstractText Label="CONCLUSIONS">The ferroptosis suppressors CD44, HSPB1, and SLC40A1 were significantly associated with prognosis in GBM and correlated with immunosuppression (i.e., T-cell exhaustion and cytotoxic T-lymphocyte evasion). Acetaminophen might have an antitumor function in GBM by regulating CD44, HSPB1, and SLC40A1 to induce ferroptosis. Our results are expected to be of great significance in developing new immunotherapy strategies for GBM.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Shaokang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Yaofeng</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mo</LastName>
            <ForeName>Yunzhao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Xiangdong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yuxuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jianqiu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Yixin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ke</LastName>
            <ForeName>Yiquan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital, Southern Medical University, Guangzhou, China. Electronic address: kyquan@smu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>World Neurosurg</MedlineTA>
        <NlmUniqueID>101528275</NlmUniqueID>
        <ISSNLinking>1878-8750</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497483">CD44 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C057725">HSPB1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018960">Hyaluronan Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C409881">metal transporting protein 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>362O9ITL9D</RegistryNumber>
          <NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000082" MajorTopicYN="N">Acetaminophen</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027682" MajorTopicYN="N">Cation Transport Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018960" MajorTopicYN="N">Hyaluronan Receptors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007165" MajorTopicYN="Y">Immunosuppression Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Acetaminophen</Keyword>
        <Keyword MajorTopicYN="N">CTL evasion</Keyword>
        <Keyword MajorTopicYN="N">Ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">GBM</Keyword>
        <Keyword MajorTopicYN="N">Immunosuppression</Keyword>
        <Keyword MajorTopicYN="N">T-cell exhaustion</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>20</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34062295</ArticleId>
        <ArticleId IdType="doi">10.1016/j.wneu.2021.05.098</ArticleId>
        <ArticleId IdType="pii">S1878-8750(21)00793-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33926261</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>07</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1535-3699</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>246</Volume>
            <Issue>13</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Experimental biology and medicine (Maywood, N.J.)</Title>
          <ISOAbbreviation>Exp Biol Med (Maywood)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibitory effect of hydnocarpin D on T-cell acute lymphoblastic leukemia via induction of autophagy-dependent ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>1541</StartPage>
          <EndPage>1553</EndPage>
          <MedlinePgn>1541-1553</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/15353702211004870</ELocationID>
        <Abstract>
          <AbstractText>Hydnocarpin D (HD) is a bioactive flavonolignan compound that possesses promising anti-tumor activity, although the mechanism is not fully understood. Using T cell acute lymphoblastic leukemia (T-ALL) cell lines Jurkat and Molt-4 as model system, we found that HD suppressed T-ALL proliferation in vitro, via induction of cell cycle arrest and subsequent apoptosis. Furthermore, HD increased the LC3-II levels and the formation of autophagolysosome vacuoles, both of which are markers for autophagy. The inhibition of autophagy by either knockdown of ATG5/7 or pre-treatment of 3-MA partially rescued HD-induced apoptosis, thus suggesting that autophagy enhanced the efficacy of HD. Interestingly, this cytotoxic autophagy triggered ferroptosis, as evidenced by the accumulation of lipid ROS and decrease of GSH and GPX4, while inhibition of autophagy impeded ferroptotic cell death. Our study suggests that HD triggers multiple cell death processes and is an interesting compound that should be evaluated in future preclinical studies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lou</LastName>
            <ForeName>Siyue</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hong</LastName>
            <ForeName>Huanwu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maihesuti</LastName>
            <ForeName>Liwaliding</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Plant Resources and Chemistry of Arid Zone, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Chemical Sciences, University of Chinese Academy of Sciences, Beijing, 100049, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Hang</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Zhihui</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Lili</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Shasha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kai</LastName>
            <ForeName>Guoyin</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Guozheng</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-5730-9549</Identifier>
            <AffiliationInfo>
              <Affiliation>College of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan 243002, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Huajun</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0001-8643-4261</Identifier>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Exp Biol Med (Maywood)</MedlineTA>
        <NlmUniqueID>100973463</NlmUniqueID>
        <ISSNLinking>1535-3699</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071183">Autophagy-Related Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D044947">Flavonolignans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>51419-48-8</RegistryNumber>
          <NameOfSubstance UI="C073621">hydnocarpin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.9</RegistryNumber>
          <NameOfSubstance UI="D005979">Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071183" MajorTopicYN="N">Autophagy-Related Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044947" MajorTopicYN="N">Flavonolignans</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005979" MajorTopicYN="N">Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054198" MajorTopicYN="N">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Hydnocarpin D</Keyword>
        <Keyword MajorTopicYN="N">T-ALL</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
      </KeywordList>
      <CoiStatement>DECLARATION OF CONFLICTING INTERESTS: The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33926261</ArticleId>
        <ArticleId IdType="pmc">PMC8283251</ArticleId>
        <ArticleId IdType="doi">10.1177/15353702211004870</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371:1030&#x2013;43</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18358930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34&#x2013;43</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3251235</ArticleId>
            <ArticleId IdType="pubmed">22086414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Frankfurt O, Greer JP, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Mattison R, Park J, Rubnitz J, Saad A, Uy GL, Wang ES, Gregory KM, Ogba N. NCCN guidelines insights: Acute lymphoblastic leukemia, version 12017. J Natl Compr Canc Netw 2017; 15:1091102</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28874594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raetz EA, Teachey DTT. Cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016; 2016:580&#x2013;8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6142501</ArticleId>
            <ArticleId IdType="pubmed">27913532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kansagra A, Dahiya S, Litzow M. Continuing challenges and current issues in acute lymphoblastic leukemia. Leuk Lymphoma 2018; 59:526&#x2013;41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28604239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jahanafrooz Z, Motamed N, Rinner B, Mokhtarzadeh A, Baradaran B. Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator. Life Sci 2018; 213:236&#x2013;47</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30308184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahoo MR, Dhanabal SP, Jadhav AN, Reddy V, Muguli G, Babu UV, Rangesh P. Hydnocarpus: an ethnopharmacological, phytochemical and pharmacological review. J Ethnopharmacol 2014; 154:17&#x2013;25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24732111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guz NR, Stermitz FR. Synthesis and structures of regioisomeric hydnocarpin-type flavonolignans. J Nat Prod 2000; 63:1140&#x2013;5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10978213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy SV, Tiwari AK, Kumar US, Rao RJ, Rao JM. Free radical scavenging, enzyme inhibitory constituents from antidiabetic ayurvedic medicinal plant hydnocarpus wightiana blume. Phytother Res 2005; 19:277&#x2013;81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16041766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma DK, Hall IH. Hypolipidemic, anti-inflammatory, and antineoplastic activity and cytotoxicity of flavonolignans isolated from hydnocarpus wightiana seeds. J Nat Prod 1991; 54:1298&#x2013;302</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1800632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee MA, Kim WK, Park HJ, Kang SS, Lee SK. Anti-proliferative activity of hydnocarpin, a natural lignan, is associated with the suppression of wnt/beta-catenin signaling pathway in Colon cancer cells. Bioorg Med Chem Lett 2013; 23:5511&#x2013;4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24018191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bueno Perez L, Pan L, Sass E, Gupta SV, Lehman A, Kinghorn AD, Lucas DM. Potentiating effect of the flavonolignan (-)-hydnocarpin in combination with vincristine in a sensitive and Pgp-expressing acute lymphoblastic leukemia cell line. Phytother Res 2013; 27:1735&#x2013;8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3639301</ArticleId>
            <ArticleId IdType="pubmed">23280566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Alg&#xfc;l H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, B&#xe1;nhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolom&#xe9; A, Bassham DC, Bassi MT, Bast RC, Jr, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Jr., Becker C, Beckham JD, B&#xe9;dard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, B&#xe9;nard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, B&#xf6;ckler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouch&#xe9; M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, B&#xfc;tikofer P, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Camougrand N, Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Ce&#xf1;a V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen G, Chen H, Chen JW, Chen JK, Chen M, Chen M, Chen P, Chen Q, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen W, Chen X, Chen YH, Chen YG, Chen Y, Chen Y, Chen Y, Chen YJ, Chen YQ, Chen Y, Chen Z, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, Ciarcia R, Ciechomska IA, Ciriolo MR, Cirone M, Claerhout S, Clague MJ, Cl&#xe0;ria J, Clarke PG, Clarke R, Clementi E, Cleyrat C, Cnop M, Coccia EM, Cocco T, Codogno P, Coers J, Cohen EE, Colecchia D, Coletto L, Coll NS, Colucci-Guyon E, Comincini S, Condello M, Cook KL, Coombs GH, Cooper CD, Cooper JM, Coppens I, Corasaniti MT, Corazzari M, Corbalan R, Corcelle-Termeau E, Cordero MD, Corral-Ramos C, Corti O, Cossarizza A, Costelli P, Costes S, Cotman SL, Coto-Montes A, Cottet S, Couve E, Covey LR, Cowart LA, Cox JS, Coxon FP, Coyne CB, Cragg MS, Craven RJ, Crepaldi T, Crespo JL, Criollo A, Crippa V, Cruz MT, Cuervo AM, Cuezva JM, Cui T, Cutillas PR, Czaja MJ, Czyzyk-Krzeska MF, Dagda RK, Dahmen U, Dai C, Dai W, Dai Y, Dalby KN, Dalla Valle L, Dalmasso G, D'Amelio M, Damme M, Darfeuille-Michaud A, Dargemont C, Darley-Usmar VM, Dasarathy S, Dasgupta B, Dash S, Dass CR, Davey HM, Davids LM, D&#xe1;vila D, Davis RJ, Dawson TM, Dawson VL, Daza P, de Belleroche J, de Figueiredo P, de Figueiredo RC, de la Fuente J, De Martino L, De Matteis A, De Meyer GR, De Milito A, De Santi M, de Souza W, De Tata V, De Zio D, Debnath J, Dechant R, Decuypere JP, Deegan S, Dehay B, Del Bello B, Del Re DP, Delage-Mourroux R, Delbridge LM, Deldicque L, Delorme-Axford E, Deng Y, Dengjel J, Denizot M, Dent P, Der CJ, Deretic V, Derrien B, Deutsch E, Devarenne TP, Devenish RJ, Di Bartolomeo S, Di Daniele N, Di Domenico F, Di Nardo A, Di Paola S, Di Pietro A, Di Renzo L, DiAntonio A, D&#xed;az-Araya G, D&#xed;az-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dickey CA, Dickson RC, Diederich M, Digard P, Dikic I, Dinesh-Kumar SP, Ding C, Ding WX, Ding Z, Dini L, Distler JH, Diwan A, Djavaheri-Mergny M, Dmytruk K, Dobson RC, Doetsch V, Dokladny K, Dokudovskaya S, Donadelli M, Dong XC, Dong X, Dong Z, Donohue TM, Jr, Doran KS, D'Orazi G, Dorn GW, 2nd, Dosenko V, Dridi S, Drucker L, Du J, Du LL, Du L, du Toit A, Dua P, Duan L, Duann P, Dubey VK, Duchen MR, Duchosal MA, Duez H, Dugail I, Dumit VI, Duncan MC, Dunlop EA, Dunn WA, Jr, Dupont N, Dupuis L, Dur&#xe1;n RV, Durcan TM, Duvezin-Caubet S, Duvvuri U, Eapen V, Ebrahimi-Fakhari D, Echard A, Eckhart L, Edelstein CL, Edinger AL, Eichinger L, Eisenberg T, Eisenberg-Lerner A, Eissa NT, El-Deiry WS, El-Khoury V, Elazar Z, Eldar-Finkelman H, Elliott CJ, Emanuele E, Emmenegger U, Engedal N, Engelbrecht AM, Engelender S, Enserink JM, Erdmann R, Erenpreisa J, Eri R, Eriksen JL, Erman A, Escalante R, Eskelinen EL, Espert L, Esteban-Mart&#xed;nez L, Evans TJ, Fabri M, Fabrias G, Fabrizi C, Facchiano A, F&#xe6;rgeman NJ, Faggioni A, Fairlie WD, Fan C, Fan D, Fan J, Fang S, Fanto M, Fanzani A, Farkas T, Faure M, Favier FB, Fearnhead H, Federici M, Fei E, Felizardo TC, Feng H, Feng Y, Feng Y, Ferguson TA, Fern&#xe1;ndez &#xc1; F, Fernandez-Barrena MG, Fernandez-Checa JC, Fern&#xe1;ndez-L&#xf3;pez A, Fernandez-Zapico ME, Feron O, Ferraro E, Ferreira-Halder CV, Fesus L, Feuer R, Fiesel FC, Filippi-Chiela EC, Filomeni G, Fimia GM, Fingert JH, Finkbeiner S, Finkel T, Fiorito F, Fisher PB, Flajolet M, Flamigni F, Florey O, Florio S, Floto RA, Folini M, Follo C, Fon EA, Fornai F, Fortunato F, Fraldi A, Franco R, Francois A, Fran&#xe7;ois A, Frankel LB, Fraser ID, Frey N, Freyssenet DG, Frezza C, Friedman SL, Frigo DE, Fu D, Fuentes JM, Fueyo J, Fujitani Y, Fujiwara Y, Fujiya M, Fukuda M, Fulda S, Fusco C, Gabryel B, Gaestel M, Gailly P, Gajewska M, Galadari S, Galili G, Galindo I, Galindo MF, Galliciotti G, Galluzzi L, Galluzzi L, Galy V, Gammoh N, Gandy S, Ganesan AK, Ganesan S, Ganley IG, Gannag&#xe9; M, Gao FB, Gao F, Gao JX, Garc&#xed;a Nannig L, Garc&#xed;a V&#xe9;scovi E, Garcia-Mac&#xed;a M, Garcia-Ruiz C, Garg AD, Garg PK, Gargini R, Gassen NC, Gatica D, Gatti E, Gavard J, Gavathiotis E, Ge L, Ge P, Ge S, Gean PW, Gelmetti V, Genazzani AA, Geng J, Genschik P, Gerner L, Gestwicki JE, Gewirtz DA, Ghavami S, Ghigo E, Ghosh D, Giammarioli AM, Giampieri F, Giampietri C, Giatromanolaki A, Gibbings DJ, Gibellini L, Gibson SB, Ginet V, Giordano A, Giorgini F, Giovannetti E, Girardin SE, Gispert S, Giuliano S, Gladson CL, Glavic A, Gleave M, Godefroy N, Gogal RM, Jr, Gokulan K, Goldman GH, Goletti D, Goligorsky MS, Gomes AV, Gomes LC, Gomez H, Gomez-Manzano C, G&#xf3;mez-S&#xe1;nchez R, Gon&#xe7;alves DA, Goncu E, Gong Q, Gongora C, Gonzalez CB, Gonzalez-Alegre P, Gonzalez-Cabo P, Gonz&#xe1;lez-Polo RA, Goping IS, Gorbea C, Gorbunov NV, Goring DR, Gorman AM, Gorski SM, Goruppi S, Goto-Yamada S, Gotor C, Gottlieb RA, Gozes I, Gozuacik D, Graba Y, Graef M, Granato GE, Grant GD, Grant S, Gravina GL, Green DR, Greenhough A, Greenwood MT, Grimaldi B, Gros F, Grose C, Groulx JF, Gruber F, Grumati P, Grune T, Guan JL, Guan KL, Guerra B, Guillen C, Gulshan K, Gunst J, Guo C, Guo L, Guo M, Guo W, Guo XG, Gust AA, Gustafsson &#xc5; B, Gutierrez E, Gutierrez MG, Gwak HS, Haas A, Haber JE, Hadano S, Hagedorn M, Hahn DR, Halayko AJ, Hamacher-Brady A, Hamada K, Hamai A, Hamann A, Hamasaki M, Hamer I, Hamid Q, Hammond EM, Han F, Han W, Handa JT, Hanover JA, Hansen M, Harada M, Harhaji-Trajkovic L, Harper JW, Harrath AH, Harris AL, Harris J, Hasler U, Hasselblatt P, Hasui K, Hawley RG, Hawley TS, He C, He CY, He F, He G, He RR, He XH, He YW, He YY, Heath JK, H&#xe9;bert MJ, Heinzen RA, Helgason GV, Hensel M, Henske EP, Her C, Herman PK, Hern&#xe1;ndez A, Hernandez C, Hern&#xe1;ndez-Tiedra S, Hetz C, Hiesinger PR, Higaki K, Hilfiker S, Hill BG, Hill JA, Hill WD, Hino K, Hofius D, Hofman P, H&#xf6;glinger GU, H&#xf6;hfeld J, Holz MK, Hong Y, Hood DA, Hoozemans JJ, Hoppe T, Hsu C, Hsu CY, Hsu LC, Hu D, Hu G, Hu HM, Hu H, Hu MC, Hu YC, Hu ZW, Hua F, Hua Y, Huang C, Huang HL, Huang KH, Huang KY, Huang S, Huang S, Huang WP, Huang YR, Huang Y, Huang Y, Huber TB, Huebbe P, Huh WK, Hulmi JJ, Hur GM, Hurley JH, Husak Z, Hussain SN, Hussain S, Hwang JJ, Hwang S, Hwang TI, Ichihara A, Imai Y, Imbriano C, Inomata M, Into T, Iovane V, Iovanna JL, Iozzo RV, Ip NY, Irazoqui JE, Iribarren P, Isaka Y, Isakovic AJ, Ischiropoulos H, Isenberg JS, Ishaq M, Ishida H, Ishii I, Ishmael JE, Isidoro C, Isobe K, Isono E, Issazadeh-Navikas S, Itahana K, Itakura E, Ivanov AI, Iyer AK, Izquierdo JM, Izumi Y, Izzo V, J&#xe4;&#xe4;ttel&#xe4; M, Jaber N, Jackson DJ, Jackson WT, Jacob TG, Jacques TS, Jagannath C, Jain A, Jana NR, Jang BK, Jani A, Janji B, Jannig PR, Jansson PJ, Jean S, Jendrach M, Jeon JH, Jessen N, Jeung EB, Jia K, Jia L, Jiang H, Jiang H, Jiang L, Jiang T, Jiang X, Jiang X, Jiang X, Jiang Y, Jiang Y, Jim&#xe9;nez A, Jin C, Jin H, Jin L, Jin M, Jin S, Jinwal UK, Jo EK, Johansen T, Johnson DE, Johnson GV, Johnson JD, Jonasch E, Jones C, Joosten LA, Jordan J, Joseph AM, Joseph B, Joubert AM, Ju D, Ju J, Juan HF, Juenemann K, Juh&#xe1;sz G, Jung HS, Jung JU, Jung YK, Jungbluth H, Justice MJ, Jutten B, Kaakoush NO, Kaarniranta K, Kaasik A, Kabuta T, Kaeffer B, K&#xe5;gedal K, Kahana A, Kajimura S, Kakhlon O, Kalia M, Kalvakolanu DV, Kamada Y, Kambas K, Kaminskyy VO, Kampinga HH, Kandouz M, Kang C, Kang R, Kang TC, Kanki T, Kanneganti TD, Kanno H, Kanthasamy AG, Kantorow M, Kaparakis-Liaskos M, Kapuy O, Karantza V, Karim MR, Karmakar P, Kaser A, Kaushik S, Kawula T, Kaynar AM, Ke PY, Ke ZJ, Kehrl JH, Keller KE, Kemper JK, Kenworthy AK, Kepp O, Kern A, Kesari S, Kessel D, Ketteler R, Kettelhut Ido C, Khambu B, Khan MM, Khandelwal VK, Khare S, Kiang JG, Kiger AA, Kihara A, Kim AL, Kim CH, Kim DR, Kim DH, Kim EK, Kim HY, Kim HR, Kim JS, Kim JH, Kim JC, Kim JH, Kim KW, Kim MD, Kim MM, Kim PK, Kim SW, Kim SY, Kim YS, Kim Y, Kimchi A, Kimmelman AC, Kimura T, King JS, Kirkegaard K, Kirkin V, Kirshenbaum LA, Kishi S, Kitajima Y, Kitamoto K, Kitaoka Y, Kitazato K, Kley RA, Klimecki WT, Klinkenberg M, Klucken J, Kn&#xe6;velsrud H, Knecht E, Knuppertz L, Ko JL, Kobayashi S, Koch JC, Koechlin-Ramonatxo C, Koenig U, Koh YH, K&#xf6;hler K, Kohlwein SD, Koike M, Komatsu M, Kominami E, Kong D, Kong HJ, Konstantakou EG, Kopp BT, Korcsmaros T, Korhonen L, Korolchuk VI, Koshkina NV, Kou Y, Koukourakis MI, Koumenis C, Kov&#xe1;cs AL, Kov&#xe1;cs T, Kovacs WJ, Koya D, Kraft C, Krainc D, Kramer H, Kravic-Stevovic T, Krek W, Kretz-Remy C, Krick R, Krishnamurthy M, Kriston-Vizi J, Kroemer G, Kruer MC, Kruger R, Ktistakis NT, Kuchitsu K, Kuhn C, Kumar AP, Kumar A, Kumar A, Kumar D, Kumar D, Kumar R, Kumar S, Kundu M, Kung HJ, Kuno A, Kuo SH, Kuret J, Kurz T, Kwok T, Kwon TK, Kwon YT, Kyrmizi I, La Spada AR, Lafont F, Lahm T, Lakkaraju A, Lam T, Lamark T, Lancel S, Landowski TH, Lane DJ, Lane JD, Lanzi C, Lapaquette P, Lapierre LR, Laporte J, Laukkarinen J, Laurie GW, Lavandero S, Lavie L, LaVoie MJ, Law BY, Law HK, Law KB, Layfield R, Lazo PA, Le Cam L, Le Roch KG, Le Stunff H, Leardkamolkarn V, Lecuit M, Lee BH, Lee CH, Lee EF, Lee GM, Lee HJ, Lee H, Lee JK, Lee J, Lee JH, Lee JH, Lee M, Lee MS, Lee PJ, Lee SW, Lee SJ, Lee SJ, Lee SY, Lee SH, Lee SS, Lee SJ, Lee S, Lee YR, Lee YJ, Lee YH, Leeuwenburgh C, Lefort S, Legouis R, Lei J, Lei QY, Leib DA, Leibowitz G, Lekli I, Lemaire SD, Lemasters JJ, Lemberg MK, Lemoine A, Leng S, Lenz G, Lenzi P, Lerman LO, Lettieri Barbato D, Leu JI, Leung HY, Levine B, Lewis PA, Lezoualc'h F, Li C, Li F, Li FJ, Li J, Li K, Li L, Li M, Li M, Li Q, Li R, Li S, Li W, Li W, Li X, Li Y, Lian J, Liang C, Liang Q, Liao Y, Liberal J, Liberski PP, Lie P, Lieberman AP, Lim HJ, Lim KL, Lim K, Lima RT, Lin CS, Lin CF, Lin F, Lin F, Lin FC, Lin K, Lin KH, Lin PH, Lin T, Lin WW, Lin YS, Lin Y, Linden R, Lindholm D, Lindqvist LM, Lingor P, Linkermann A, Liotta LA, Lipinski MM, Lira VA, Lisanti MP, Liton PB, Liu B, Liu C, Liu CF, Liu F, Liu HJ, Liu J, Liu JJ, Liu JL, Liu K, Liu L, Liu L, Liu Q, Liu RY, Liu S, Liu S, Liu W, Liu XD, Liu X, Liu XH, Liu X, Liu X, Liu X, Liu Y, Liu Y, Liu Z, Liu Z, Liuzzi JP, Lizard G, Ljujic M, Lodhi IJ, Logue SE, Lokeshwar BL, Long YC, Lonial S, Loos B, L&#xf3;pez-Ot&#xed;n C, L&#xf3;pez-Vicario C, Lorente M, Lorenzi PL, L&#xf5;rincz P, Los M, Lotze MT, Lovat PE, Lu B, Lu B, Lu J, Lu Q, Lu SM, Lu S, Lu Y, Luciano F, Luckhart S, Lucocq JM, Ludovico P, Lugea A, Lukacs NW, Lum JJ, Lund AH, Luo H, Luo J, Luo S, Luparello C, Lyons T, Ma J, Ma Y, Ma Y, Ma Z, Machado J, Machado-Santelli GM, Macian F, MacIntosh GC, MacKeigan JP, Macleod KF, MacMicking JD, MacMillan-Crow LA, Madeo F, Madesh M, Madrigal-Matute J, Maeda A, Maeda T, Maegawa G, Maellaro E, Maes H, Magari&#xf1;os M, Maiese K, Maiti TK, Maiuri L, Maiuri MC, Maki CG, Malli R, Malorni W, Maloyan A, Mami-Chouaib F, Man N, Mancias JD, Mandelkow EM, Mandell MA, Manfredi AA, Mani&#xe9; SN, Manzoni C, Mao K, Mao Z, Mao ZW, Marambaud P, Marconi AM, Marelja Z, Marfe G, Margeta M, Margittai E, Mari M, Mariani FV, Marin C, Marinelli S, Mari&#xf1;o G, Markovic I, Marquez R, Martelli AM, Martens S, Martin KR, Martin SJ, Martin S, Martin-Acebes MA, Mart&#xed;n-Sanz P, Martinand-Mari C, Martinet W, Martinez J, Martinez-Lopez N, Martinez-Outschoorn U, Mart&#xed;nez-Vel&#xe1;zquez M, Martinez-Vicente M, Martins WK, Mashima H, Mastrianni JA, Matarese G, Matarrese P, Mateo R, Matoba S, Matsumoto N, Matsushita T, Matsuura A, Matsuzawa T, Mattson MP, Matus S, Maugeri N, Mauvezin C, Mayer A, Maysinger D, Mazzolini GD, McBrayer MK, McCall K, McCormick C, McInerney GM, McIver SC, McKenna S, McMahon JJ, McNeish IA, Mechta-Grigoriou F, Medema JP, Medina DL, Megyeri K, Mehrpour M, Mehta JL, Mei Y, Meier UC, Meijer AJ, Mel&#xe9;ndez A, Melino G, Melino S, de Melo EJ, Mena MA, Meneghini MD, Menendez JA, Menezes R, Meng L, Meng LH, Meng S, Menghini R, Menko AS, Menna-Barreto RF, Menon MB, Meraz-R&#xed;os MA, Merla G, Merlini L, Merlot AM, Meryk A, Meschini S, Meyer JN, Mi MT, Miao CY, Micale L, Michaeli S, Michiels C, Migliaccio AR, Mihailidou AS, Mijaljica D, Mikoshiba K, Milan E, Miller-Fleming L, Mills GB, Mills IG, Minakaki G, Minassian BA, Ming XF, Minibayeva F, Minina EA, Mintern JD, Minucci S, Miranda-Vizuete A, Mitchell CH, Miyamoto S, Miyazawa K, Mizushima N, Mnich K, Mograbi B, Mohseni S, Moita LF, Molinari M, Molinari M, M&#xf8;ller AB, Mollereau B, Mollinedo F, Mongillo M, Monick MM, Montagnaro S, Montell C, Moore DJ, Moore MN, Mora-Rodriguez R, Moreira PI, Morel E, Morelli MB, Moreno S, Morgan MJ, Moris A, Moriyasu Y, Morrison JL, Morrison LA, Morselli E, Moscat J, Moseley PL, Mostowy S, Motori E, Mottet D, Mottram JC, Moussa CE, Mpakou VE, Mukhtar H, Mulcahy Levy JM, Muller S, Mu&#xf1;oz-Moreno R, Mu&#xf1;oz-Pinedo C, M&#xfc;nz C, Murphy ME, Murray JT, Murthy A, Mysorekar IU, Nabi IR, Nabissi M, Nader GA, Nagahara Y, Nagai Y, Nagata K, Nagelkerke A, Nagy P, Naidu SR, Nair S, Nakano H, Nakatogawa H, Nanjundan M, Napolitano G, Naqvi NI, Nardacci R, Narendra DP, Narita M, Nascimbeni AC, Natarajan R, Navegantes LC, Nawrocki ST, Nazarko TY, Nazarko VY, Neill T, Neri LM, Netea MG, Netea-Maier RT, Neves BM, Ney PA, Nezis IP, Nguyen HT, Nguyen HP, Nicot AS, Nilsen H, Nilsson P, Nishimura M, Nishino I, Niso-Santano M, Niu H, Nixon RA, Njar VC, Noda T, Noegel AA, Nolte EM, Norberg E, Norga KK, Noureini SK, Notomi S, Notterpek L, Nowikovsky K, Nukina N, N&#xfc;rnberger T, O'Donnell VB, O'Donovan T, O'Dwyer PJ, Oehme I, Oeste CL, Ogawa M, Ogretmen B, Ogura Y, Oh YJ, Ohmuraya M, Ohshima T, Ojha R, Okamoto K, Okazaki T, Oliver FJ, Ollinger K, Olsson S, Orban DP, Ordonez P, Orhon I, Orosz L, O'Rourke EJ, Orozco H, Ortega AL, Ortona E, Osellame LD, Oshima J, Oshima S, Osiewacz HD, Otomo T, Otsu K, Ou JH, Outeiro TF, Ouyang DY, Ouyang H, Overholtzer M, Ozbun MA, Ozdinler PH, Ozpolat B, Pacelli C, Paganetti P, Page G, Pages G, Pagnini U, Pajak B, Pak SC, Pakos-Zebrucka K, Pakpour N, Palkov&#xe1; Z, Palladino F, Pallauf K, Pallet N, Palmieri M, Paludan SR, Palumbo C, Palumbo S, Pampliega O, Pan H, Pan W, Panaretakis T, Pandey A, Pantazopoulou A, Papackova Z, Papademetrio DL, Papassideri I, Papini A, Parajuli N, Pardo J, Parekh VV, Parenti G, Park JI, Park J, Park OK, Parker R, Parlato R, Parys JB, Parzych KR, Pasquet JM, Pasquier B, Pasumarthi KB, Patschan D, Patterson C, Pattingre S, Pattison S, Pause A, Pavenst&#xe4;dt H, Pavone F, Pedrozo Z, Pe&#xf1;a FJ, Pe&#xf1;alva MA, Pende M, Peng J, Penna F, Penninger JM, Pensalfini A, Pepe S, Pereira GJ, Pereira PC, P&#xe9;rez-de la Cruz V, P&#xe9;rez-P&#xe9;rez ME, P&#xe9;rez-Rodr&#xed;guez D, P&#xe9;rez-Sala D, Perier C, Perl A, Perlmutter DH, Perrotta I, Pervaiz S, Pesonen M, Pessin JE, Peters GJ, Petersen M, Petrache I, Petrof BJ, Petrovski G, Phang JM, Piacentini M, Pierdominici M, Pierre P, Pierrefite-Carle V, Pietrocola F, Pimentel-Mui&#xf1;os FX, Pinar M, Pineda B, Pinkas-Kramarski R, Pinti M, Pinton P, Piperdi B, Piret JM, Platanias LC, Platta HW, Plowey ED, P&#xf6;ggeler S, Poirot M, Pol&#x10d;ic P, Poletti A, Poon AH, Popelka H, Popova B, Poprawa I, Poulose SM, Poulton J, Powers SK, Powers T, Pozuelo-Rubio M, Prak K, Prange R, Prescott M, Priault M, Prince S, Proia RL, Proikas-Cezanne T, Prokisch H, Promponas VJ, Przyklenk K, Puertollano R, Pugazhenthi S, Puglielli L, Pujol A, Puyal J, Pyeon D, Qi X, Qian WB, Qin ZH, Qiu Y, Qu Z, Quadrilatero J, Quinn F, Raben N, Rabinowich H, Radogna F, Ragusa MJ, Rahmani M, Raina K, Ramanadham S, Ramesh R, Rami A, Randall-Demllo S, Randow F, Rao H, Rao VA, Rasmussen BB, Rasse TM, Ratovitski EA, Rautou PE, Ray SK, Razani B, Reed BH, Reggiori F, Rehm M, Reichert AS, Rein T, Reiner DJ, Reits E, Ren J, Ren X, Renna M, Reusch JE, Revuelta JL, Reyes L, Rezaie AR, Richards RI, Richardson DR, Richetta C, Riehle MA, Rihn BH, Rikihisa Y, Riley BE, Rimbach G, Rippo MR, Ritis K, Rizzi F, Rizzo E, Roach PJ, Robbins J, Roberge M, Roca G, Roccheri MC, Rocha S, Rodrigues CM, Rodr&#xed;guez CI, de Cordoba SR, Rodriguez-Muela N, Roelofs J, Rogov VV, Rohn TT, Rohrer B, Romanelli D, Romani L, Romano PS, Roncero MI, Rosa JL, Rosello A, Rosen KV, Rosenstiel P, Rost-Roszkowska M, Roth KA, Rou&#xe9; G, Rouis M, Rouschop KM, Ruan DT, Ruano D, Rubinsztein DC, Rucker EB, 3rd, Rudich A, Rudolf E, Rudolf R, Ruegg MA, Ruiz-Roldan C, Ruparelia AA, Rusmini P, Russ DW, Russo GL, Russo G, Russo R, Rusten TE, Ryabovol V, Ryan KM, Ryter SW, Sabatini DM, Sacher M, Sachse C, Sack MN, Sadoshima J, Saftig P, Sagi-Eisenberg R, Sahni S, Saikumar P, Saito T, Saitoh T, Sakakura K, Sakoh-Nakatogawa M, Sakuraba Y, Salazar-Roa M, Salomoni P, Saluja AK, Salvaterra PM, Salvioli R, Samali A, Sanchez AM, S&#xe1;nchez-Alc&#xe1;zar JA, Sanchez-Prieto R, Sandri M, Sanjuan MA, Santaguida S, Santambrogio L, Santoni G, Dos Santos CN, Saran S, Sardiello M, Sargent G, Sarkar P, Sarkar S, Sarrias MR, Sarwal MM, Sasakawa C, Sasaki M, Sass M, Sato K, Sato M, Satriano J, Savaraj N, Saveljeva S, Schaefer L, Schaible UE, Scharl M, Schatzl HM, Schekman R, Scheper W, Schiavi A, Schipper HM, Schmeisser H, Schmidt J, Schmitz I, Schneider BE, Schneider EM, Schneider JL, Schon EA, Sch&#xf6;nenberger MJ, Sch&#xf6;nthal AH, Schorderet DF, Schr&#xf6;der B, Schuck S, Schulze RJ, Schwarten M, Schwarz TL, Sciarretta S, Scotto K, Scovassi AI, Screaton RA, Screen M, Seca H, Sedej S, Segatori L, Segev N, Seglen PO, Segu&#xed;-Simarro JM, Segura-Aguilar J, Seki E, Sell C, Seiliez I, Semenkovich CF, Semenza GL, Sen U, Serra AL, Serrano-Puebla A, Sesaki H, Setoguchi T, Settembre C, Shacka JJ, Shajahan-Haq AN, Shapiro IM, Sharma S, She H, Shen CK, Shen CC, Shen HM, Shen S, Shen W, Sheng R, Sheng X, Sheng ZH, Shepherd TG, Shi J, Shi Q, Shi Q, Shi Y, Shibutani S, Shibuya K, Shidoji Y, Shieh JJ, Shih CM, Shimada Y, Shimizu S, Shin DW, Shinohara ML, Shintani M, Shintani T, Shioi T, Shirabe K, Shiri-Sverdlov R, Shirihai O, Shore GC, Shu CW, Shukla D, Sibirny AA, Sica V, Sigurdson CJ, Sigurdsson EM, Sijwali PS, Sikorska B, Silveira WA, Silvente-Poirot S, Silverman GA, Simak J, Simmet T, Simon AK, Simon HU, Simone C, Simons M, Simonsen A, Singh R, Singh SV, Singh SK, Sinha D, Sinha S, Sinicrope FA, Sirko A, Sirohi K, Sishi BJ, Sittler A, Siu PM, Sivridis E, Skwarska A, Slack R, Slaninov&#xe1; I, Slavov N, Smaili SS, Smalley KS, Smith DR, Soenen SJ, Soleimanpour SA, Solhaug A, Somasundaram K, Son JH, Sonawane A, Song C, Song F, Song HK, Song JX, Song W, Soo KY, Sood AK, Soong TW, Soontornniyomkij V, Sorice M, Sotgia F, Soto-Pantoja DR, Sotthibundhu A, Sousa MJ, Spaink HP, Span PN, Spang A, Sparks JD, Speck PG, Spector SA, Spies CD, Springer W, Clair DS, Stacchiotti A, Staels B, Stang MT, Starczynowski DT, Starokadomskyy P, Steegborn C, Steele JW, Stefanis L, Steffan J, Stellrecht CM, Stenmark H, Stepkowski TM, Stern ST, Stevens C, Stockwell BR, Stoka V, Storchova Z, Stork B, Stratoulias V, Stravopodis DJ, Strnad P, Strohecker AM, Str&#xf6;m AL, Stromhaug P, Stulik J, Su YX, Su Z, Subauste CS, Subramaniam S, Sue CM, Suh SW, Sui X, Sukseree S, Sulzer D, Sun FL, Sun J, Sun J, Sun SY, Sun Y, Sun Y, Sun Y, Sundaramoorthy V, Sung J, Suzuki H, Suzuki K, Suzuki N, Suzuki T, Suzuki YJ, Swanson MS, Swanton C, Sw&#xe4;rd K, Swarup G, Sweeney ST, Sylvester PW, Szatmari Z, Szegezdi E, Szlosarek PW, Taegtmeyer H, Tafani M, Taillebourg E, Tait SW, Takacs-Vellai K, Takahashi Y, Tak&#xe1;ts S, Takemura G, Takigawa N, Talbot NJ, Tamagno E, Tamburini J, Tan CP, Tan L, Tan ML, Tan M, Tan YJ, Tanaka K, Tanaka M, Tang D, Tang D, Tang G, Tanida I, Tanji K, Tannous BA, Tapia JA, Tasset-Cuevas I, Tatar M, Tavassoly I, Tavernarakis N, Taylor A, Taylor GS, Taylor GA, Taylor JP, Taylor MJ, Tchetina EV, Tee AR, Teixeira-Clerc F, Telang S, Tencomnao T, Teng BB, Teng RJ, Terro F, Tettamanti G, Theiss AL, Theron AE, Thomas KJ, Thom&#xe9; MP, Thomes PG, Thorburn A, Thorner J, Thum T, Thumm M, Thurston TL, Tian L, Till A, Ting JP, Titorenko VI, Toker L, Toldo S, Tooze SA, Topisirovic I, Torgersen ML, Torosantucci L, Torriglia A, Torrisi MR, Tournier C, Towns R, Trajkovic V, Travassos LH, Triola G, Tripathi DN, Trisciuoglio D, Troncoso R, Trougakos IP, Truttmann AC, Tsai KJ, Tschan MP, Tseng YH, Tsukuba T, Tsung A, Tsvetkov AS, Tu S, Tuan HY, Tucci M, Tumbarello DA, Turk B, Turk V, Turner RF, Tveita AA, Tyagi SC, Ubukata M, Uchiyama Y, Udelnow A, Ueno T, Umekawa M, Umemiya-Shirafuji R, Underwood BR, Ungermann C, Ureshino RP, Ushioda R, Uversky VN, Uzc&#xe1;tegui NL, Vaccari T, Vaccaro MI, V&#xe1;chov&#xe1; L, Vakifahmetoglu-Norberg H, Valdor R, Valente EM, Vallette F, Valverde AM, Van den Berghe G, Van Den Bosch L, van den Brink GR, van der Goot FG, van der Klei IJ, van der Laan LJ, van Doorn WG, van Egmond M, van Golen KL, Van Kaer L, van Lookeren Campagne M, Vandenabeele P, Vandenberghe W, Vanhorebeek I, Varela-Nieto I, Vasconcelos MH, Vasko R, Vavvas DG, Vega-Naredo I, Velasco G, Velentzas AD, Velentzas PD, Vellai T, Vellenga E, Vendelbo MH, Venkatachalam K, Ventura N, Ventura S, Veras PS, Verdier M, Vertessy BG, Viale A, Vidal M, Vieira HL, Vierstra RD, Vigneswaran N, Vij N, Vila M, Villar M, Villar VH, Villarroya J, Vindis C, Viola G, Viscomi MT, Vitale G, Vogl DT, Voitsekhovskaja OV, von Haefen C, von Schwarzenberg K, Voth DE, Vouret-Craviari V, Vuori K, Vyas JM, Waeber C, Walker CL, Walker MJ, Walter J, Wan L, Wan X, Wang B, Wang C, Wang CY, Wang C, Wang C, Wang C, Wang D, Wang F, Wang F, Wang G, Wang HJ, Wang H, Wang HG, Wang H, Wang HD, Wang J, Wang J, Wang M, Wang MQ, Wang PY, Wang P, Wang RC, Wang S, Wang TF, Wang X, Wang XJ, Wang XW, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang YJ, Wang Y, Wang Y, Wang YT, Wang Y, Wang ZN, Wappner P, Ward C, Ward DM, Warnes G, Watada H, Watanabe Y, Watase K, Weaver TE, Weekes CD, Wei J, Weide T, Weihl CC, Weindl G, Weis SN, Wen L, Wen X, Wen Y, Westermann B, Weyand CM, White AR, White E, Whitton JL, Whitworth AJ, Wiels J, Wild F, Wildenberg ME, Wileman T, Wilkinson DS, Wilkinson S, Willbold D, Williams C, Williams K, Williamson PR, Winklhofer KF, Witkin SS, Wohlgemuth SE, Wollert T, Wolvetang EJ, Wong E, Wong GW, Wong RW, Wong VK, Woodcock EA, Wright KL, Wu C, Wu D, Wu GS, Wu J, Wu J, Wu M, Wu M, Wu S, Wu WK, Wu Y, Wu Z, Xavier CP, Xavier RJ, Xia GX, Xia T, Xia W, Xia Y, Xiao H, Xiao J, Xiao S, Xiao W, Xie CM, Xie Z, Xie Z, Xilouri M, Xiong Y, Xu C, Xu C, Xu F, Xu H, Xu H, Xu J, Xu J, Xu J, Xu L, Xu X, Xu Y, Xu Y, Xu ZX, Xu Z, Xue Y, Yamada T, Yamamoto A, Yamanaka K, Yamashina S, Yamashiro S, Yan B, Yan B, Yan X, Yan Z, Yanagi Y, Yang DS, Yang JM, Yang L, Yang M, Yang PM, Yang P, Yang Q, Yang W, Yang WY, Yang X, Yang Y, Yang Y, Yang Z, Yang Z, Yao MC, Yao PJ, Yao X, Yao Z, Yao Z, Yasui LS, Ye M, Yedvobnick B, Yeganeh B, Yeh ES, Yeyati PL, Yi F, Yi L, Yin XM, Yip CK, Yoo YM, Yoo YH, Yoon SY, Yoshida K, Yoshimori T, Young KH, Yu H, Yu JJ, Yu JT, Yu J, Yu L, Yu WH, Yu XF, Yu Z, Yuan J, Yuan ZM, Yue BY, Yue J, Yue Z, Zacks DN, Zacksenhaus E, Zaffaroni N, Zaglia T, Zakeri Z, Zecchini V, Zeng J, Zeng M, Zeng Q, Zervos AS, Zhang DD, Zhang F, Zhang G, Zhang GC, Zhang H, Zhang H, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang JP, Zhang L, Zhang L, Zhang L, Zhang L, Zhang MY, Zhang X, Zhang XD, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhao M, Zhao WL, Zhao X, Zhao YG, Zhao Y, Zhao Y, Zhao YX, Zhao Z, Zhao ZJ, Zheng D, Zheng XL, Zheng X, Zhivotovsky B, Zhong Q, Zhou GZ, Zhou G, Zhou H, Zhou SF, Zhou XJ, Zhu H, Zhu H, Zhu WG, Zhu W, Zhu XF, Zhu Y, Zhuang SM, Zhuang X, Ziparo E, Zois CE, Zoladek T, Zong WX, Zorzano A, Zughaier SM. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 2016; 12:1&#x2013;222</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4835977</ArticleId>
            <ArticleId IdType="pubmed">26799652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147:728&#x2013;41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22078875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evangelisti C, Evangelisti C, Chiarini F, Lonetti A, Buontempo F, Neri LM, McCubrey JA, Martelli AM. Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. Biochim Biophys Acta 2015; 1853:14&#x2013;26</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25284725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang G, Schramm S, Heilmann J, Biedermann D, K&#x159;en V, Decker M. Unconventional application of the mitsunobu reaction: selective flavonolignan dehydration yielding hydnocarpins. Beilstein J Org Chem 2016; 12:662&#x2013;9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4901995</ArticleId>
            <ArticleId IdType="pubmed">27340458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukhopadhyay S, Panda PK, Sinha N, Das DN, Bhutia SK. Autophagy and apoptosis: where do they meet? Apoptosis 2014; 19:555&#x2013;66</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24415198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D. Ferroptosis: process and function. Cell Death Differ 2016; 23:369&#x2013;79</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ, 3rd, Kang R, Tang D. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 2016; 12:1425&#x2013;8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4968231</ArticleId>
            <ArticleId IdType="pubmed">27245739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, 3rd, Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149:1060&#x2013;72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014; 156:317&#x2013;31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. Free Radic Biol Med 2020; 152:175&#x2013;85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32165281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gasc&#xf3;n S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017; 171:273&#x2013;85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res 2016; 26:1021&#x2013;32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5034113</ArticleId>
            <ArticleId IdType="pubmed">27514700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doree M, Hunt T. From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner? J Cell Sci 2002; 115:2461&#x2013;4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12045216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grandori C, Cowley SM, James LP, Eisenman RN. The myc/max/mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000; 16:653&#x2013;99</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11031250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ZQ, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K, Wagner EF. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 1997; 11:2347&#x2013;58</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC316515</ArticleId>
            <ArticleId IdType="pubmed">9308963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 326:1&#x2013;16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1218630</ArticleId>
            <ArticleId IdType="pubmed">9337844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic Biol Med 2019; 133:130&#x2013;43</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6368883</ArticleId>
            <ArticleId IdType="pubmed">30268886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng DW, Lei Q, Zhu JY, Fan JX, Li CX, Li C, Xu Z, Cheng SX, Zhang XZ. Switching apoptosis to ferroptosis: metal-organic network for High-Efficiency anticancer therapy. Nano Lett 2017; 17:284&#x2013;91</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28027643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong SH, Lee DH, Lee YS, Jo MJ, Jeong YA, Kwon WT, Choudry HA, Bartlett DL, Lee YJ. Molecular crosstalk between ferroptosis and apoptosis: emerging role of ER stress-induced p53-independent PUMA expression. Oncotarget 2017; 8:115164&#x2013;78</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5777762</ArticleId>
            <ArticleId IdType="pubmed">29383150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forman HJ, Dickinson DA, Iles KE. HNE&#x2013;signaling pathways leading to its elimination. Molecular Aspects of Medicine 2003; 24:189&#x2013;94</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12892996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, Rosenberg PA, Lo DC, Weinberg JM, Linkermann A, Stockwell BR. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc 2014; 136:45516</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3985476</ArticleId>
            <ArticleId IdType="pubmed">24592866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park E, Chung SW. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. Cell Death Dis 2019; 10:&#x2013;822</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6817894</ArticleId>
            <ArticleId IdType="pubmed">31659150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vue B, Chen QH. The potential of flavonolignans in prostate cancer management. Curr Med Chem 2016; 23:3925&#x2013;50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27557939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald BR, Nibbs AE, Scheidt KA. A B, Strategy T. Access the silybins: total synthesis of (-)-isosilybin A. Org Lett 2015; 17:98&#x2013;101</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4284651</ArticleId>
            <ArticleId IdType="pubmed">25517432</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33691090</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1932-7420</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>33</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell metabolism</Title>
          <ISOAbbreviation>Cell Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CD36-mediated ferroptosis dampens intratumoral CD8[+] T cell effector function and impairs their antitumor ability.</ArticleTitle>
        <Pagination>
          <StartPage>1001</StartPage>
          <EndPage>1012.e5</EndPage>
          <MedlinePgn>1001-1012.e5</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmet.2021.02.015</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1550-4131(21)00071-1</ELocationID>
        <Abstract>
          <AbstractText>Understanding the mechanisms underlying how T cells become dysfunctional in a tumor microenvironment (TME) will greatly benefit cancer immunotherapy. We found that increased CD36 expression in tumor-infiltrating CD8[+] T cells, which was induced by TME cholesterol, was associated with tumor progression and poor survival in human and murine cancers. Genetic ablation of Cd36 in effector CD8[+] T cells exhibited increased cytotoxic cytokine production and enhanced tumor eradication. CD36 mediated uptake of fatty acids by tumor-infiltrating CD8[+] T cells in TME, induced lipid peroxidation and ferroptosis, and led to reduced cytotoxic cytokine production and impaired antitumor ability. Blocking CD36 or inhibiting ferroptosis in CD8[+] T cells effectively restored their antitumor activity and, more importantly, possessed greater antitumor efficacy in combination with anti-PD-1 antibodies. This study reveals a new mechanism of CD36 regulating the function of CD8[+] effector T cells and therapeutic potential of targeting CD36 or inhibiting ferroptosis to restore T cell function.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Xingzhe</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston Methodist, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Liuling</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston Methodist, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Lintao</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston Methodist, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Lingqun</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston Methodist, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Pan</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston Methodist, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bi</LastName>
            <ForeName>Enguang</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston Methodist, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qiang</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston Methodist, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Maojie</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston Methodist, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qian</LastName>
            <ForeName>Jianfei</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston Methodist, Houston, TX 77030, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yi</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center/Houston Methodist Research Institute, Houston Methodist, Houston, TX 77030, USA. Electronic address: qyi@houstonmethodist.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA200539</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA211073</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA214811</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA239255</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Metab</MedlineTA>
        <NlmUniqueID>101233170</NlmUniqueID>
        <ISSNLinking>1550-4131</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018955">CD36 Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>QOG25L6Z8Z</RegistryNumber>
          <NameOfSubstance UI="C000711728">spartalizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Cell Metab. 2021 Aug 3;33(8):1509-1511</RefSource>
          <PMID Version="1">34348095</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018955" MajorTopicYN="N">CD36 Antigens</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="N">Melanoma, Experimental</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CD36</Keyword>
        <Keyword MajorTopicYN="N">CD8(+) T cells</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">lipid peroxidation</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>20</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33691090</ArticleId>
        <ArticleId IdType="mid">NIHMS1683057</ArticleId>
        <ArticleId IdType="pmc">PMC8102368</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cmet.2021.02.015</ArticleId>
        <ArticleId IdType="pii">S1550-4131(21)00071-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>A, I. S. S., C, A. B. &amp; A, J. S. 2019. Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes. Nutrients, 11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6770316</ArticleId>
            <ArticleId IdType="pubmed">31466350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ALMEIDA L, LOCHNER M, BEROD L. &amp; SPARWASSER T. 2016. Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol, 28, 514&#x2013;524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27825556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AYALA A, MUNOZ MF &amp; ARGUELLES S. 2014. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev, 2014, 360438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4066722</ArticleId>
            <ArticleId IdType="pubmed">24999379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CHANG CH &amp; PEARCE EL 2016. Emerging concepts of T cell metabolism as a target of immunotherapy. Nat Immunol, 17, 364&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4990080</ArticleId>
            <ArticleId IdType="pubmed">27002844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>COOKE RE, GHERARDIN NA, HARRISON SJ, QUACH H, GODFREY DI, PRINCE M, KOLDEJ R. &amp; RITCHIE DS 2016. Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma. J Transl Med, 14, 259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5011922</ArticleId>
            <ArticleId IdType="pubmed">27599546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DOLL S, PRONETH B, TYURINA YY, PANZILIUS E, KOBAYASHI S, INGOLD I, IRMLER M, BECKERS J, AICHLER M, WALCH A, PROKISCH H, TRUMBACH D, MAO G, QU F, BAYIR H, FULLEKRUG J, SCHEEL CH, WURST W, SCHICK JA, KAGAN VE, ANGELI JP &amp; CONRAD M. 2017. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol, 13, 91&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FAGERBERG J, YI Q, GIGLIOTTI D, HARMENBERG U, RUDEN U, PERSSON B, OSTERBORG A. &amp; MELLSTEDT H. 1999. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int J Cancer, 80, 671&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10048965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GAJEWSKI TF, SCHREIBER H. &amp; FU YX 2013. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol, 14, 1014&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4118725</ArticleId>
            <ArticleId IdType="pubmed">24048123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GUO C, SUN L, CHEN X. &amp; ZHANG D. 2013. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res, 8, 2003&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4145906</ArticleId>
            <ArticleId IdType="pubmed">25206509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GUO X, ZHANG Y, ZHENG L, ZHENG C, SONG J, ZHANG Q, KANG B, LIU Z, JIN L, XING R, GAO R, ZHANG L, DONG M, HU X, REN X, KIRCHHOFF D, ROIDER HG, YAN T. &amp; ZHANG Z. 2018. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med, 24, 978&#x2013;985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29942094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>HROUDOVA J. &amp; FISAR Z. 2013. Control mechanisms in mitochondrial oxidative phosphorylation. Neural Regen Res, 8, 363&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4107533</ArticleId>
            <ArticleId IdType="pubmed">25206677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>HUGO W, ZARETSKY JM, SUN L, SONG C, MORENO BH, HU-LIESKOVAN S, BERENT-MAOZ B, PANG J, CHMIELOWSKI B, CHERRY G, SEJA E, LOMELI S, KONG X, KELLEY MC, SOSMAN JA, JOHNSON DB, RIBAS A. &amp; LO RS 2017. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 168, 542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28129544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>JOYCE JA &amp; FEARON DT 2015. T cell exclusion, immune privilege, and the tumor microenvironment. Science, 348, 74&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25838376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MA X, BI E, HUANG C, LU Y, XUE G, GUO X, WANG A, YANG M, QIAN J, DONG C. &amp; YI Q. 2018. Cholesterol negatively regulates IL-9-producing CD8(+) T cell differentiation and antitumor activity. J Exp Med, 215, 1555&#x2013;1569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5987919</ArticleId>
            <ArticleId IdType="pubmed">29743292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MA X, BI E, LU Y, SU P, HUANG C, LIU L, WANG Q, YANG M, KALADY MF, QIAN J, ZHANG A, GUPTE AA, HAMILTON DJ, ZHENG C. &amp; YI Q. 2019. Cholesterol Induces CD8(+) T Cell Exhaustion in the Tumor Microenvironment. Cell Metab, 30, 143&#x2013;156 e5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7061417</ArticleId>
            <ArticleId IdType="pubmed">31031094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MA X. &amp; YI Q. 2019. Cholesterol induces T cell exhaustion. Aging (Albany NY), 11, 7334&#x2013;7335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6781989</ArticleId>
            <ArticleId IdType="pubmed">31532755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MATSUSHITA M, FREIGANG S, SCHNEIDER C, CONRAD M, BORNKAMM GW &amp; KOPF M. 2015. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J Exp Med, 212, 555&#x2013;68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4387287</ArticleId>
            <ArticleId IdType="pubmed">25824823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MET O, JENSEN KM, CHAMBERLAIN CA, DONIA M. &amp; SVANE IM 2019. Principles of adoptive T cell therapy in cancer. Semin Immunopathol, 41, 49&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30187086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MOHAMED E, AL-KHAMI AA &amp; RODRIGUEZ PC 2018. The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates. Cellular &amp; Molecular Immunology, 15, 421&#x2013;427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6068094</ArticleId>
            <ArticleId IdType="pubmed">29568118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>OCQUETEAU M, ORFAO A, ALMEIDA J, BLADE J, GONZALEZ M, GARCIA-SANZ R, LOPEZ-BERGES C, MORO MJ, HERNANDEZ J, ESCRIBANO L, CABALLERO D, ROZMAN M. &amp; SAN MIGUEL JF 1998. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol, 152, 1655&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1858455</ArticleId>
            <ArticleId IdType="pubmed">9626070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PEPINO MY, KUDA O, SAMOVSKI D. &amp; ABUMRAD NA 2014. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr, 34, 281&#x2013;303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4329921</ArticleId>
            <ArticleId IdType="pubmed">24850384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PERRY JSA, RUSSLER-GERMAIN EV, ZHOU YW, PURTHA W, COOPER ML, CHOI J, SCHROEDER MA, SALAZAR V, EGAWA T, LEE BC, ABUMRAD NA, KIM BS, ANDERSON MS, DIPERSIO JF &amp; HSIEH CS 2018. Transfer of Cell-Surface Antigens by Scavenger Receptor CD36 Promotes Thymic Regulatory T Cell Receptor Repertoire Development and Allo-tolerance. Immunity, 48, 1271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6015728</ArticleId>
            <ArticleId IdType="pubmed">29924978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SADE-FELDMAN M, YIZHAK K, BJORGAARD SL, RAY JP, DE BOER CG, JENKINS RW, LIEB DJ, CHEN JH, FREDERICK DT, BARZILY-ROKNI M, FREEMAN SS, REUBEN A, HOOVER PJ, VILLANI AC, IVANOVA E, PORTELL A, LIZOTTE PH, AREF AR, ELIANE JP, HAMMOND MR, VITZTHUM H, BLACKMON SM, LI B, GOPALAKRISHNAN V, REDDY SM, COOPER ZA, PAWELETZ CP, BARBIE DA, STEMMER-RACHAMIMOV A, FLAHERTY KT, WARGO JA, BOLAND GM, SULLIVAN RJ, GETZ G. &amp; HACOHEN N. 2019. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell, 176, 404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6647017</ArticleId>
            <ArticleId IdType="pubmed">30633907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SILVERSTEIN RL &amp; FEBBRAIO M. 2009. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal, 2, re3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2811062</ArticleId>
            <ArticleId IdType="pubmed">19471024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SINGH CK, CHHABRA G, NDIAYE MA, GARCIA-PETERSON LM, MACK NJ &amp; AHMAD N. 2018. The Role of Sirtuins in Antioxidant and Redox Signaling. Antioxid Redox Signal, 28, 643&#x2013;661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5824489</ArticleId>
            <ArticleId IdType="pubmed">28891317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SPEISER DE, HO PC &amp; VERDEIL G. 2016. Regulatory circuits of T cell function in cancer. Nat Rev Immunol, 16, 599&#x2013;611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27526640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>STOCKWELL BR, FRIEDMANN ANGELI JP, BAYIR H, BUSH AI, CONRAD M, DIXON SJ, FULDA S, GASCON S, HATZIOS SK, KAGAN VE, NOEL K, JIANG X, LINKERMANN A, MURPHY ME, OVERHOLTZER M, OYAGI A, PAGNUSSAT GC, PARK J, RAN Q, ROSENFELD CS, SALNIKOW K, TANG D, TORTI FM, TORTI SV, TOYOKUNI S, WOERPEL KA &amp; ZHANG DD 2017. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell, 171, 273&#x2013;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SU P, WANG Q, BI E, MA X, LIU L, YANG M, QIAN J. &amp; YI Q. 2020. Enhanced Lipid Accumulation and Metabolism Are Required for the Differentiation and Activation of Tumor-Associated Macrophages. Cancer Res, 80, 1438&#x2013;1450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7127942</ArticleId>
            <ArticleId IdType="pubmed">32015091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SUBRAMANIAN A, TAMAYO P, MOOTHA VK, MUKHERJEE S, EBERT BL, GILLETTE MA, PAULOVICH A, POMEROY SL, GOLUB TR, LANDER ES &amp; MESIROV JP 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 102, 15545&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1239896</ArticleId>
            <ArticleId IdType="pubmed">16199517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>TAGLIANI E, GUERMONPREZ P, SEPULVEDA J, LOPEZ-BRAVO M, ARDAVIN C, AMIGORENA S, BENVENUTI F. &amp; BURRONE OR 2008. Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha(+) dendritic cells. Journal of Immunology, 180, 3201&#x2013;3209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18292544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>THOMMEN DS &amp; SCHUMACHER TN 2018. T Cell Dysfunction in Cancer. Cancer Cell, 33, 547&#x2013;562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7116508</ArticleId>
            <ArticleId IdType="pubmed">29634943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>TUMEH PC, HARVIEW CL, YEARLEY JH, SHINTAKU IP, TAYLOR EJ, ROBERT L, CHMIELOWSKI B, SPASIC M, HENRY G, CIOBANU V, WEST AN, CARMONA M, KIVORK C, SEJA E, CHERRY G, GUTIERREZ AJ, GROGAN TR, MATEUS C, TOMASIC G, GLASPY JA, EMERSON RO, ROBINS H, PIERCE RH, ELASHOFF DA, ROBERT C. &amp; RIBAS A. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 515, 568&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4246418</ArticleId>
            <ArticleId IdType="pubmed">25428505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>VERDIN E, HIRSCHEY MD, FINLEY LW &amp; HAIGIS MC 2010. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci, 35, 669&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2992946</ArticleId>
            <ArticleId IdType="pubmed">20863707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WANG H, FRANCO F, TSUI YC, XIE X, TREFNY MP, ZAPPASODI R, MOHMOOD SR, FERNANDEZ-GARCIA J, TSAI CH, SCHULZE I, PICARD F, MEYLAN E, SILVERSTEIN R, GOLDBERG I, FENDT SM, WOLCHOK JD, MERGHOUB T, JANDUS C, ZIPPELIUS A. &amp; HO PC 2020. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol, 21, 298&#x2013;308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7043937</ArticleId>
            <ArticleId IdType="pubmed">32066953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WANG W, GREEN M, CHOI JE, GIJON M, KENNEDY PD, JOHNSON JK, LIAO P, LANG X, KRYCZEK I, SELL A, XIA H, ZHOU J, LI G, LI J, LI W, WEI S, VATAN L, ZHANG H, SZELIGA W, GU W, LIU R, LAWRENCE TS, LAMB C, TANNO Y, CIESLIK M, STONE E, GEORGIOU G, CHAN TA, CHINNAIYAN A. &amp; ZOU W. 2019. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature, 569, 270&#x2013;274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WOLCHOK JD, NEYNS B, LINETTE G, NEGRIER S, LUTZKY J, THOMAS L, WATERFIELD W, SCHADENDORF D, SMYLIE M, GUTHRIE T JR., GROB JJ, CHESNEY J, CHIN K, CHEN K, HOOS A, O&#x2019;DAY SJ &amp; LEBBE C. 2010. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol, 11, 155&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20004617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YANG WS, KIM KJ, GASCHLER MM, PATEL M, SHCHEPINOV MS &amp; STOCKWELL BR 2016. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A, 113, E4966&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5003261</ArticleId>
            <ArticleId IdType="pubmed">27506793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YANG WS, SRIRAMARATNAM R, WELSCH ME, SHIMADA K, SKOUTA R, VISWANATHAN VS, CHEAH JH, CLEMONS PA, SHAMJI AF, CLISH CB, BROWN LM, GIROTTI AW, CORNISH VW, SCHREIBER SL &amp; STOCKWELL BR 2014. Regulation of ferroptotic cancer cell death by GPX4. Cell, 156, 317&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YANG WS &amp; STOCKWELL BR 2016. Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol, 26, 165&#x2013;176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YI Q, ERIKSSON I, HE W, HOLM G, MELLSTEDT H. &amp; OSTERBORG A. 1997. Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. Br J Haematol, 96, 338&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9029023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ZAROUR HM 2016. Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res, 22, 1856&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4872712</ArticleId>
            <ArticleId IdType="pubmed">27084739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ZHANG M, DI MARTINO JS, BOWMAN RL, CAMPBELL NR, BAKSH SC, SIMON-VERMOT T, KIM IS, HALDEMAN P, MONDAL C, YONG-GONZALES V, ABU-AKEEL M, MERGHOUB T, JONES DR, ZHU XG, ARORA A, ARIYAN CE, BIRSOY K, WOLCHOK JD, PANAGEAS KS, HOLLMANN T, BRAVO-CORDERO JJ &amp; WHITE RM 2018. Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. Cancer Discov, 8, 1006&#x2013;1025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6192670</ArticleId>
            <ArticleId IdType="pubmed">29903879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ZYSSET D, WEBER B, RIHS S, BRASSEIT J, FREIGANG S, RIETHER C, BANZ Y, CERWENKA A, SIMILLION C, MARQUES-VIDAL P, OCHSENBEIN AF, SAURER L. &amp; MUELLER C. 2016. TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. Nat Commun, 7, 13151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5080444</ArticleId>
            <ArticleId IdType="pubmed">27762264</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33547170</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1550-6606</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>206</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
          <ISOAbbreviation>J Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Asah2 Represses the p53-Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells from Ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>1395</StartPage>
          <EndPage>1404</EndPage>
          <MedlinePgn>1395-1404</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.2000500</ELocationID>
        <Abstract>
          <AbstractText>Myeloid-derived suppressor cells (MDSCs) are immune suppressive cells that massively accumulate under pathological conditions to suppress T cell immune response. Dysregulated cell death contributes to MDSC accumulation, but the molecular mechanism underlying this cell death dysregulation is not fully understood. In this study, we report that neutral ceramidase (N-acylsphingosine amidohydrolase [ASAH2]) is highly expressed in tumor-infiltrating MDSCs in colon carcinoma and acts as an MDSC survival factor. To target ASAH2, we performed molecular docking based on human ASAH2 protein structure. Enzymatic inhibition analysis of identified hits determined NC06 as an ASAH2 inhibitor. Chemical and nuclear magnetic resonance analysis determined NC06 as 7-chloro-2-(3-chloroanilino)pyrano[3,4-e][1,3]oxazine-4,5-dione. NC06 inhibits ceramidase activity with an IC50 of 10.16-25.91 μM for human ASAH2 and 18.6-30.2 μM for mouse Asah2 proteins. NC06 induces MDSC death in a dose-dependent manner, and inhibition of ferroptosis decreased NC06-induced MDSC death. NC06 increases glutathione synthesis and decreases lipid reactive oxygen species to suppress ferroptosis in MDSCs. Gene expression profiling identified the p53 pathway as the Asah2 target in MDSCs. Inhibition of Asah2 increased p53 protein stability to upregulate Hmox1 expression to suppress lipid reactive oxygen species production to suppress ferroptosis in MDSCs. NC06 therapy increases MDSC death and reduces MDSC accumulation in tumor-bearing mice, resulting in increased activation of tumor-infiltrating CTLs and suppression of tumor growth in vivo. Our data indicate that ASAH2 protects MDSCs from ferroptosis through destabilizing p53 protein to suppress the p53 pathway in MDSCs in the tumor microenvironment. Targeting ASAH2 with NC06 to induce MDSC ferroptosis is potentially an effective therapy to suppress MDSC accumulation in cancer immunotherapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 by The American Association of Immunologists, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Huabin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Charlie Norwood VA Medical Center, Augusta, GA 30904.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klement</LastName>
            <ForeName>John D</ForeName>
            <Initials>JD</Initials>
            <Identifier Source="ORCID">0000-0003-4334-4076</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Charlie Norwood VA Medical Center, Augusta, GA 30904.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Chunwan</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Charlie Norwood VA Medical Center, Augusta, GA 30904.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Redd</LastName>
            <ForeName>Priscilla S</ForeName>
            <Initials>PS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Charlie Norwood VA Medical Center, Augusta, GA 30904.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Dafeng</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Charlie Norwood VA Medical Center, Augusta, GA 30904.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Alyssa D</ForeName>
            <Initials>AD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Charlie Norwood VA Medical Center, Augusta, GA 30904.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Poschel</LastName>
            <ForeName>Dakota B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Charlie Norwood VA Medical Center, Augusta, GA 30904.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Juan</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-3236-5998</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Physics, Augusta University, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Ding</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Georgia State University, Atlanta, GA 30303.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Peng George</ForeName>
            <Initials>PG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Georgia State University, Atlanta, GA 30303.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ostrov</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-4696-875X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32610.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coant</LastName>
            <ForeName>Nicolas</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0001-9237-2132</Identifier>
            <AffiliationInfo>
              <Affiliation>Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY 11794.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hannun</LastName>
            <ForeName>Yusuf A</ForeName>
            <Initials>YA</Initials>
            <Identifier Source="ORCID">0000-0003-3349-3369</Identifier>
            <AffiliationInfo>
              <Affiliation>Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY 11794.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Colby</LastName>
            <ForeName>Aaron H</ForeName>
            <Initials>AH</Initials>
            <AffiliationInfo>
              <Affiliation>Ionic Pharmaceuticals, Brookline, MA 02445; and.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Boston University, Boston, MA 02215.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grinstaff</LastName>
            <ForeName>Mark W</ForeName>
            <Initials>MW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, Boston University, Boston, MA 02215.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Kebin</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-1965-7240</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912; Kliu@augusta.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta, GA 30912.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Charlie Norwood VA Medical Center, Augusta, GA 30904.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>I01 CX001364</GrantID>
            <Acronym>CX</Acronym>
            <Agency>CSRD VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA133085</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>F30 CA236436</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA097132</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>F31 CA257212</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 GM118128</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>IS1 BX004009</GrantID>
            <Acronym>BX</Acronym>
            <Agency>BLRD VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA227433</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Immunol</MedlineTA>
        <NlmUniqueID>2985117R</NlmUniqueID>
        <ISSNLinking>0022-1767</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000628667">Trp53 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="D051547">Heme Oxygenase-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="C496542">Hmox1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.23</RegistryNumber>
          <NameOfSubstance UI="C526744">ASAH2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.23</RegistryNumber>
          <NameOfSubstance UI="C526747">Asah2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.23</RegistryNumber>
          <NameOfSubstance UI="D055576">Neutral Ceramidase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
          <QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051547" MajorTopicYN="N">Heme Oxygenase-1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072737" MajorTopicYN="N">Myeloid-Derived Suppressor Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055576" MajorTopicYN="N">Neutral Ceramidase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055550" MajorTopicYN="N">Protein Stability</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081246" MajorTopicYN="N">RNA-Seq</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>6</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33547170</ArticleId>
        <ArticleId IdType="mid">NIHMS1664082</ArticleId>
        <ArticleId IdType="pmc">PMC7946776</ArticleId>
        <ArticleId IdType="doi">10.4049/jimmunol.2000500</ArticleId>
        <ArticleId IdType="pii">jimmunol.2000500</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hanahan D, and Weinberg RA 2011. Hallmarks of cancer: the next generation. Cell 144: 646&#x2013;674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura K, and Smyth MJ 2020. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol 17: 1&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6952382</ArticleId>
            <ArticleId IdType="pubmed">31611651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV, Donthireddy L, To TKJ, Schug Z, Basu S, Wang F, Ricciotti E, DiRusso C, Murphy ME, Vonderheide RH, Lieberman PM, Mulligan C, Nam B, Hockstein N, Masters G, Guarino M, Lin C, Nefedova Y, Black P, Kagan VE, and Gabrilovich DI 2019. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature 569: 73&#x2013;78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6557120</ArticleId>
            <ArticleId IdType="pubmed">30996346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lasry A, Zinger A, and Ben-Neriah Y 2016. Inflammatory networks underlying colorectal cancer. Nat Immunol 17: 230&#x2013;240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26882261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sceneay J, Parker BS, Smyth MJ, and Moller A 2013. Hypoxia-driven immunosuppression contributes to the pre-metastatic niche. Oncoimmunology 2: e22355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3583916</ArticleId>
            <ArticleId IdType="pubmed">23482904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibrahim ML, Klement JD, Lu C, Redd PS, Xiao W, Yang D, Browning DD, Savage NM, Buckhaults PJ, Morse HC 3rd, and Liu K 2018. Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis. Cell Rep 25: 3036&#x2013;3046 e3036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6319669</ArticleId>
            <ArticleId IdType="pubmed">30540937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj S, and Gabrilovich DI 2008. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68: 2561&#x2013;2563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18413722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunt SK, Sinha P, Clements VK, Leips J, and Ostrand-Rosenberg S 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 176: 284&#x2013;290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16365420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, and Umansky V 2018. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Front Immunol 9: 398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5840207</ArticleId>
            <ArticleId IdType="pubmed">29552012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, and Zou W 2018. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 128: 805&#x2013;815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5785251</ArticleId>
            <ArticleId IdType="pubmed">29337305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H, Peng H, and Fu YX 2018. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest 128: 580&#x2013;588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5785245</ArticleId>
            <ArticleId IdType="pubmed">29337303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu C, Redd PS, Lee JR, Savage N, and Liu K 2016. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. Oncoimmunology 5: e1247135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5214087</ArticleId>
            <ArticleId IdType="pubmed">28123883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber J, Gibney G, Kudchadkar R, Yu B, Cheng P, Martinez AJ, Kroeger J, Richards A, McCormick L, Moberg V, Cronin H, Zhao X, Schell M, and Chen YA 2016. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 4: 345&#x2013;353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4818672</ArticleId>
            <ArticleId IdType="pubmed">26873574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, Utikal J, and Umansky V 2018. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Front Immunol 9: 1310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6004385</ArticleId>
            <ArticleId IdType="pubmed">29942309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrand-Rosenberg S, Beury DW, Parker KH, and Horn LA 2019. Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironment. Cancer Immunol Immunother.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7004852</ArticleId>
            <ArticleId IdType="pubmed">31501954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, Green DR, Opferman JT, and Murray PJ 2014. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity 41: 947&#x2013;959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4272664</ArticleId>
            <ArticleId IdType="pubmed">25500368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, and Gabrilovich DI 2014. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest 124: 2626&#x2013;2639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4038578</ArticleId>
            <ArticleId IdType="pubmed">24789911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker KH, Horn LA, and Ostrand-Rosenberg S 2016. High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy. J Leukoc Biol 100: 463&#x2013;470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4982609</ArticleId>
            <ArticleId IdType="pubmed">26864266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao X, Rong L, Zhao X, Li X, Liu X, Deng J, Wu H, Xu X, Erben U, Wu P, Syrbe U, Sieper J, and Qin Z 2012. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 122: 4094&#x2013;4104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3484453</ArticleId>
            <ArticleId IdType="pubmed">23064360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roth F, De La Fuente AC, Vella JL, Zoso A, Inverardi L, and Serafini P 2012. Aptamer-mediated blockade of IL4Ralpha triggers apoptosis of MDSCs and limits tumor progression. Cancer Res 72: 1373&#x2013;1383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22282665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, and Ostrand-Rosenberg S 2011. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 117: 5381&#x2013;5390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3109712</ArticleId>
            <ArticleId IdType="pubmed">21450901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alissafi T, Hatzioannou A, Mintzas K, Barouni RM, Banos A, Sormendi S, Polyzos A, Xilouri M, Wielockx B, Gogas H, and Verginis P 2018. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. J Clin Invest 128: 3840&#x2013;3852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6118632</ArticleId>
            <ArticleId IdType="pubmed">29920188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, Forero A, Bendell J, Witt R, Hockstein N, Kumar P, and Gabrilovich DI 2017. Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. Clin Cancer Res 23: 2942&#x2013;2950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5468499</ArticleId>
            <ArticleId IdType="pubmed">27965309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodge JW, and Schlom J 1999. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res 59: 5106&#x2013;5111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10537283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zimmerman M, Hu X, and Liu K 2010. Experimental metastasis and CTL adoptive transfer immunotherapy mouse model. J Vis Exp.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3159593</ArticleId>
            <ArticleId IdType="pubmed">21178954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O&#x2019;Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, and Hutchison GR 2011. Open Babel: An open chemical toolbox. Journal of cheminformatics 3: 33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3198950</ArticleId>
            <ArticleId IdType="pubmed">21982300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trott O, and Olson AJ 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455&#x2013;461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3041641</ArticleId>
            <ArticleId IdType="pubmed">19499576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Airola MV, Allen WJ, Pulkoski-Gross MJ, Obeid LM, Rizzo RC, and Hannun YA 2015. Structural Basis for Ceramide Recognition and Hydrolysis by Human Neutral Ceramidase. Structure 23: 1482&#x2013;1491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4830088</ArticleId>
            <ArticleId IdType="pubmed">26190575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casasampere M, Bielsa N, Riba D, Bassas L, Xu RJ, Mao CG, Fabrias G, Abad JL, Delgado A, and Casas J 2019. New fluorogenic probes for neutral and alkaline ceramidases. Journal of Lipid Research 60: 1174&#x2013;1181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6547634</ArticleId>
            <ArticleId IdType="pubmed">30926626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Barros M, Coant N, Kawamori T, Wada M, Snider AJ, Truman JP, Wu BX, Furuya H, Clarke CJ, Bialkowska AB, Ghaleb A, Yang VW, Obeid LM, and Hannun YA 2016. Role of neutral ceramidase in colon cancer. FASEB J 30: 4159&#x2013;4171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5102116</ArticleId>
            <ArticleId IdType="pubmed">27609772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogretmen B 2006. Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS Lett 580: 5467&#x2013;5476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16970943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogretmen B, and Hannun YA 2004. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604&#x2013;616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15286740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, and Stockwell BR 2012. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149: 1060&#x2013;1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarangelo A, Magtanong L, Bieging-Rolett KT, Li Y, Ye J, Attardi LD, and Dixon SJ 2018. p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells. Cell Rep 22: 569&#x2013;575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5791910</ArticleId>
            <ArticleId IdType="pubmed">29346757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascon S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, and Zhang DD 2017. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 171: 273&#x2013;285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee WC, Hsu PY, and Hsu HY 2020. Stem cell factor produced by tumor cells expands myeloid-derived suppressor cells in mice. Sci Rep 10: 11257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7347545</ArticleId>
            <ArticleId IdType="pubmed">32647215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bosiljcic M, Cederberg RA, Hamilton MJ, LePard NE, Harbourne BT, Collier JL, Halvorsen EC, Shi R, Franks SE, Kim AY, Banath JP, Hamer M, Rossi FM, and Bennewith KL 2019. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs. Breast Cancer Res 21: 103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6727565</ArticleId>
            <ArticleId IdType="pubmed">31488209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Clements VK, and Ostrand-Rosenberg S 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174: 636&#x2013;645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15634881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dany M, and Ogretmen B 2015. Ceramide induced mitophagy and tumor suppression. Biochim Biophys Acta 1853: 2834&#x2013;2845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4515393</ArticleId>
            <ArticleId IdType="pubmed">25634657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang W, and Ogretmen B 2014. Autophagy paradox and ceramide. Biochim Biophys Acta 1841: 783&#x2013;792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3960371</ArticleId>
            <ArticleId IdType="pubmed">24055889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senkal CE, Ponnusamy S, Bielawski J, Hannun YA, and Ogretmen B 2010. Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. Faseb J 24: 296&#x2013;308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2797032</ArticleId>
            <ArticleId IdType="pubmed">19723703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park MA, Reinehr R, Haussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, and Dent P 2010. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther 9: 2220&#x2013;2231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2933415</ArticleId>
            <ArticleId IdType="pubmed">20682655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White-Gilbertson S, Mullen T, Senkal C, Lu P, Ogretmen B, Obeid L, and Voelkel-Johnson C 2009. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene 28: 1132&#x2013;1141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2648838</ArticleId>
            <ArticleId IdType="pubmed">19137010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coe GL, Redd PS, Paschall AV, Lu C, Gu L, Cai H, Albers T, Lebedyeva IO, and Liu K 2016. Ceramide mediates FasL-induced caspase 8 activation in colon carcinoma cells to enhance FasL-induced cytotoxicity by tumor-specific cytotoxic T lymphocytes. Sci Rep 6: 30816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4973238</ArticleId>
            <ArticleId IdType="pubmed">27487939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oleinik N, Kim J, Roth BM, Selvam SP, Gooz M, Johnson RH, Lemasters JJ, and Ogretmen B 2019. Mitochondrial protein import is regulated by p17/PERMIT to mediate lipid metabolism and cellular stress. Sci Adv 5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6739097</ArticleId>
            <ArticleId IdType="pubmed">31535025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agmon E, and Stockwell BR 2017. Lipid homeostasis and regulated cell death. Curr Opin Chem Biol 39: 83&#x2013;89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5581689</ArticleId>
            <ArticleId IdType="pubmed">28645028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coant N, and Hannun YA 2019. Neutral ceramidase: Advances in mechanisms, cell regulation, and roles in cancer. Adv Biol Regul 71: 141&#x2013;146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6347532</ArticleId>
            <ArticleId IdType="pubmed">30389354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, and Gu W 2015. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520: 57&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4455927</ArticleId>
            <ArticleId IdType="pubmed">25799988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meiller A, Alvarez S, Drane P, Lallemand C, Blanchard B, Tovey M, and May E 2007. p53-dependent stimulation of redox-related genes in the lymphoid organs of gamma-irradiated--mice identification of Haeme-oxygenase 1 as a direct p53 target gene. Nucleic Acids Res 35: 6924&#x2013;6934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2175302</ArticleId>
            <ArticleId IdType="pubmed">17933770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang LC, Chiang SK, Chen SE, Yu YL, Chou RH, and Chang WC 2018. Heme oxygenase-1 mediates BAY 11&#x2013;7085 induced ferroptosis. Cancer Lett 416: 124&#x2013;137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29274359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang X, Wang H, Han D, Xie E, Yang X, Wei J, Gu S, Gao F, Zhu N, Yin X, Cheng Q, Zhang P, Dai W, Chen J, Yang F, Yang HT, Linkermann A, Gu W, Min J, and Wang F 2019. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A 116: 2672&#x2013;2680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6377499</ArticleId>
            <ArticleId IdType="pubmed">30692261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, and Zhang DD 2009. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 34: 663&#x2013;673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2714804</ArticleId>
            <ArticleId IdType="pubmed">19560419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pawelec G, Verschoor CP, and Ostrand-Rosenberg S 2019. Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity. Front Immunol 10: 1099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6529572</ArticleId>
            <ArticleId IdType="pubmed">31156644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B, Vandenabeele P, and Vanden Berghe T 2019. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell 35: 830&#x2013;849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, and Zou W 2019. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569: 270&#x2013;274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, Sirohi K, Li X, Wei Y, Lee H, Zhuang L, Chen G, Xiao ZD, Hung MC, Chen J, Huang P, Li W, and Gan B 2018. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 20: 1181&#x2013;1192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6170713</ArticleId>
            <ArticleId IdType="pubmed">30202049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiang SK, Chen SE, and Chang LC 2019. A Dual Role of Heme Oxygenase-1 in Cancer Cells. International Journal of Molecular Sciences 20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6337503</ArticleId>
            <ArticleId IdType="pubmed">30583467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jenkins NL, James SA, Salim A, Sumardy F, Speed TP, Conrad M, Richardson DR, Bush AI, and McColl G 2020. Ferrous-glutathione coupling mediates ferroptosis and frailty in Caenorhabditis elegans. bioRxiv: 10.1101/594408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/594408</ArticleId>
            <ArticleId IdType="pmc">PMC7373428</ArticleId>
            <ArticleId IdType="pubmed">32690135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papanikolaou G, and Pantopoulos K 2005. Iron metabolism and toxicity. Toxicol Appl Pharmacol 202: 199&#x2013;211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15629195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, and Stockwell BR 2014. Regulation of ferroptotic cancer cell death by GPX4. Cell 156: 317&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, and Mattson MP 2004. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A 101: 2070&#x2013;2075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC357053</ArticleId>
            <ArticleId IdType="pubmed">14970312</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33311482</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-1723</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature communications</Title>
          <ISOAbbreviation>Nat Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway.</ArticleTitle>
        <Pagination>
          <StartPage>6339</StartPage>
          <MedlinePgn>6339</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">6339</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-020-20154-8</ELocationID>
        <Abstract>
          <AbstractText>Ferroptosis is a more recently recognized form of cell death that relies on iron-mediated oxidative damage. Here, we evaluate the impact of high-iron diets or depletion of Gpx4, an antioxidant enzyme reported as an important ferroptosis suppressor, in the pancreas of mice with cerulean- or L-arginine-induced pancreatitis, and in an oncogenic Kras murine model of spontaneous pancreatic ductal adenocarcinoma (PDAC). We find that either high-iron diets or Gpx4 depletion promotes 8-OHG release and thus activates the TMEM173/STING-dependent DNA sensor pathway, which results in macrophage infiltration and activation during Kras-driven PDAC in mice. Consequently, the administration of liproxstatin-1 (a ferroptosis inhibitor), clophosome-mediated macrophage depletion, or pharmacological and genetic inhibition of the 8-OHG-TMEM173 pathway suppresses Kras-driven pancreatic tumorigenesis in mice. GPX4 is also a prognostic marker in patients with PDAC. These findings provide pathological and mechanistic insights into ferroptotic damage in PDAC tumorigenesis in mice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Enyong</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Leng</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jiao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Protein Modification and Degradation Lab, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Yangchun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zeh</LastName>
            <ForeName>Herbert J</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kang</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bai</LastName>
            <ForeName>Lulu</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-8163-2071</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Hematology, First Hospital of Jilin University, Changchun, Jilin, 130021, China. bailulu@jlu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Daolin</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-1903-6180</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA. daolin.tang@utsouthwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA211070</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Commun</MedlineTA>
        <NlmUniqueID>101528555</NlmUniqueID>
        <ISSNLinking>2041-1723</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013141">Spiro Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C530855">Sting1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000595890">liproxstatin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.9</RegistryNumber>
          <NameOfSubstance UI="C000611332">glutathione peroxidase 4, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.2</RegistryNumber>
          <NameOfSubstance UI="C495971">Hras protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.2</RegistryNumber>
          <NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021441" MajorTopicYN="N">Carcinoma, Pancreatic Ductal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010179" MajorTopicYN="N">Pancreas</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013141" MajorTopicYN="N">Spiro Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>10</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33311482</ArticleId>
        <ArticleId IdType="pmc">PMC7732843</ArticleId>
        <ArticleId IdType="doi">10.1038/s41467-020-20154-8</ArticleId>
        <ArticleId IdType="pii">10.1038/s41467-020-20154-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kleeff J, et al. Pancreatic cancer. Nat. Rev. Dis. Prim. 2016;2:16022. doi: 10.1038/nrdp.2016.22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2016.22</ArticleId>
            <ArticleId IdType="pubmed">27158978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waters, A. M. &amp; Der, C. J. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect. Med.8, a031435 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5995645</ArticleId>
            <ArticleId IdType="pubmed">29229669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feig C, et al. The pancreas cancer microenvironment. Clin. Cancer Res. 2012;18:4266&#x2013;4276. doi: 10.1158/1078-0432.CCR-11-3114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-3114</ArticleId>
            <ArticleId IdType="pmc">PMC3442232</ArticleId>
            <ArticleId IdType="pubmed">22896693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seifert L, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature. 2016;532:245&#x2013;249. doi: 10.1038/nature17403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature17403</ArticleId>
            <ArticleId IdType="pmc">PMC4833566</ArticleId>
            <ArticleId IdType="pubmed">27049944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Lotze MT, Kang R, Zeh HJ. Apoptosis promotes early tumorigenesis. Oncogene. 2011;30:1851&#x2013;1854. doi: 10.1038/onc.2010.573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2010.573</ArticleId>
            <ArticleId IdType="pubmed">21151175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Kroemer G. Ferroptosis. Curr. Biol. 2020;30:R1292&#x2013;R1297. doi: 10.1016/j.cub.2020.09.068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2020.09.068</ArticleId>
            <ArticleId IdType="pubmed">33142092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol. Cell. Oncol. 2015;2:e1054549. doi: 10.1080/23723556.2015.1054549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/23723556.2015.1054549</ArticleId>
            <ArticleId IdType="pmc">PMC4905356</ArticleId>
            <ArticleId IdType="pubmed">27308510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep. 2017;20:1692&#x2013;1704. doi: 10.1016/j.celrep.2017.07.055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.07.055</ArticleId>
            <ArticleId IdType="pubmed">28813679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 2014;16:1180&#x2013;1191. doi: 10.1038/ncb3064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3064</ArticleId>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369&#x2013;379. doi: 10.1038/cdd.2015.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.158</ArticleId>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang, D., Chen, X., Kang, R. &amp;&#xa0;Kroemer, G.&#xa0;Ferroptosis: molecular mechanisms and health implications. Cell&#xa0;Rec.&#xa0;1&#x2013;19 10.1038/s41422-020-00441-1 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33268902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830&#x2013;849. doi: 10.1016/j.ccell.2019.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2019.04.002</ArticleId>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuang F, Liu J, Tang D, Kang R. Oxidative damage and antioxidant defense in ferroptosis. Front. Cell Dev. Biol. 2020;8:586578. doi: 10.3389/fcell.2020.586578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2020.586578</ArticleId>
            <ArticleId IdType="pmc">PMC7527737</ArticleId>
            <ArticleId IdType="pubmed">33043019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hingorani SR, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437&#x2013;450. doi: 10.1016/S1535-6108(03)00309-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1535-6108(03)00309-X</ArticleId>
            <ArticleId IdType="pubmed">14706336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mielgo A, Schmid MC. Impact of tumour associated macrophages in pancreatic cancer. BMB Rep. 2013;46:131&#x2013;138. doi: 10.5483/BMBRep.2013.46.3.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5483/BMBRep.2013.46.3.036</ArticleId>
            <ArticleId IdType="pmc">PMC4133870</ArticleId>
            <ArticleId IdType="pubmed">23527856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Y, et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity. 2017;47:597. doi: 10.1016/j.immuni.2017.08.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2017.08.018</ArticleId>
            <ArticleId IdType="pmc">PMC5664180</ArticleId>
            <ArticleId IdType="pubmed">28930665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in cancer. Trends Immunol. 2019;40:310&#x2013;327. doi: 10.1016/j.it.2019.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2019.02.003</ArticleId>
            <ArticleId IdType="pubmed">30890304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raes G, et al. Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J. Immunol. 2005;174:6561. doi: 10.4049/jimmunol.174.11.6561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.174.11.6561</ArticleId>
            <ArticleId IdType="pubmed">15905489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griesmann H, et al. Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. Gut. 2017;66:1278&#x2013;1285. doi: 10.1136/gutjnl-2015-310049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2015-310049</ArticleId>
            <ArticleId IdType="pubmed">27013602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol. Rev. 2012;249:158&#x2013;175. doi: 10.1111/j.1600-065X.2012.01146.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-065X.2012.01146.x</ArticleId>
            <ArticleId IdType="pmc">PMC3662247</ArticleId>
            <ArticleId IdType="pubmed">22889221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura K, et al. Beta-blockers and oxidative stress in patients with heart failure. Pharmaceuticals. 2011;4:1088&#x2013;1100. doi: 10.3390/ph4081088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph4081088</ArticleId>
            <ArticleId IdType="pmc">PMC4058661</ArticleId>
            <ArticleId IdType="pubmed">26791643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003;17:1195&#x2013;1214. doi: 10.1096/fj.02-0752rev.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.02-0752rev</ArticleId>
            <ArticleId IdType="pubmed">12832285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barber GN. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 2015;15:760&#x2013;770. doi: 10.1038/nri3921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3921</ArticleId>
            <ArticleId IdType="pmc">PMC5004891</ArticleId>
            <ArticleId IdType="pubmed">26603901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motwani, M., Pesiridis, S. &amp; Fitzgerald, K. A. DNA sensing by the cGAS-STING pathway in health and disease. Nat. Rev. Genet.20, 657&#x2013;674 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31358977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gehrke N, et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity. 2013;39:482&#x2013;495. doi: 10.1016/j.immuni.2013.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2013.08.004</ArticleId>
            <ArticleId IdType="pubmed">23993650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badgley MA, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368:85&#x2013;89. doi: 10.1126/science.aaw9872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaw9872</ArticleId>
            <ArticleId IdType="pmc">PMC7681911</ArticleId>
            <ArticleId IdType="pubmed">32241947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486&#x2013;541. doi: 10.1038/s41418-017-0012-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-017-0012-4</ArticleId>
            <ArticleId IdType="pmc">PMC5864239</ArticleId>
            <ArticleId IdType="pubmed">29362479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29:347&#x2013;364. doi: 10.1038/s41422-019-0164-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-019-0164-5</ArticleId>
            <ArticleId IdType="pmc">PMC6796845</ArticleId>
            <ArticleId IdType="pubmed">30948788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen, X., Li, J., Kang, R., Klionsky, D. J. &amp; Tang, D. Ferroptosis: machinery and regulation. Autophagy10.1080/15548627.2020.1810918, 1&#x2013;28 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 2016;7:e2253. doi: 10.1038/cddis.2016.105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2016.105</ArticleId>
            <ArticleId IdType="pmc">PMC5143371</ArticleId>
            <ArticleId IdType="pubmed">27277675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Kim J, Bae JS. ROS homeostasis and metabolism: a critical liaison for cancer therapy. Exp. Mol. Med. 2016;48:e269. doi: 10.1038/emm.2016.119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emm.2016.119</ArticleId>
            <ArticleId IdType="pmc">PMC5133371</ArticleId>
            <ArticleId IdType="pubmed">27811934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai, E. et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy&#xa0;16, 2069&#x2013;2083 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7595620</ArticleId>
            <ArticleId IdType="pubmed">31920150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;274. doi: 10.1038/s41586-019-1170-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57&#x2013;62. doi: 10.1038/nature14344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14344</ArticleId>
            <ArticleId IdType="pmc">PMC4455927</ArticleId>
            <ArticleId IdType="pubmed">25799988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei, G. et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res.30, 1&#x2013;17 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7015061</ArticleId>
            <ArticleId IdType="pubmed">31949285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B, et al. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. J. Clin. Invest. 2018;128:3341&#x2013;3355. doi: 10.1172/JCI99032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI99032</ArticleId>
            <ArticleId IdType="pmc">PMC6063467</ArticleId>
            <ArticleId IdType="pubmed">29939160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie, Y., Kuang, F., Liu, J., Tang, D. &amp; Kang, R. DUSP1 blocks autophagy-dependent ferroptosis in pancreatic cancer. J. Pancreatol.3, 154&#x2013;160 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Kang R, et al. Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res. 2017;27:916&#x2013;932. doi: 10.1038/cr.2017.51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2017.51</ArticleId>
            <ArticleId IdType="pmc">PMC5518983</ArticleId>
            <ArticleId IdType="pubmed">28374746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 2013;73:6359&#x2013;6374. doi: 10.1158/0008-5472.CAN-13-1558-T.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-1558-T</ArticleId>
            <ArticleId IdType="pmc">PMC3831882</ArticleId>
            <ArticleId IdType="pubmed">24097820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, et al. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Oncotarget. 2016;7:52993&#x2013;53004. doi: 10.18632/oncotarget.10323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.10323</ArticleId>
            <ArticleId IdType="pmc">PMC5288163</ArticleId>
            <ArticleId IdType="pubmed">27367029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinowaki Y, et al. Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma. Lab Invest. 2018;98:609&#x2013;619. doi: 10.1038/s41374-017-0008-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41374-017-0008-1</ArticleId>
            <ArticleId IdType="pubmed">29463878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem. Biol. 2019;26:e629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6525071</ArticleId>
            <ArticleId IdType="pubmed">30799221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez GR, et al. Oxidative and alkylating damage in DNA. Mutat. Res. 2003;544:115&#x2013;127. doi: 10.1016/j.mrrev.2003.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mrrev.2003.05.005</ArticleId>
            <ArticleId IdType="pubmed">14644314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harima H, et al. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. BMC Cancer. 2016;16:702. doi: 10.1186/s12885-016-2744-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-016-2744-9</ArticleId>
            <ArticleId IdType="pmc">PMC5007806</ArticleId>
            <ArticleId IdType="pubmed">27582255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovacevic Z, Chikhani S, Lovejoy DB, Richardson DR. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol. Pharm. 2011;80:598&#x2013;609. doi: 10.1124/mol.111.073627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.111.073627</ArticleId>
            <ArticleId IdType="pubmed">21719465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C, et al. PINK1 and PARK2 suppress pancreatic tumorigenesis through control of mitochondrial iron-mediated immunometabolism. Dev. Cell. 2018;46:e448. doi: 10.1016/j.devcel.2018.07.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2018.07.012</ArticleId>
            <ArticleId IdType="pmc">PMC7654182</ArticleId>
            <ArticleId IdType="pubmed">30100261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinkead, H. L. et al. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. JCI Insight3, e122857 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6237485</ArticleId>
            <ArticleId IdType="pubmed">30333318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakhoum SF, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553:467&#x2013;472. doi: 10.1038/nature25432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature25432</ArticleId>
            <ArticleId IdType="pmc">PMC5785464</ArticleId>
            <ArticleId IdType="pubmed">29342134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang R, et al. Intracellular Hmgb1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. Gastroenterology. 2014;146:1097&#x2013;1107. doi: 10.1053/j.gastro.2013.12.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2013.12.015</ArticleId>
            <ArticleId IdType="pmc">PMC3965592</ArticleId>
            <ArticleId IdType="pubmed">24361123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mareninova OA, et al. Impaired autophagic flux mediates acinar cell vacuole formation and trypsinogen activation in rodent models of acute pancreatitis. J. Clin. Invest. 2009;119:3340&#x2013;3355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2769194</ArticleId>
            <ArticleId IdType="pubmed">19805911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramu I, et al. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer. EBioMedicine. 2019;48:161&#x2013;168. doi: 10.1016/j.ebiom.2019.09.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ebiom.2019.09.024</ArticleId>
            <ArticleId IdType="pmc">PMC6838446</ArticleId>
            <ArticleId IdType="pubmed">31597597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X, et al. JTC801 induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice. Gastroenterology. 2018;154:1480&#x2013;1493. doi: 10.1053/j.gastro.2017.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2017.12.004</ArticleId>
            <ArticleId IdType="pmc">PMC5880694</ArticleId>
            <ArticleId IdType="pubmed">29248440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang, J. et al. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Gut10.1136/gutjnl-2019-320441&#xa0;(2020).&#xa0;</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32816920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, et al. Inhibition of aurora kinase A induces necroptosis in pancreatic carcinoma. Gastroenterology. 2017;153:e1425. doi: 10.1053/j.gastro.2017.07.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2017.07.036</ArticleId>
            <ArticleId IdType="pmc">PMC5670014</ArticleId>
            <ArticleId IdType="pubmed">28764929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weischenfeldt, J. &amp; Porse, B. Bone marrow-derived macrophages (BMM): isolation and applications. CSH Protoc.2008, pdb prot5080 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21356739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, et al. TMEM173 drives lethal coagulation in sepsis. Cell Host Microbe. 2020;27:e556. doi: 10.1016/j.chom.2020.02.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2020.02.004</ArticleId>
            <ArticleId IdType="pmc">PMC7316085</ArticleId>
            <ArticleId IdType="pubmed">32142632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dizdaroglu M, Jaruga P, Rodriguez H. Measurement of 8-hydroxy-2&#x2019;-deoxyguanosine in DNA by high-performance liquid chromatography-mass spectrometry: comparison with measurement by gas chromatography-mass spectrometry. Nucleic Acids Res. 2001;29:E12. doi: 10.1093/nar/29.3.e12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/29.3.e12</ArticleId>
            <ArticleId IdType="pmc">PMC30413</ArticleId>
            <ArticleId IdType="pubmed">11160914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ceylan D, et al. Oxidatively-induced DNA damage and base excision repair in euthymic patients with bipolar disorder. DNA Rep. 2018;65:64&#x2013;72. doi: 10.1016/j.dnarep.2018.03.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dnarep.2018.03.006</ArticleId>
            <ArticleId IdType="pmc">PMC7243967</ArticleId>
            <ArticleId IdType="pubmed">29626765</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33277233</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>10</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2326-6074</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer immunology research</Title>
          <ISOAbbreviation>Cancer Immunol Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8[+] T Cells.</ArticleTitle>
        <Pagination>
          <StartPage>184</StartPage>
          <EndPage>199</EndPage>
          <MedlinePgn>184-199</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/2326-6066.CIR-20-0384</ELocationID>
        <Abstract>
          <AbstractText>Metabolic constraints in the tumor microenvironment constitute a barrier to effective antitumor immunity and similarities in the metabolic properties of T cells and cancer cells impede the specific therapeutic targeting of metabolism in either population. To identify distinct metabolic vulnerabilities of CD8[+] T cells and cancer cells, we developed a high-throughput in vitro pharmacologic screening platform and used it to measure the cell type-specific sensitivities of activated CD8[+] T cells and B16 melanoma cells to a wide array of metabolic perturbations during antigen-specific killing of cancer cells by CD8[+] T cells. We illustrated the applicability of this screening platform by showing that CD8[+] T cells were more sensitive to ferroptosis induction by inhibitors of glutathione peroxidase 4 (GPX4) than B16 and MC38 cancer cells. Overexpression of ferroptosis suppressor protein 1 (FSP1) or cytosolic GPX4 yielded ferroptosis-resistant CD8[+] T cells without compromising their function, while genetic deletion of the ferroptosis sensitivity-promoting enzyme acyl-CoA synthetase long-chain family member 4 (ACSL4) protected CD8[+] T cells from ferroptosis but impaired antitumor CD8[+] T-cell responses. Our screen also revealed high T cell-specific vulnerabilities for compounds targeting NAD[+] metabolism or autophagy and endoplasmic reticulum (ER) stress pathways. We focused the current screening effort on metabolic agents. However, this in vitro screening platform may also be valuable for rapid testing of other types of compounds to identify regulators of antitumor CD8[+] T-cell function and potential therapeutic targets.</AbstractText>
          <CopyrightInformation>&#xa9;2020 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Drijvers</LastName>
            <ForeName>Jefte M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Gillis</LastName>
            <ForeName>Jacob E</ForeName>
            <Initials>JE</Initials>
            <Identifier Source="ORCID">0000-0001-6248-693X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Muijlwijk</LastName>
            <ForeName>Tara</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0003-3827-5694</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Nguyen</LastName>
            <ForeName>Thao H</ForeName>
            <Initials>TH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gaudiano</LastName>
            <ForeName>Emily F</ForeName>
            <Initials>EF</Initials>
            <Identifier Source="ORCID">0000-0001-9523-1183</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harris</LastName>
            <ForeName>Isaac S</ForeName>
            <Initials>IS</Initials>
            <Identifier Source="ORCID">0000-0002-6855-2763</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>LaFleur</LastName>
            <ForeName>Martin W</ForeName>
            <Initials>MW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ringel</LastName>
            <ForeName>Alison E</ForeName>
            <Initials>AE</Initials>
            <Identifier Source="ORCID">0000-0002-6451-9376</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Cong-Hui</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kurmi</LastName>
            <ForeName>Kiran</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Juneja</LastName>
            <ForeName>Vikram R</ForeName>
            <Initials>VR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trombley</LastName>
            <ForeName>Justin D</ForeName>
            <Initials>JD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haigis</LastName>
            <ForeName>Marcia C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts. arlene_sharpe@hms.harvard.edu marcia_haigis@hms.harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharpe</LastName>
            <ForeName>Arlene H</ForeName>
            <Initials>AH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Blavatnik Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts. arlene_sharpe@hms.harvard.edu marcia_haigis@hms.harvard.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>F31 CA224601</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 CA207021</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U19 AI133524</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 CA225088</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Immunol Res</MedlineTA>
        <NlmUniqueID>101614637</NlmUniqueID>
        <ISSNLinking>2326-6066</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33277233</ArticleId>
        <ArticleId IdType="mid">NIHMS1651264</ArticleId>
        <ArticleId IdType="pmc">PMC7864883</ArticleId>
        <ArticleId IdType="doi">10.1158/2326-6066.CIR-20-0384</ArticleId>
        <ArticleId IdType="pii">2326-6066.CIR-20-0384</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019;234:8509&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30520029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7238960</ArticleId>
            <ArticleId IdType="pubmed">32433532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaFleur MW, Muroyama Y, Drake CG, Sharpe AH. Inhibitors of the PD-1 Pathway in Tumor Therapy. J Immunol. 2018;200:375&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5924692</ArticleId>
            <ArticleId IdType="pubmed">29311378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>June CH, O&#x2019;Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29567707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dougan M, Dranoff G, Dougan SK. Cancer Immunotherapy: Beyond Checkpoint Blockade. Annu Rev Cancer Biol. 2019;3:55&#x2013;75.</Citation>
        </Reference>
        <Reference>
          <Citation>Newick K, O&#x2019;Brien S, Moon E, Albelda SM. CAR T Cell Therapy for Solid Tumors. Annu Rev Med. 2017;68:139&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27860544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8214555</ArticleId>
            <ArticleId IdType="pubmed">30837712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM. Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunol Res. 2017;5:9&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5340074</ArticleId>
            <ArticleId IdType="pubmed">27941003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, et al. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction Immunity. Elsevier Inc.; 2016;45:374&#x2013;88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5207350</ArticleId>
            <ArticleId IdType="pubmed">27496732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scharping NE, Delgoffe GM. Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. Vaccines. 2016;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5192366</ArticleId>
            <ArticleId IdType="pubmed">27929420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI insight. 2017;2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5470888</ArticleId>
            <ArticleId IdType="pubmed">28614802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugiura A, Rathmell JC. Metabolic Barriers to T Cell Function in Tumors. J Immunol. 2018;200:400&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5777533</ArticleId>
            <ArticleId IdType="pubmed">29311381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drijvers JM, Sharpe AH, Haigis MC. The effects of age and systemic metabolism on anti-tumor T cell responses. Elife. 2020;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7655106</ArticleId>
            <ArticleId IdType="pubmed">33170123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang C-H, Qiu J, O&#x2019;Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162:1229&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4864363</ArticleId>
            <ArticleId IdType="pubmed">26321679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho PC, Bihuniak JD, MacIntyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses Cell. Elsevier Inc.; 2015;162:1217&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4567953</ArticleId>
            <ArticleId IdType="pubmed">26321681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang CH, Curtis JD, Maggi LB, Faubert B, Villarino AV., O&#x2019;Sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis Cell. Elsevier Inc.; 2013;153:1239&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3804311</ArticleId>
            <ArticleId IdType="pubmed">23746840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte Activation Immunity. Elsevier Inc.; 2011;35:871&#x2013;82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3248798</ArticleId>
            <ArticleId IdType="pubmed">22195744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ron-Harel N, Santos D, Ghergurovich JM, Sage PT, Reddy A, Lovitch SB, et al. Mitochondrial Biogenesis and Proteome Remodeling Promote One-Carbon Metabolism for T Cell Activation Cell Metab. Elsevier Inc.; 2016;24:104&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5330619</ArticleId>
            <ArticleId IdType="pubmed">27411012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic Instruction of Immunity. Cell. 2017;169:570&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5648021</ArticleId>
            <ArticleId IdType="pubmed">28475890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity. 2013;39:1&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23890059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrejeva G, Rathmell JC. Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. Cell Metab. 2017;26:49&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5555084</ArticleId>
            <ArticleId IdType="pubmed">28683294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaFleur MW, Nguyen TH, Coxe MA, Yates KB, Trombley JD, Weiss SA, et al. A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system. Nat Commun. 2019;10:1668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6458184</ArticleId>
            <ArticleId IdType="pubmed">30971695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaFleur MW, Nguyen TH, Coxe MA, Miller BC, Yates KB, Gillis JE, et al. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat Immunol. 2019;20:1335&#x2013;47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6754306</ArticleId>
            <ArticleId IdType="pubmed">31527834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20:326&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6673650</ArticleId>
            <ArticleId IdType="pubmed">30778252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurachi M, Kurachi J, Chen Z, Johnson J, Khan O, Bengsch B, et al. Optimized retroviral transduction of mouse T cells for in vivo assessment of gene function. Nat Protoc. 2017;12:1980&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6020692</ArticleId>
            <ArticleId IdType="pubmed">28858287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895&#x2013;904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5379970</ArticleId>
            <ArticleId IdType="pubmed">28302645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke SR, Barnden M, Kurts C, Carbone FR, Miller JF, Heath WR. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol Cell Biol. 2000;78:110&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10762410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehrotra PT, Wu D, Crim JA, Mostowski HS, Siegel JP. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol. 1993;151:2444&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8103066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Havele C, Paetkau V. Cyclosporine blocks the activation of antigen-dependent cytotoxic T lymphocytes directly by an IL-2-independent mechanism. J Immunol. 1988;140:3303&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2966195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris IS, Endress JE, Coloff JL, Selfors LM, McBrayer SK, Rosenbluth JM, et al. Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell Metab. 2019;29:1166&#x2013;1181. e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6506399</ArticleId>
            <ArticleId IdType="pubmed">30799286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsushita M, Freigang S, Schneider C, Conrad M, Bornkamm GW, Kopf M. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J Exp Med. 2015;212:555&#x2013;68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4387287</ArticleId>
            <ArticleId IdType="pubmed">25824823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brigelius-Floh&#xe9; R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta. 2013;1830:3289&#x2013;303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23201771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35:830&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31105042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee H-J, Purohit V, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368:85&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7681911</ArticleId>
            <ArticleId IdType="pubmed">32241947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, Gij&#xf3;n M, Kennedy PD, Johnson JK, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M, Pratt DA. The chemical basis of ferroptosis. Nat Chem Biol. 2019;15:1137&#x2013;47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31740834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Stockwell BR. The Hallmarks of Ferroptosis. Annu Rev Cancer Biol. 2019;3:35&#x2013;54.</Citation>
        </Reference>
        <Reference>
          <Citation>Weinberg F, Ramnath N, Nagrath D. Reactive Oxygen Species in the Tumor Microenvironment: An Overview. Cancers (Basel). 2019;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6721577</ArticleId>
            <ArticleId IdType="pubmed">31426364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MWL, Ngiow SF, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010;70:7788&#x2013;99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20924102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31634899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Mao G, Qu F, Angeli JPF, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Li X, Zhang X, Kang R, Tang D. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016;478:1338&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27565726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, et al. Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem Biol. 2015;10:1604&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4509420</ArticleId>
            <ArticleId IdType="pubmed">25965523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Horn CG, Caviglia JM, Li LO, Wang S, Granger DA, Coleman RA. Characterization of recombinant long-chain rat acyl-CoA synthetase isoforms 3 and 6: identification of a novel variant of isoform 6. Biochemistry. 2005;44:1635&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15683247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ursini F, Maiorino M, Gregolin C. The selenoenzyme phospholipid hydroperoxide glutathione peroxidase. Biochim Biophys Acta. 1985;839:62&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3978121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5667900</ArticleId>
            <ArticleId IdType="pubmed">28678785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5933935</ArticleId>
            <ArticleId IdType="pubmed">29088702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu W, Kang Y. Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis. Dev Cell. 2019;49:361&#x2013;74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6506183</ArticleId>
            <ArticleId IdType="pubmed">31063755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa A, Scholer-Dahirel A, Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin Cancer Biol. 2014;25:23&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24406211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agmon E, Stockwell BR. Lipid homeostasis and regulated cell death. Curr Opin Chem Biol. 2017;39:83&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5581689</ArticleId>
            <ArticleId IdType="pubmed">28645028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lone AM, Task&#xe9;n K. Proinflammatory and immunoregulatory roles of eicosanoids in T cells. Front Immunol. 2013;4:130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3671288</ArticleId>
            <ArticleId IdType="pubmed">23760108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A, et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One. 2009;4:e7897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2774509</ArticleId>
            <ArticleId IdType="pubmed">19936064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chatterjee S, Daenthanasanmak A, Chakraborty P, Wyatt MW, Dhar P, Selvam SP, et al. CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell Metab. 2018;27:85&#x2013;100. e8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5837048</ArticleId>
            <ArticleId IdType="pubmed">29129787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song M, Cubillos-Ruiz JR. Endoplasmic Reticulum Stress Responses in Intratumoral Immune Cells: Implications for Cancer Immunotherapy. Trends Immunol. 2019;40:128&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30612925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song M, Sandoval TA, Chae C-S, Chopra S, Tan C, Rutkowski MR, et al. IRE1&#x3b1;-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature. 2018;562:423&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6237282</ArticleId>
            <ArticleId IdType="pubmed">30305738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma EH, Verway MJ, Johnson RM, Roy DG, Steadman M, Hayes S, et al. Metabolic Profiling Using Stable Isotope Tracing Reveals Distinct Patterns of Glucose Utilization by Physiologically Activated CD8+ T Cells. Immunity. 2019;51:856&#x2013;870. e5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31747582</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33236624</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1944-8252</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>49</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS applied materials &amp; interfaces</Title>
          <ISOAbbreviation>ACS Appl Mater Interfaces</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Intravesical In Situ Immunostimulatory Gel for Triple Therapy of Bladder Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>54367</StartPage>
          <EndPage>54377</EndPage>
          <MedlinePgn>54367-54377</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acsami.0c15176</ELocationID>
        <Abstract>
          <AbstractText>Bladder cancer displays multiple biological features aided in drug resistance; therefore, single therapy fails to induce complete tumor regression. To address this issue, various kinds of cell death of cancer cells as well as restoring tumor immune microenvironment need to be taken into consideration. Here, we introduce a gel system termed AuNRs&amp;IONs@Gel, which target-delivers a combination of photothermal, ferroptotic, and immune therapy through intravesical instillation. AuNRs&amp;IONs@Gel consists of a gel delivery platform, embedded gold nanorods (AuNRs), and iron oxide nanoparticles (IONs). The targeted delivery gel platform provides dextran aldehyde-selective adhesion with cancer collagen. In this condition, photothermal therapy can be performed by gold nanorods (AuNRs) under imaging-guided near-infrared radiation. Local high concentrations of IONs can be absorbed by cancer cell to induce ferroptosis. Moreover, tumor-associated macrophages which often display an immune-suppressive M2-like phenotype will be repolarized by IONs into the antitumor M1-like phenotype, exerting a direct antitumor effect and professional antigen presentation of dead cancer cells. This process triggers a potent immune response of innate and adapt immunities to protect tumor rechallenge in long terms. Our triple-therapy strategy employs FDA-approved nanoparticles to inhibit bladder cancer which may possess great potential for clinical translation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Pengyu</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Urology Surgery Department, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Heilongjiang Key Laboratory of Scientific Research in Urology, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Hospital of Harbin Medical University, Harbin 150001, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Urology Surgery Department, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Heilongjiang Key Laboratory of Scientific Research in Urology, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Hospital of Harbin Medical University, Harbin 150001, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shang</LastName>
            <ForeName>Wenting</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jiuwei</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Urology Surgery Department, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Heilongjiang Key Laboratory of Scientific Research in Urology, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Hospital of Harbin Medical University, Harbin 150001, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Ziyin</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Urology Surgery Department, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Heilongjiang Key Laboratory of Scientific Research in Urology, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Hospital of Harbin Medical University, Harbin 150001, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiong</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Urology Surgery Department, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Heilongjiang Key Laboratory of Scientific Research in Urology, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Hospital of Harbin Medical University, Harbin 150001, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ziqi</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Urology Surgery Department, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Heilongjiang Key Laboratory of Scientific Research in Urology, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Hospital of Harbin Medical University, Harbin 150001, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tong</LastName>
            <ForeName>Zhichao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Urology Surgery Department, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Heilongjiang Key Laboratory of Scientific Research in Urology, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Hospital of Harbin Medical University, Harbin 150001, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Keliang</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Urology Surgery Department, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Heilongjiang Key Laboratory of Scientific Research in Urology, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Hospital of Harbin Medical University, Harbin 150001, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Liming</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathophysiology, Key Laboratory of Cardiovascular Pathophysiology, Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-0498-0432</Identifier>
            <AffiliationInfo>
              <Affiliation>CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Wanhai</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0003-0123-2826</Identifier>
            <AffiliationInfo>
              <Affiliation>Urology Surgery Department, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Heilongjiang Key Laboratory of Scientific Research in Urology, The Fourth Hospital of Harbin Medical University, Harbin 150081, P. R. China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, The Fourth Hospital of Harbin Medical University, Harbin 150001, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ACS Appl Mater Interfaces</MedlineTA>
        <NlmUniqueID>101504991</NlmUniqueID>
        <ISSNLinking>1944-8244</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003911">Dextrans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005290">Ferric Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005782">Gels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1K09F3G675</RegistryNumber>
          <NameOfSubstance UI="C000499">ferric oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7440-57-5</RegistryNumber>
          <NameOfSubstance UI="D006046">Gold</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003911" MajorTopicYN="N">Dextrans</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005290" MajorTopicYN="N">Ferric Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005782" MajorTopicYN="N">Gels</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006046" MajorTopicYN="N">Gold</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007259" MajorTopicYN="N">Infrared Rays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049329" MajorTopicYN="N">Nanostructures</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">PTT</Keyword>
        <Keyword MajorTopicYN="N">bladder cancer</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">intravesical therapy</Keyword>
        <Keyword MajorTopicYN="N">macrophage</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>25</Day>
          <Hour>8</Hour>
          <Minute>36</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33236624</ArticleId>
        <ArticleId IdType="doi">10.1021/acsami.0c15176</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32814895</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-4687</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>585</Volume>
            <Issue>7823</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature</Title>
          <ISOAbbreviation>Nature</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lymph protects metastasizing melanoma cells from ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>113</StartPage>
          <EndPage>118</EndPage>
          <MedlinePgn>113-118</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2623-z</ELocationID>
        <Abstract>
          <AbstractText>Cancer cells, including melanoma cells, often metastasize regionally through the lymphatic system before metastasizing systemically through the blood[1-4]; however, the reason for this is unclear. Here we show that melanoma cells in lymph experience less oxidative stress and form more metastases than melanoma cells in blood. Immunocompromised mice with melanomas derived from patients, and immunocompetent mice with mouse melanomas, had more melanoma cells per microlitre in tumour-draining lymph than in tumour-draining blood. Cells that metastasized through blood, but not those that metastasized through lymph, became dependent on the ferroptosis inhibitor GPX4. Cells that were pretreated with chemical ferroptosis inhibitors formed more metastases than untreated cells after intravenous, but not intralymphatic, injection. We observed multiple differences between lymph fluid and blood plasma that may contribute to decreased oxidative stress and ferroptosis in lymph, including higher levels of glutathione and oleic acid and less free iron in lymph. Oleic acid protected melanoma cells from ferroptosis in an Acsl3-dependent manner and increased their capacity to form metastatic tumours. Melanoma cells from lymph nodes were more resistant to ferroptosis and formed more metastases after intravenous injection than did melanoma cells from subcutaneous tumours. Exposure to the lymphatic environment thus protects melanoma cells from ferroptosis and increases their ability to survive during subsequent metastasis through the blood.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ubellacker</LastName>
            <ForeName>Jessalyn M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tasdogan</LastName>
            <ForeName>Alpaslan</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramesh</LastName>
            <ForeName>Vijayashree</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-5237-6144</Identifier>
            <AffiliationInfo>
              <Affiliation>Children's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mitchell</LastName>
            <ForeName>Evann C</ForeName>
            <Initials>EC</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martin-Sandoval</LastName>
            <ForeName>Misty S</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Zhimin</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McCormick</LastName>
            <ForeName>Michael L</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Free Radical and Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Durham</LastName>
            <ForeName>Alison B</ForeName>
            <Initials>AB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spitz</LastName>
            <ForeName>Douglas R</ForeName>
            <Initials>DR</Initials>
            <AffiliationInfo>
              <Affiliation>Free Radical and Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Zhiyu</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0001-6308-6997</Identifier>
            <AffiliationInfo>
              <Affiliation>Children's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mathews</LastName>
            <ForeName>Thomas P</ForeName>
            <Initials>TP</Initials>
            <AffiliationInfo>
              <Affiliation>Children's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morrison</LastName>
            <ForeName>Sean J</ForeName>
            <Initials>SJ</Initials>
            <Identifier Source="ORCID">0000-0003-1587-8329</Identifier>
            <AffiliationInfo>
              <Affiliation>Children's Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA. Sean.Morrison@UTSouthwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA. Sean.Morrison@UTSouthwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA. Sean.Morrison@UTSouthwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA086862</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 CA228608</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>F32 HL139016</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA217797</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 ES005605</GrantID>
            <Acronym>ES</Acronym>
            <Agency>NIEHS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nature</MedlineTA>
        <NlmUniqueID>0410462</NlmUniqueID>
        <ISSNLinking>0028-0836</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>2UMI9U37CP</RegistryNumber>
          <NameOfSubstance UI="D019301">Oleic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.9</RegistryNumber>
          <NameOfSubstance UI="C000611332">glutathione peroxidase 4, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.1.2.3</RegistryNumber>
          <NameOfSubstance UI="C000633565">Acsl3 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.2.1.-</RegistryNumber>
          <NameOfSubstance UI="D003066">Coenzyme A Ligases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Nature. 2020 Sep;585(7823):36-37</RefSource>
          <PMID Version="1">32814912</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Cancer Cell. 2020 Oct 12;38(4):446-448</RefSource>
          <PMID Version="1">32916127</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Signal Transduct Target Ther. 2020 Nov 4;5(1):261</RefSource>
          <PMID Version="1">33149129</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003066" MajorTopicYN="N">Coenzyme A Ligases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008196" MajorTopicYN="N">Lymph</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019301" MajorTopicYN="N">Oleic Acid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025341" MajorTopicYN="N">Principal Component Analysis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32814895</ArticleId>
        <ArticleId IdType="mid">NIHMS1610560</ArticleId>
        <ArticleId IdType="pmc">PMC7484468</ArticleId>
        <ArticleId IdType="doi">10.1038/s41586-020-2623-z</ArticleId>
        <ArticleId IdType="pii">10.1038/s41586-020-2623-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sleeman J, Schmid A &amp; Thiele W Tumor lymphatics. Semin Cancer Biol 19, 285&#x2013;297, (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19482087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alitalo A &amp; Detmar M Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 31, 4499&#x2013;4508, (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22179834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leong SP et al. Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol 103, 538&#x2013;549, (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21480247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willis RA The spread of tumours in the human body. 3d edn, (Butterworths, 1973).</Citation>
        </Reference>
        <Reference>
          <Citation>Naxerova K et al. Origins of lymphatic and distant metastases in human colorectal cancer. Science 357, 55&#x2013;60, (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5536201</ArticleId>
            <ArticleId IdType="pubmed">28684519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gundem G et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353&#x2013;357, (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4413032</ArticleId>
            <ArticleId IdType="pubmed">25830880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanborn JZ et al. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci U S A 112, 10995&#x2013;11000, (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4568214</ArticleId>
            <ArticleId IdType="pubmed">26286987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McFadden DG et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156, 1298&#x2013;1311, (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4040459</ArticleId>
            <ArticleId IdType="pubmed">24630729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pereira ER et al. Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science 359, 1403&#x2013;1407, (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6002772</ArticleId>
            <ArticleId IdType="pubmed">29567713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown M et al. Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science 359, 1408&#x2013;1411, (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29567714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morton DL et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370, 599&#x2013;609, (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4058881</ArticleId>
            <ArticleId IdType="pubmed">24521106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leiter U et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17, 757&#x2013;767, (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27161539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faries MB et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 376, 2211&#x2013;2222, (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5548388</ArticleId>
            <ArticleId IdType="pubmed">28591523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace AC &amp; Hollenberg NK The Transplantability of Tumours by Intravenous and Intralymphatic Routes. Br J Cancer 19, 338&#x2013;342, (1965).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2071375</ArticleId>
            <ArticleId IdType="pubmed">14316210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshida T et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res 66, 8065&#x2013;8075, (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16912183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CK et al. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science 363, 644&#x2013;649, (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30733421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pascual G et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541, 41&#x2013;45, (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27974793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Q et al. Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread. Sci Adv 4, eaat4758, (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6082649</ArticleId>
            <ArticleId IdType="pubmed">30101193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanharanta S &amp; Massague J Origins of metastatic traits. Cancer Cell 24, 410&#x2013;421, (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3998120</ArticleId>
            <ArticleId IdType="pubmed">24135279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piskounova E et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186&#x2013;191, (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4644103</ArticleId>
            <ArticleId IdType="pubmed">26466563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Gal K et al. Antioxidants can increase melanoma metastasis in mice. Sci Transl Med 7, 308re308, (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26446958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ and Stockwell BR The hallmarks of ferroptosis. Annu. Rev. Cancer Biol. 3, 35&#x2013;54, (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Wang W et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270&#x2013;274, (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y et al. Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model. Cell Chem Biol 26, 623&#x2013;633 e629, (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6525071</ArticleId>
            <ArticleId IdType="pubmed">30799221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature 572, 402&#x2013;406, (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6697195</ArticleId>
            <ArticleId IdType="pubmed">31341276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viswanathan VS et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453&#x2013;457, (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5667900</ArticleId>
            <ArticleId IdType="pubmed">28678785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quintana E et al. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci Transl Med 4, 159ra149, (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4501487</ArticleId>
            <ArticleId IdType="pubmed">23136044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meeth K, Wang JX, Micevic G, Damsky W &amp; Bosenberg MW The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res 29, 590&#x2013;597, (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5331933</ArticleId>
            <ArticleId IdType="pubmed">27287723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hangai-Hoger N, Cabrales P, Briceno JC, Tsai AG &amp; Intaglietta M Microlymphatic and tissue oxygen tension in the rat mesentery. Am J Physiol Heart Circ Physiol 286, H878&#x2013;883, (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14630627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tasdogan A et al. Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature 577, 115&#x2013;120, (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6930341</ArticleId>
            <ArticleId IdType="pubmed">31853067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 16, 1180&#x2013;1191, (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seiler A et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab 8, 237&#x2013;248, (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18762024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13, 91&#x2013;98, (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kayden HJ, Karmen A &amp; Dumont A Alterations in the Fatty Acid Composition of Human Lymph and Serum Lipoproteins by Single Feedings. J Clin Invest 42, 1373&#x2013;1381, (1963).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC289411</ArticleId>
            <ArticleId IdType="pubmed">14060981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magtanong L et al. Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State. Cell Chem Biol 26, 420&#x2013;432 e429, (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6430697</ArticleId>
            <ArticleId IdType="pubmed">30686757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spitz DR, Kinter MT, Kehrer JP &amp; Roberts RJ The effect of monosaturated and polyunsaturated fatty acids on oxygen toxicity in cultured cells. Pediatr Res 32, 366&#x2013;372, (1992).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1408477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowden JA et al. Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58, 2275&#x2013;2288, (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5711491</ArticleId>
            <ArticleId IdType="pubmed">28986437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher EA &amp; Ginsberg HN Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 277, 17377&#x2013;17380, (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12006608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y, Zhou J, Hooi SC, Jiang YM &amp; Lu GD Fatty acid activation in carcinogenesis and cancer development: Essential roles of long-chain acyl-CoA synthetases. Oncol Lett 16, 1390&#x2013;1396, (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6036470</ArticleId>
            <ArticleId IdType="pubmed">30008815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen WC et al. Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer. PLoS One 11, e0155660, (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4865206</ArticleId>
            <ArticleId IdType="pubmed">27171439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060&#x2013;1072, (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693&#x2013;698, (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31634899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature, (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veglia F et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature 569, 73&#x2013;78, (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6557120</ArticleId>
            <ArticleId IdType="pubmed">30996346</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
      <ReferenceList>
        <Title>SUPPLEMENTAL REFERENCES</Title>
        <Reference>
          <Citation>Kassan A et al. Acyl-CoA synthetase 3 promotes lipid droplet biogenesis in ER microdomains. J Cell Biol 203, 985&#x2013;1001, (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3871434</ArticleId>
            <ArticleId IdType="pubmed">24368806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agathocleous M et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature 549, 476&#x2013;481, (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5910063</ArticleId>
            <ArticleId IdType="pubmed">28825709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y &amp; Smyth GK ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347, 70&#x2013;78, (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19567251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chong JW, D.S. and Xia J Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis. Current Protocols in Bioinformatics 68 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31756036</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32778843</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-4469</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature chemical biology</Title>
          <ISOAbbreviation>Nat Chem Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers.</ArticleTitle>
        <Pagination>
          <StartPage>1351</StartPage>
          <EndPage>1360</EndPage>
          <MedlinePgn>1351-1360</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41589-020-0613-y</ELocationID>
        <Abstract>
          <AbstractText>Cancer cells rewire their metabolism and rely on endogenous antioxidants to mitigate lethal oxidative damage to lipids. However, the metabolic processes that modulate the response to lipid peroxidation are poorly defined. Using genetic screens, we compared metabolic genes essential for proliferation upon inhibition of cystine uptake or glutathione peroxidase-4 (GPX4). Interestingly, very few genes were commonly required under both conditions, suggesting that cystine limitation and GPX4 inhibition may impair proliferation via distinct mechanisms. Our screens also identify tetrahydrobiopterin (BH4) biosynthesis as an essential metabolic pathway upon GPX4 inhibition. Mechanistically, BH4 is a potent radical-trapping antioxidant that protects lipid membranes from autoxidation, alone and in synergy with vitamin E. Dihydrofolate reductase catalyzes the regeneration of BH4, and its inhibition by methotrexate synergizes with GPX4 inhibition. Altogether, our work identifies the mechanism by which BH4 acts as an endogenous antioxidant and provides a compendium of metabolic modifiers of lipid peroxidation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Soula</LastName>
            <ForeName>Mariluz</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Weber</LastName>
            <ForeName>Ross A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zilka</LastName>
            <ForeName>Omkar</ForeName>
            <Initials>O</Initials>
            <Identifier Source="ORCID">0000-0003-3534-0470</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alwaseem</LastName>
            <ForeName>Hanan</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-4946-1436</Identifier>
            <AffiliationInfo>
              <Affiliation>The Proteomics Resource Center, The Rockefeller University, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>La</LastName>
            <ForeName>Konnor</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yen</LastName>
            <ForeName>Frederick</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0001-7300-9370</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Molina</LastName>
            <ForeName>Henrik</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>The Proteomics Resource Center, The Rockefeller University, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garcia-Bermudez</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA. jgarciaber@rockefeller.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pratt</LastName>
            <ForeName>Derek A</ForeName>
            <Initials>DA</Initials>
            <Identifier Source="ORCID">0000-0002-7305-745X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Ontario, Canada. dpratt@uottawa.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Birsoy</LastName>
            <ForeName>Kıvanç</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-7579-9895</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA. kbirsoy@rockefeller.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DP2 CA228042</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 GM066699</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Nat Chem Biol</MedlineTA>
        <NlmUniqueID>101231976</NlmUniqueID>
        <ISSNLinking>1552-4450</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002243">Carbolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005493">Folic Acid Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C587550">RSL3 compound</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477224">erastin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1406-18-4</RegistryNumber>
          <NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>22150-76-1</RegistryNumber>
          <NameOfSubstance UI="D001708">Biopterin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>48TCX9A1VT</RegistryNumber>
          <NameOfSubstance UI="D003553">Cystine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.5.1.3</RegistryNumber>
          <NameOfSubstance UI="D013762">Tetrahydrofolate Dehydrogenase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EGX657432I</RegistryNumber>
          <NameOfSubstance UI="C003402">sapropterin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
          <NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001708" MajorTopicYN="N">Biopterin</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003553" MajorTopicYN="N">Cystine</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005493" MajorTopicYN="N">Folic Acid Antagonists</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013762" MajorTopicYN="N">Tetrahydrofolate Dehydrogenase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32778843</ArticleId>
        <ArticleId IdType="mid">NIHMS1696190</ArticleId>
        <ArticleId IdType="pmc">PMC8299533</ArticleId>
        <ArticleId IdType="doi">10.1038/s41589-020-0613-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s41589-020-0613-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sies H, Berndt C &amp; Jones DP Oxidative Stress. Annu. Rev. Biochem 86, 715&#x2013;748 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28441057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin H, Xu L &amp; Porter NA Free radical lipid peroxidation: mechanisms and analysis. Chem. Rev 111, 5944&#x2013;5972 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21861450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bersuker K et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575, 688&#x2013;692 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6883167</ArticleId>
            <ArticleId IdType="pubmed">31634900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693&#x2013;698 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31634899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ingold KU &amp; Pratt DA Advances in Radical-Trapping Antioxidant Chemistry in the 21st Century: A Kinetics and Mechanisms Perspective. Chem. Rev 114, 9022&#x2013;9046 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25180889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS et al. Regulation of Ferroptotic Cancer Cell Death by GPX4. Cell 156, 317&#x2013;331 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060&#x2013;1072 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skouta R et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc 136, 4551&#x2013;4556 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3985476</ArticleId>
            <ArticleId IdType="pubmed">24592866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerutti P Prooxidant states and tumor promotion. Science 227, 375&#x2013;381 (1985).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2981433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei G et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res 30, 146&#x2013;162 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7015061</ArticleId>
            <ArticleId IdType="pubmed">31949285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W et al. CD8 + T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270&#x2013;274 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu B et al. Identification of PRDX6 as a regulator of ferroptosis. Acta Pharmacol. Sin 40, 1334&#x2013;1342 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6786318</ArticleId>
            <ArticleId IdType="pubmed">31036877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kory N et al. SFXN1 is a mitochondrial serine transporter required for one-carbon metabolism. Science 362, (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6300058</ArticleId>
            <ArticleId IdType="pubmed">30442778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M &amp; Pratt DA The chemical basis of ferroptosis. Nat. Chem. Biol 15, 1137&#x2013;1147 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31740834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol 13, 91&#x2013;98 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Y et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat. Commun 10, 1617 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6453886</ArticleId>
            <ArticleId IdType="pubmed">30962421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ et al. Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem. Biol 10, 1604&#x2013;1609 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4509420</ArticleId>
            <ArticleId IdType="pubmed">25965523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki K, Shindou H, Hishikawa D &amp; Shimizu T Characterization of mouse lysophosphatidic acid acyltransferase 3: an enzyme with dual functions in the testis. J. Lipid Res 50, 860&#x2013;869 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2666172</ArticleId>
            <ArticleId IdType="pubmed">19114731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aguado B &amp; Campbell RD Characterization of a Human Lysophosphatidic Acid Acyltransferase That Is Encoded by a Gene Located in the Class III Region of the Human Major Histocompatibility Complex. J. Biol. Chem 273, 4096&#x2013;4105 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9461603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorninger F et al. Homeostasis of phospholipids &#x2014; The level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens. Biochim. Biophys. Acta 1851, 117&#x2013;128 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4331674</ArticleId>
            <ArticleId IdType="pubmed">25463479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu XG et al. CHP1 Regulates Compartmentalized Glycerolipid Synthesis by Activating GPAT4. Mol. Cell 74, 45&#x2013;58.e7 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6450717</ArticleId>
            <ArticleId IdType="pubmed">30846317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain IH et al. Genetic Screen for Cell Fitness in High or Low Oxygen Highlights Mitochondrial and Lipid Metabolism. Cell 181, 716&#x2013;727.e11 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7293541</ArticleId>
            <ArticleId IdType="pubmed">32259488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen R &amp; Zhang Y Reduced Pterins as Scavengers for Reactive Oxygen Species. in Chemistry and Biology of Pteridines and Folates (eds. Ayling JE, Nair MG &amp; Baugh CM) 351&#x2013;354 (Springer US, 1993). doi:10.1007/978-1-4615-2960-6_73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4615-2960-6_73</ArticleId>
            <ArticleId IdType="pubmed">8304137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kojima S et al. Antioxidative Activity of 5,6,7,8-Tetrahydrobiopterin and its Inhibitory Effect on Paraquat-Induced Cell Toxicity in Cultured Rat Hepatocytes. Free Radic. Res 23, 419&#x2013;430 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7581825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kraft VAN et al. GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling. ACS Cent. Sci 6, 41&#x2013;53 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6978838</ArticleId>
            <ArticleId IdType="pubmed">31989025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cronin SJF et al. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature 563, 564&#x2013;568 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6438708</ArticleId>
            <ArticleId IdType="pubmed">30405245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol 13, 81&#x2013;90 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosen GM et al. The role of tetrahydrobiopterin in the regulation of neuronal nitric-oxide synthase-generated superoxide. J. Biol. Chem 277, 40275&#x2013;40280 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12183447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapralov AA et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat. Chem. Biol 16, 278&#x2013;290 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7233108</ArticleId>
            <ArticleId IdType="pubmed">32080625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watschinger K et al. Tetrahydrobiopterin and alkylglycerol monooxygenase substantially alter the murine macrophage lipidome. Proc. Natl. Acad. Sci. U. S. A 112, 2431&#x2013;2436 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4345615</ArticleId>
            <ArticleId IdType="pubmed">25675482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen RS Inhibition of dopamine autoxidation by tetrahydrobiopterin and NADH in the presence of dihydropteridine reductase. Neurotoxicology 12, 201&#x2013;208 (1991).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1956581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah R, Farmer LA, Zilka O, Van Kessel ATM &amp; Pratt DA Beyond DPPH: Use of Fluorescence-Enabled Inhibited Autoxidation to Predict Oxidative Cell Death Rescue. Cell Chem. Biol 26, 1594&#x2013;1607.e7 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31564533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O et al. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death. ACS Cent. Sci 3, 232&#x2013;243 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah R, Shchepinov MS &amp; Pratt DA Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis. ACS Cent. Sci 4, 387&#x2013;396 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5879472</ArticleId>
            <ArticleId IdType="pubmed">29632885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haidasz EA, Van Kessel ATM &amp; Pratt DA A Continuous Visible Light Spectrophotometric Approach To Accurately Determine the Reactivity of Radical-Trapping Antioxidants. J. Org. Chem 81, 737&#x2013;744 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26529543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chauvin J-PR, Griesser M &amp; Pratt DA Hydropersulfides: H-Atom Transfer Agents Par Excellence. J. Am. Chem. Soc 139, 6484&#x2013;6493 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28419803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valgimigli L et al. The Unusual Reaction of Semiquinone Radicals with Molecular Oxygen. J. Org. Chem 73, 1830&#x2013;1841 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18260673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zielinski Z, Presseau N, Amorati R, Valgimigli L &amp; Pratt DA Redox Chemistry of Selenenic Acids and the Insight It Brings on Transition State Geometry in the Reactions of Peroxyl Radicals. J. Am. Chem. Soc 136, 1570&#x2013;1578 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24383573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burton GW &amp; Ingold KU Vitamin E: application of the principles of physical organic chemistry to the exploration of its structure and function. Acc. Chem. Res 19, 194&#x2013;201 (1986).</Citation>
        </Reference>
        <Reference>
          <Citation>Kallen RG &amp; Jencks WP The Dissociation Constants of Tetrahydrofolic Acid. J. Biol. Chem 241, 5845&#x2013;5850 (1966).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5954362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis MD &amp; Kaufman S Products of the tyrosine-dependent oxidation of tetrahydrobiopterin by rat liver phenylalanine hydroxylase. Arch. Biochem. Biophys 304, 9&#x2013;16 (1993).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8323303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel KB, Stratford MRL, Wardman P &amp; Everett SA Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. Free Radic. Biol. Med 32, 203&#x2013;211 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11827745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armarego WL, Randles D &amp; Waring P Dihydropteridine reductase (DHPR), its cofactors, and its mode of action. Med. Res. Rev 4, 267&#x2013;321 (1984).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6379341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curtius HC et al. Tetrahydrobiopterin biosynthesis. Studies with specifically labeled (2H)NAD(P)H and 2H2O and of the enzymes involved. Eur. J. Biochem 148, 413&#x2013;419 (1985).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3888618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niki E Interaction of ascorbate and alpha-tocopherol. Ann. N. Y. Acad. Sci 498, 186&#x2013;199 (1987).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3304060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Bermudez J et al. Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death. Nature 567, 118&#x2013;122 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6405297</ArticleId>
            <ArticleId IdType="pubmed">30760928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novera W et al. Cysteine deprivation targets ovarian clear cell carcinoma via oxidative stress and iron-sulfur cluster biogenesis deficit. Antioxid. Redox Signal (2020) doi:10.1089/ars.2019.7850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2019.7850</ArticleId>
            <ArticleId IdType="pubmed">32336105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cramer SL et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat. Med 23, 120&#x2013;127 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5218918</ArticleId>
            <ArticleId IdType="pubmed">27869804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aruoma OI, Halliwell B, Hoey BM &amp; Butler J The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem. J 256, 251&#x2013;255 (1988).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1135395</ArticleId>
            <ArticleId IdType="pubmed">2851980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sayin VI et al. Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. eLife 6, e28083 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5624783</ArticleId>
            <ArticleId IdType="pubmed">28967864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eaton JK et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat. Chem. Biol 16, 497&#x2013;506 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7251976</ArticleId>
            <ArticleId IdType="pubmed">32231343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birsoy K et al. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162, 540&#x2013;551 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4522279</ArticleId>
            <ArticleId IdType="pubmed">26232224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chong J et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res 46, W486&#x2013;W494 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6030889</ArticleId>
            <ArticleId IdType="pubmed">29762782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mellacheruvu D et al. The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat. Methods 10, 730&#x2013;736 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3773500</ArticleId>
            <ArticleId IdType="pubmed">23921808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen WW, Freinkman E, Wang T, Birsoy K &amp; Sabatini DM Absolute quantification of matrix metabolites reveals the dynamics of mitochondrial metabolism. Cell 166, 1324&#x2013;1337.e11 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5030821</ArticleId>
            <ArticleId IdType="pubmed">27565352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pino LK et al. The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics. Mass Spectrom. Rev (2017) doi:10.1002/mas.21540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mas.21540</ArticleId>
            <ArticleId IdType="pmc">PMC5799042</ArticleId>
            <ArticleId IdType="pubmed">28691345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu C et al. RPLC-Ion-Trap-FTMS Method for Lipid Profiling of Plasma: Method Validation and Application to p53 Mutant Mouse Model. J. Proteome Res 7, 4982&#x2013;4991 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18841877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taguchi R &amp; Ishikawa M Precise and global identification of phospholipid molecular species by an Orbitrap mass spectrometer and automated search engine Lipid Search. J. Chromatogr. A 1217, 4229&#x2013;4239 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20452604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada T et al. Development of a lipid profiling system using reverse-phase liquid chromatography coupled to high-resolution mass spectrometry with rapid polarity switching and an automated lipid identification software. J. Chromatogr. A 1292, 211&#x2013;218 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23411146</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32686685</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>08</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-1723</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jul</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature communications</Title>
          <ISOAbbreviation>Nat Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>3637</StartPage>
          <MedlinePgn>3637</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">3637</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-020-17380-5</ELocationID>
        <Abstract>
          <AbstractText>We report a strategy to boost Fenton reaction triggered by an exogenous circularly polarized magnetic field (MF) to enhance ferroptosis-like cell-death mediated immune response, as well as endow a responsive MRI capability by using a hybrid core-shell vesicles (HCSVs). HCSVs are prepared by loading ascorbic acid (AA) in the core and poly(lactic-co-glycolic acid) shell incorporating iron oxide nanocubes (IONCs). MF triggers the release of AA, resulting in the increase of ferrous ions through the redox reaction between AA and IONCs. A significant tumor suppression is achieved by Fenton reaction-mediated ferroptosis-like cell-death. The oxidative stress induced by the Fenton reaction leads to the exposure of calreticulin on tumor cells, which leads to dendritic cells maturation and the infiltration of cytotoxic T lymphocytes in tumor. Furthermore, the depletion of ferric ions during treatment enables monitoring of the Fe reaction in MRI-R2* signal change. This strategy provides a perspective on ferroptosis-based immunotherapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Bongseo</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-8754-9199</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Weiguo</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0001-8125-3824</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, 60607, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Dong-Hyun</ForeName>
            <Initials>DH</Initials>
            <Identifier Source="ORCID">0000-0001-6815-3319</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA. dhkim@northwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, 60607, USA. dhkim@northwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, 60611, USA. dhkim@northwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, McCormick School of Engineering, Evanston, IL, 60208, USA. dhkim@northwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA218659</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 EB026207</GrantID>
            <Acronym>EB</Acronym>
            <Agency>NIBIB NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Commun</MedlineTA>
        <NlmUniqueID>101528555</NlmUniqueID>
        <ISSNLinking>2041-1723</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037282">Calreticulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005290">Ferric Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058185">Magnetite Nanoparticles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1K09F3G675</RegistryNumber>
          <NameOfSubstance UI="C000499">ferric oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PQ6CK8PD0R</RegistryNumber>
          <NameOfSubstance UI="D001205">Ascorbic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001205" MajorTopicYN="N">Ascorbic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037282" MajorTopicYN="N">Calreticulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005290" MajorTopicYN="N">Ferric Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060526" MajorTopicYN="Y">Magnetic Fields</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058185" MajorTopicYN="Y">Magnetite Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050997" MajorTopicYN="N">Nanomedicine</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32686685</ArticleId>
        <ArticleId IdType="pmc">PMC7371635</ArticleId>
        <ArticleId IdType="doi">10.1038/s41467-020-17380-5</ArticleId>
        <ArticleId IdType="pii">10.1038/s41467-020-17380-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hu QY, Sun WJ, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv. Drug Deliv. Rev. 2016;98:19&#x2013;34. doi: 10.1016/j.addr.2015.10.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.addr.2015.10.022</ArticleId>
            <ArticleId IdType="pmc">PMC4998845</ArticleId>
            <ArticleId IdType="pubmed">26546751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou F, et al. Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade. Adv. Mater. 2019;31:e1805888. doi: 10.1002/adma.201805888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201805888</ArticleId>
            <ArticleId IdType="pubmed">30762908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng B, et al. Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment. Adv. Mater. 2018;30:e1803001. doi: 10.1002/adma.201803001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201803001</ArticleId>
            <ArticleId IdType="pubmed">30063262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, et al. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy. Adv. Mater. 2019;31:e1802228. doi: 10.1002/adma.201802228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201802228</ArticleId>
            <ArticleId IdType="pubmed">30663118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv. Cancer Res. 2002;85:145&#x2013;174. doi: 10.1016/S0065-230X(02)85005-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0065-230X(02)85005-9</ArticleId>
            <ArticleId IdType="pubmed">12374285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat. Rev. Cancer. 2014;14:199&#x2013;208. doi: 10.1038/nrc3672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3672</ArticleId>
            <ArticleId IdType="pubmed">24561446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen ZY, et al. Emerging strategies of cancer therapy based on ferroptosis. Adv. Mater. 2018;30:e1704007. doi: 10.1002/adma.201704007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201704007</ArticleId>
            <ArticleId IdType="pmc">PMC6377162</ArticleId>
            <ArticleId IdType="pubmed">29356212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang SF, et al. Arginine-rich manganese silicate nanobubbles as a ferroptosis-inducing agent for tumor-targeted theranostics. ACS Nano. 2018;12:12380&#x2013;12392. doi: 10.1021/acsnano.8b06399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b06399</ArticleId>
            <ArticleId IdType="pubmed">30495919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447:864&#x2013;868. doi: 10.1038/nature05859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05859</ArticleId>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369&#x2013;379. doi: 10.1038/cdd.2015.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.158</ArticleId>
            <ArticleId IdType="pmc">PMC5072448</ArticleId>
            <ArticleId IdType="pubmed">26794443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angeli JPF, Shah R, Pratt DA, Conrad M. Ferroptosis inhibition: mechanisms and opportunities. Trends Pharmacol. Sci. 2017;38:489&#x2013;498. doi: 10.1016/j.tips.2017.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2017.02.005</ArticleId>
            <ArticleId IdType="pubmed">28363764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroemer G, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16:3&#x2013;11. doi: 10.1038/cdd.2008.150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2008.150</ArticleId>
            <ArticleId IdType="pmc">PMC2744427</ArticleId>
            <ArticleId IdType="pubmed">18846107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107&#x2013;120. doi: 10.1038/cdd.2011.96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2011.96</ArticleId>
            <ArticleId IdType="pmc">PMC3252826</ArticleId>
            <ArticleId IdType="pubmed">21760595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue W, et al. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. Nat. Commun. 2019;10:2025. doi: 10.1038/s41467-019-09760-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-09760-3</ArticleId>
            <ArticleId IdType="pmc">PMC6497709</ArticleId>
            <ArticleId IdType="pubmed">31048681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang YJ, et al. Oxidative stress-induced calreticulin expression and translocation: new insights into the destruction of melanocytes. J. Investig. Dermatol. 2014;134:183&#x2013;191. doi: 10.1038/jid.2013.268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jid.2013.268</ArticleId>
            <ArticleId IdType="pubmed">23771121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, et al. Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano. 2018;12:11355&#x2013;11365. doi: 10.1021/acsnano.8b06201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b06201</ArticleId>
            <ArticleId IdType="pubmed">30375848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, et al. Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized fenton reaction. Angew. Chem. Int. Ed. 2016;55:2101&#x2013;2106. doi: 10.1002/anie.201510031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.201510031</ArticleId>
            <ArticleId IdType="pubmed">26836344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao W, et al. Nanolongan with multiple on-demand conversions for ferroptosis&#x2013;apoptosis combined anticancer therapy. ACS Nano. 2019;13:260&#x2013;273. doi: 10.1021/acsnano.8b05602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b05602</ArticleId>
            <ArticleId IdType="pubmed">30616348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng DW, et al. Switching apoptosis to ferroptosis: metal-organic network for high-efficiency anticancer therapy. Nano Lett. 2017;17:284&#x2013;291. doi: 10.1021/acs.nanolett.6b04060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.6b04060</ArticleId>
            <ArticleId IdType="pubmed">28027643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duesterberg CK, Mylon SE, Waite TD. pH effects on iron-catalyzed oxidation using Fenton&#x2019;s reagent. Environ. Sci. Technol. 2008;42:8522&#x2013;8527. doi: 10.1021/es801720d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/es801720d</ArticleId>
            <ArticleId IdType="pubmed">19068842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim. Biophys. Acta. 2012;1826:443&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3608474</ArticleId>
            <ArticleId IdType="pubmed">22728050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta H, Paul P, Kumar N, Baxi S, Das DP. One pot synthesis of water-dispersible dehydroascorbic acid coated Fe3O4 nanoparticles under atmospheric air: blood cell compatibility and enhanced magnetic resonance imaging. J. Colloid Interface Sci. 2014;430:221&#x2013;228. doi: 10.1016/j.jcis.2014.05.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcis.2014.05.043</ArticleId>
            <ArticleId IdType="pubmed">24956575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drummen GP, van Liebergen LC, Op den Kamp JA, Post JA. C11-BODIPY(581/591), an oxidation-sensitive fluorescent lipid peroxidation probe: (micro)spectroscopic characterization and validation of methodology. Free Radic. Biol. Med. 2002;33:473&#x2013;490. doi: 10.1016/S0891-5849(02)00848-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0891-5849(02)00848-1</ArticleId>
            <ArticleId IdType="pubmed">12160930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koppula P, Zhang YL, Zhuang L, Gan BY. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 2018;38:12. doi: 10.1186/s40880-018-0288-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40880-018-0288-x</ArticleId>
            <ArticleId IdType="pmc">PMC5993148</ArticleId>
            <ArticleId IdType="pubmed">29764521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G, Guo G, Zhou X, Chen H. Potential mechanism of ferroptosis in pancreatic cancer. Oncol. Lett. 2020;19:579&#x2013;587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6923864</ArticleId>
            <ArticleId IdType="pubmed">31897173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dietrich O, et al. MR imaging differentiation of Fe(2+) and Fe(3+) based on relaxation and magnetic susceptibility properties. Neuroradiology. 2017;59:403&#x2013;409. doi: 10.1007/s00234-017-1813-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00234-017-1813-3</ArticleId>
            <ArticleId IdType="pubmed">28324122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poon W, et al. Elimination pathways of nanoparticles. ACS Nano. 2019;13:5785&#x2013;5798. doi: 10.1021/acsnano.9b01383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.9b01383</ArticleId>
            <ArticleId IdType="pubmed">30990673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Syed AM, Sindhwani S, Chan WCW. Making vessels more permeable. Nat. Biomed. Eng. 2017;1:629&#x2013;631. doi: 10.1038/s41551-017-0123-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41551-017-0123-8</ArticleId>
            <ArticleId IdType="pubmed">31015603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DH. Image-guided cancer nanomedicine. J. Imaging. 2018;4:18. doi: 10.3390/jimaging4010018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jimaging4010018</ArticleId>
            <ArticleId IdType="pmc">PMC6197060</ArticleId>
            <ArticleId IdType="pubmed">30364459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumoto MM, Kim DH, Larson AC, Mouli SK. Interventional nanotheranostics: advancing nanotechnology applications with IR. J. Vasc. Interv. Radio. 2019;30:1824&#x2013;1829 e1821. doi: 10.1016/j.jvir.2019.07.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jvir.2019.07.026</ArticleId>
            <ArticleId IdType="pubmed">31655765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park W, et al. Immunomodulatory magnetic microspheres for augmenting tumor-specific infiltration of natural killer (NK) cells. ACS Appl. Mater. Interfaces. 2017;9:13819&#x2013;13824. doi: 10.1021/acsami.7b02258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.7b02258</ArticleId>
            <ArticleId IdType="pmc">PMC5719880</ArticleId>
            <ArticleId IdType="pubmed">28406012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang P, et al. Engineering dendritic-cell-based vaccines and PD-1 blockade in self-assembled peptide nanofibrous hydrogel to amplify antitumor T-cell immunity. Nano Lett. 2018;18:4377&#x2013;4385. doi: 10.1021/acs.nanolett.8b01406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.8b01406</ArticleId>
            <ArticleId IdType="pubmed">29932335</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32134361</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1938-5404</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>193</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Radiation research</Title>
          <ISOAbbreviation>Radiat Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anti-Ferroptosis Drug Enhances Total-Body Irradiation Mitigation by Drugs that Block Apoptosis and Necroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>435</StartPage>
          <EndPage>450</EndPage>
          <MedlinePgn>435-450</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1667/RR15486.1</ELocationID>
        <Abstract>
          <AbstractText>Mitigation of total-body irradiation (TBI) in C57BL/6 mice by two drugs, which target apoptosis and necroptosis respectively, increases survival compared to one drug alone. Here we investigated whether the biomarker (signature)directed addition of a third anti-ferroptosis drug further mitigated TBI effects. C57BL/6NTac female mice (30-33 g) received 9.25 Gy TBI, and 24 h or later received JP4-039 (20 mg/kg), necrostatin-1 (1.65 mg/kg) and/or lipoxygenase-15 inhibitor (baicalein) (50 mg/kg) in single-, dual- or three-drug regimens. Some animals were sacrificed at days 0, 1, 2, 3, 4 or 7 postirradiation, while the majority in each group were maintained beyond 30 days. For those mice sacrificed at the early time points, femur bone marrow, intestine (ileum), lung and blood plasma were collected and analyzed for radiation-induced and mitigator-modified levels of 33 pro-inflammatory and stress response proteins. Each single mitigator administered [JP4-039 (24 h), necrostatin-1 (48 h) or baicalein (24 h)] improved survival at day 30 after TBI to 25% (P = 0.0432, 0.2816 or 0.1120, respectively) compared to 5% survival of 9.25 Gy TBI controls. Mice were administered the drug individually based on weight (mg/kg). Drug vehicles comprised 30% cyclodextrin for JP4-039 and baicalein, and 10% Cremphor-EL/10% ethanol/80% water for necrostatin-1; thus, dual-vehicle controls were also tested. The dual-drug combinations further enhanced survival: necrostatin-1 (delayed to 72 h) with baicalein 40% (P = 0.0359); JP4-039 with necrostatin-1 50% (P = 0.0062); and JP4-039 with baicalein 60% (P = 0.0064). The three-drug regimen, timed to signature directed evidence of onset after TBI of each death pathway in marrow and intestine, further increased the 30-day survival to 75% (P = 0.0002), and there was optimal normalization to preirradiation levels of inflammatory cytokine and stress response protein levels in plasma, intestine and marrow. In contrast, lung protein levels were minimally altered by 9.25 Gy TBI or mitigators over 7 days. Significantly, elevated intestinal proteins at day 7 after TBI were reduced by necrostatin-1-containing regimens; however, normalization of plasma protein levels at day 7 required the addition of JP4-039 and baicalein. These findings indicate that mitigator targeting to three distinct cell death pathways increases survival after TBI.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thermozier</LastName>
            <ForeName>Stephanie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Wen</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xichen</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shields</LastName>
            <ForeName>Donna</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fisher</LastName>
            <ForeName>Renee</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bayir</LastName>
            <ForeName>Hulya</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Critical Care Medicine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kagan</LastName>
            <ForeName>Valerian</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Environmental/Occupational Health.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Pathology.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Bing</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Computational and Biology Systems.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bahar</LastName>
            <ForeName>Ivet</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Computational and Biology Systems.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Epperly</LastName>
            <ForeName>Michael W</ForeName>
            <Initials>MW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wipf</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Chemistry.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Hong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania 15260.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huq</LastName>
            <ForeName>M Saiful</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Greenberger</LastName>
            <ForeName>Joel S</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA047904</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U19 AI068021</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>03</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Radiat Res</MedlineTA>
        <NlmUniqueID>0401245</NlmUniqueID>
        <ISSNLinking>0033-7587</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011837">Radiation-Protective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001853" MajorTopicYN="N">Bone Marrow</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007082" MajorTopicYN="N">Ileum</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079302" MajorTopicYN="N">Necroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011833" MajorTopicYN="N">Radiation Injuries, Experimental</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011837" MajorTopicYN="N">Radiation-Protective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014916" MajorTopicYN="N">Whole-Body Irradiation</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32134361</ArticleId>
        <ArticleId IdType="mid">NIHMS1594622</ArticleId>
        <ArticleId IdType="pmc">PMC7299160</ArticleId>
        <ArticleId IdType="doi">10.1667/RR15486.1</ArticleId>
        <ArticleId IdType="pii">10.1667/RR15486.1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Steinman J, Epperly M, Hou W, Willis J, Wang H, Fisher R, et al. Improves total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 2018; 189:68&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5808408</ArticleId>
            <ArticleId IdType="pubmed">29140165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rwigema J-CM, Beck B, Wang W, Doemling A, Epperly MW, Shields D, et al. Two strategies for the development of mitochondrial-targeted small molecule radiation damage mitigators. Int J Radiat Oncol Biol Phys 2011; 80:860&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3104115</ArticleId>
            <ArticleId IdType="pubmed">21493014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalash R, Epperly MW, Goff J, Dixon T, Sprachman MM, Zhang X, et al. Amelioration of irradiation pulmonary fibrosis by a water soluble bi-functional sulfoxide radiation mitigator (MMS350). Radiat Res 2013; 180:474&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3894523</ArticleId>
            <ArticleId IdType="pubmed">24125487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frantz M-C, Skoda EM, Sacher JR, Epperly MW, Goff JP, Greenberger JS, et al. Synthesis of analogs of the radiation mitigator JP4&#x2013;039 and visualization of BODIPY derivatives in mitochondria. Org Biomol Chem 2013; 11: 4147&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3729477</ArticleId>
            <ArticleId IdType="pubmed">23715589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berhane H, Epperly MW, Goff J, Kalash R, Cao S, Franicola D, et al. Radiobiologic differences between bone marrow stromal and hematopoietic progenitor cell lines from Fanconi Anemia (Fancd2&#x2013;/&#x2013;) mice. Radiat Res 2014; 181:76&#x2013;89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3970166</ArticleId>
            <ArticleId IdType="pubmed">24397476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyurina YY, Poloyac SM, Tyurin VA, Kapralov AA, Jiang J, Anthonymuthus TS, et al. A mitochondrial pathway for biosynthesis of lipid mediators. Nat Chem 2014; 6:542&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4201180</ArticleId>
            <ArticleId IdType="pubmed">24848241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epperly MW, Goff JP, Franicola D, Wang H, Wipf P, Li S, et al. Esophageal radioprotection in thoracic irradiated mice with transgenic lung tumors by swallowed JP4&#x2013;039/F15. In Vivo 2014; 28:435&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6436097</ArticleId>
            <ArticleId IdType="pubmed">24982207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berhane H, Shinde A, Kalash R, Xu K, Epperly MW, Goff J, et al. Amelioration of irradiation induced oral cavity mucositis and distant bone marrow suppression in Fancd2&#x2013;/&#x2013; (FVB/N) mice by intraoral JP4&#x2013;039/F14. Radiat Res 2014; 182:35&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4101533</ArticleId>
            <ArticleId IdType="pubmed">24932534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Mao G, Qu F, Angeli JPF, Doll S, St. Croix C, et al. Oxidized arachidonic and adrenic Pes navigate cells to ferroptosis. Nat Chem Biol 2016; 13:81&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shinde A, Berhane H, Rhieu BH, Kalash R, Xu K, Goff J, et al. Intraoral mitochondrial-targeted GS-Nitroxide, JP4&#x2013;039, radio protects normal tissue in tumor-bearing radiosensitive Fancd2&#x2013;/&#x2013; (C57Bl/6) mice. Radiat Res 2016; 185:134&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4773657</ArticleId>
            <ArticleId IdType="pubmed">26789701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Z, Epperly M, Watkins SC, Greenberger JS, Kagan VE, Bayir H. Necrostatin-1 rescues mice from lethal irradiation. Biochimica at Biophysica Acta 2016; 1862:850&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4788560</ArticleId>
            <ArticleId IdType="pubmed">26802452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christner S, Guo J, Parise RA, Ringeval M, Hoye AT, Wipf P, et al. Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4&#x2013;039 in murine plasma. J Pharmaceut Biomed Anal 2017; S0731&#x2013;7085:32605&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5767136</ArticleId>
            <ArticleId IdType="pubmed">29245086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinman J, Epperly M, Hou W, Willis J, Wang H, Fisher R, et al. Improves total-body irradiation survival by delivery of two radiation mitigators that target distinct cell death pathways. Radiat Res 2018; 189:68&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5808408</ArticleId>
            <ArticleId IdType="pubmed">29140165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epperly MW, Sikora C, Defilippi S, Gretton J, Zhan Q, Kufe DW, et al. Manganese superoxide dismutase (SOD2) inhibits radiation induced apoptosis by stabilization of the mitochondrial membrane. Radiat Res 2002; 157:568&#x2013;77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11966323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epperly MW, Gretton JE, Bernarding M, Nie S, Rasul G, Greenberger JS. Mitochondrial localization of copper/zinc superoxide dismutase (Cu/ZnSOD) confers radioprotective functions in vitro and in vivo. Radiat Res 2003; 160:568&#x2013;78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14565825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyurina YY, St. Croix C, Watkins S, Epperly M, Anthonymuthu T, Kisin E, et al. Redox (phospho)lipidomics of signaling in inflammation and programmed cell death. J Leukocyte Biol 2019; 106:57&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6626990</ArticleId>
            <ArticleId IdType="pubmed">31071242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A 2016; 113:E4966&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5003261</ArticleId>
            <ArticleId IdType="pubmed">27506793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell 2017; 171:628&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5683852</ArticleId>
            <ArticleId IdType="pubmed">29053969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuch EM, Vellaramkalayil R, Zhang I, Lehnen D, Brugger B, Sreemmel W, et al. Differentially localized acyl-CoA synthetase 4 isoenzymes mediate the metabolic channeling of fatty acids towards phosphatidylinositol. Biochim Biophys Acta 2014; 1841:227&#x2013;39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24201376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li LO, Klett EL, Coleman RA. Acyl-CoA synthesis, lipid metabolism, and lipotoxicity. Biochim Biophys Acta 2010; 1801:246&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824076</ArticleId>
            <ArticleId IdType="pubmed">19818872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas JP, Maiorino M, Ursini F, Firotti AW. Protective action of phospholipid hydroperoxide glutathione peroxidase against membrane-damaging lipid peroxidation. In situ reduction of phospholipid and cholesterol hydroperoxides. J Biol Chem 1990; 265:454&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2294113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014; 156:317&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler MM, Andia AA, Liu H, Csuka JM, Hurlocker B, Vaiana CA, et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol 2018; 14:507&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5899674</ArticleId>
            <ArticleId IdType="pubmed">29610484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc 2014; 136:4551&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3985476</ArticleId>
            <ArticleId IdType="pubmed">24592866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O, Shah R, Li B, Friedmann AJP, Griesser M, Conrad M, et al. On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Cent Sci 2017; 3:232&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Y, Song X, Sun X, Huang J, Zhong M, Lotze MT, et al. Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochem Biophys Res Commun 2016; 473:775&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27037021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brand R, Epperly MW, Stottlemyer JM, Skoda E, Gao X, Li S, et al. A topical mitochondria-targeted redox cycling nitroxide mitigates oxidative stress induced skin damage. J Investigative Dermatology 2017; 137:576&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5466072</ArticleId>
            <ArticleId IdType="pubmed">27794421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epperly MW, Wipf P, Fisher R, Franicola D, Beumer J, Li S, et al. Evaluations of different formulations and routes for the delivery of the ionizing radiation mitigator GS-nitroxide (JP4&#x2013;039). In Vivo 2018; 32:1009&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6199586</ArticleId>
            <ArticleId IdType="pubmed">30150422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dar HH, Tyurina YY, Mikulska KA, Shrivastava I, Tyurin VA, Krieger J, et al. Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium. J Clin Invest 2018; 128:4639&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6159971</ArticleId>
            <ArticleId IdType="pubmed">30198910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sivananthan A, Shields D, Fisher R, Hou W, Zhang X, Franicola D, et al. Continuous 1 year oral administration of the radiation mitigator, MMS350, after total body irradiation restores bone marrow stromal cell proliferative capacity and reduces age-related senescence in Fanconi anemia (Fanca&#x2013;/&#x2013;) mice. Radiat Res 2019; 191:139&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6388094</ArticleId>
            <ArticleId IdType="pubmed">30499383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krainz T, Du L, Lewis T, Lamade AM, Calderon M, Watkins SC, et al. Synthesis and evaluation of a mitochondria-targeting Poly(ADP-ribose) Polymerase-1 inhibitor. ACS Chem Biol 2018; 13:2868&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6402482</ArticleId>
            <ArticleId IdType="pubmed">30184433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 2014; 15:135&#x2013;47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24452471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunnett CW. A multiple comparison procedure for comparing several teatments with a control. J Am Stat Assoc 1955; 50:1096&#x2013;121.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31980600</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-1723</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature communications</Title>
          <ISOAbbreviation>Nat Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxin.</ArticleTitle>
        <Pagination>
          <StartPage>473</StartPage>
          <MedlinePgn>473</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">473</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-14151-9</ELocationID>
        <Abstract>
          <AbstractText>A variant at amino acid 47 in human TP53 exists predominantly in individuals of African descent. P47S human and mouse cells show increased cancer risk due to defective ferroptosis. Here, we show that this ferroptotic defect causes iron accumulation in P47S macrophages. This high iron content alters macrophage cytokine profiles, leads to higher arginase level and activity, and decreased nitric oxide synthase activity. This leads to more productive intracellular bacterial infections but is protective against malarial toxin hemozoin. Proteomics of macrophages reveal decreased liver X receptor (LXR) activation, inflammation and antibacterial defense in P47S macrophages. Both iron chelators and LXR agonists improve the response of P47S mice to bacterial infection. African Americans with elevated saturated transferrin and serum ferritin show higher prevalence of the P47S variant (OR = 1.68 (95%CI 1.07-2.65) p = 0.023), suggestive of its role in iron accumulation in humans. This altered macrophage phenotype may confer an advantage in malaria-endemic sub-Saharan Africa.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Singh</LastName>
            <ForeName>Kumar Sachin</ForeName>
            <Initials>KS</Initials>
            <AffiliationInfo>
              <Affiliation>Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Leu</LastName>
            <ForeName>Julia I-Ju</ForeName>
            <Initials>JI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genetics, The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Barnoud</LastName>
            <ForeName>Thibaut</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, 19104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vonteddu</LastName>
            <ForeName>Prashanthi</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gnanapradeepan</LastName>
            <ForeName>Keerthana</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, 19104, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Graduate Group in Biochemistry and Molecular Biophysics, The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Cindy</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Program in Immunology, Microenvironment and Metastasis, The Wistar Institute, Philadelphia, PA, 19104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <Identifier Source="ORCID">0000-0001-9964-580X</Identifier>
            <AffiliationInfo>
              <Affiliation>Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, 19104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barton</LastName>
            <ForeName>James C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>Southern Iron Disorders Center, Birmingham AL 35209 USA and Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kossenkov</LastName>
            <ForeName>Andrew V</ForeName>
            <Initials>AV</Initials>
            <AffiliationInfo>
              <Affiliation>Bioinformatics Facility, The Wistar Institute, Philadelphia, PA, 19104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>George</LastName>
            <ForeName>Donna L</ForeName>
            <Initials>DL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genetics, The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA. georged@pennmedicine.upenn.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murphy</LastName>
            <ForeName>Maureen E</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, 19104, USA. mmurphy@wistar.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dotiwala</LastName>
            <ForeName>Farokh</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0002-7387-2219</Identifier>
            <AffiliationInfo>
              <Affiliation>Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, 19104, USA. fdotiwala@wistar.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01 CA114046</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>F32 CA220972</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R50 CA211199</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA098101</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 DK049210</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 DK050306</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA010815</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R50 CA221838</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA102184</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA201430</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 HL144991</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA139319</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>01</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Commun</MedlineTA>
        <NlmUniqueID>101528555</NlmUniqueID>
        <ISSNLinking>2041-1723</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006420">Hemeproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071518">Liver X Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014168">Transferrin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>39404-00-7</RegistryNumber>
          <NameOfSubstance UI="C020753">hemozoin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-73-2</RegistryNumber>
          <NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Nat Commun. 2020 Mar 19;11(1):1541</RefSource>
          <PMID Version="1">32193389</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017954" MajorTopicYN="N" Type="Geographic">Africa South of the Sahara</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001424" MajorTopicYN="N">Bacterial Infections</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006420" MajorTopicYN="N">Hemeproteins</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008088" MajorTopicYN="N">Listeriosis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071518" MajorTopicYN="N">Liver X Receptors</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008288" MajorTopicYN="N">Malaria</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014168" MajorTopicYN="N">Transferrin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31980600</ArticleId>
        <ArticleId IdType="pmc">PMC6981190</ArticleId>
        <ArticleId IdType="doi">10.1038/s41467-019-14151-9</ArticleId>
        <ArticleId IdType="pii">10.1038/s41467-019-14151-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lavin Y, Mortha A, Rahman A, Merad M. Regulation of macrophage development and function in peripheral tissues. Nat. Rev. Immunol. 2015;15:731&#x2013;744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4706379</ArticleId>
            <ArticleId IdType="pubmed">26603899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445&#x2013;455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3725458</ArticleId>
            <ArticleId IdType="pubmed">23619691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okabe Y, Medzhitov R. Tissue biology perspective on macrophages. Nat. Immunol. 2016;17:9&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26681457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janeway CA, Jr., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002;20:197&#x2013;216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11861602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chovatiya R, Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol. Cell. 2014;54:281&#x2013;288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4048989</ArticleId>
            <ArticleId IdType="pubmed">24766892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korolnek T, Hamza I. Macrophages and iron trafficking at the birth and death of red cells. Blood. 2015;125:2893&#x2013;2897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4424413</ArticleId>
            <ArticleId IdType="pubmed">25778532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassat JE, Skaar EP. Iron in infection and immunity. Cell Host Microbe. 2013;13:509&#x2013;519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3676888</ArticleId>
            <ArticleId IdType="pubmed">23684303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat. Rev. Immunol. 2015;15:500&#x2013;510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4801113</ArticleId>
            <ArticleId IdType="pubmed">26160612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soares MP, Weiss G. The Iron age of host-microbe interactions. EMBO Rep. 2015;16:1482&#x2013;1500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4641501</ArticleId>
            <ArticleId IdType="pubmed">26474900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamza I, Dailey HA. One ring to rule them all: trafficking of heme and heme synthesis intermediates in the metazoans. Biochim. Biophys. Acta. 2012;1823:1617&#x2013;1632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3412874</ArticleId>
            <ArticleId IdType="pubmed">22575458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta. 1996;1275:161&#x2013;203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8695634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winterbourn CC. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol. Lett. 1995;82-83:969&#x2013;974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8597169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassat JE, Skaar EP. Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity. Semin. Immunopathol. 2012;34:215&#x2013;235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3796439</ArticleId>
            <ArticleId IdType="pubmed">22048835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wells RM, et al. Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis. PLoS Pathog. 2013;9:e1003120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3561183</ArticleId>
            <ArticleId IdType="pubmed">23431276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klebba PE, Charbit A, Xiao Q, Jiang X, Newton SM. Mechanisms of iron and haem transport by Listeria monocytogenes. Mol. Membr. Biol. 2012;29:69&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22703022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wessling-Resnick M. Nramp1 and other transporters involved in metal withholding during infection. J. Biol. Chem. 2015;290:18984&#x2013;18990.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4521020</ArticleId>
            <ArticleId IdType="pubmed">26055722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Govoni G, Gros P. Macrophage NRAMP1 and its role in resistance to microbial infections. Inflamm. Res. 1998;47:277&#x2013;284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9719491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu S, Murphy ME. Genetic modifiers of the p53 pathway. Cold Spring Harb. Perspect. Med. 2016;6:a026302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4817744</ArticleId>
            <ArticleId IdType="pubmed">27037420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jennis M, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev. 2016;30:918&#x2013;930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4840298</ArticleId>
            <ArticleId IdType="pubmed">27034505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Dumont P, Della Pietra A, Shetler C, Murphy ME. The codon 47 polymorphism in p53 is functionally significant. J. Biol. Chem. 2005;280:24245&#x2013;24251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15851479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo JL, et al. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene. 2001;20:320&#x2013;328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11313961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leu JI, Murphy ME, George DL. Mechanistic basis for impaired ferroptosis in cells expressing the African-centric S47 variant of p53. Proc. Natl Acad. Sci. USA. 2019;116:8390&#x2013;8396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6486733</ArticleId>
            <ArticleId IdType="pubmed">30962386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barton JC, Barton JC, Adams PC. Clinical and laboratory associations with persistent hyperferritinemia in 373 black hemochromatosis and iron overload screening study participants. Ann. Hepatol. 2017;16:802&#x2013;811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28809726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy ME, et al. A functionally significant SNP in TP53 and breast cancer risk in African-American women. NPJ Breast Cancer. 2017;3:5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5445618</ArticleId>
            <ArticleId IdType="pubmed">28649645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fratazzi C, et al. Macrophage apoptosis in mycobacterial infections. J. Leukoc. Biol. 1999;66:763&#x2013;764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10577507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behar SM, et al. Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunol. 2011;4:279&#x2013;287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3155700</ArticleId>
            <ArticleId IdType="pubmed">21307848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rath M, Muller I, Kropf P, Closs EI, Munder M. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front. Immunol. 2014;5:532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4209874</ArticleId>
            <ArticleId IdType="pubmed">25386178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joseph SB, et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell. 2004;119:299&#x2013;309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15479645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedi B, et al. Enhanced clearance of Pseudomonas aeruginosa by peroxisome proliferator-activated receptor gamma. Infect. Immun. 2016;84:1975&#x2013;1985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4936346</ArticleId>
            <ArticleId IdType="pubmed">27091928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ckless K, et al. Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration. J. Immunol. 2008;181:4255&#x2013;4264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2892856</ArticleId>
            <ArticleId IdType="pubmed">18768883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pessanha AP, Martins RA, Mattos-Guaraldi AL, Vianna A, Moreira LO. Arginase-1 expression in granulomas of tuberculosis patients. FEMS Immunol. Med. Microbiol. 2012;66:265&#x2013;268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22827286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis ND, et al. Immune evasion by Helicobacter pylori is mediated by induction of macrophage arginase II. J. Immunol. 2011;186:3632&#x2013;3641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3069806</ArticleId>
            <ArticleId IdType="pubmed">21296975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iyamu EW, Perdew H, Woods GM. Cysteine-iron promotes arginase activity by driving the Fenton reaction. Biochem. Biophys. Res Commun. 2008;376:116&#x2013;120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2585818</ArticleId>
            <ArticleId IdType="pubmed">18762165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Purr A, Weil L. The relation of intermediary metabolic products to arginase activation. Biochem. J. 1934;28:740&#x2013;744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1253251</ArticleId>
            <ArticleId IdType="pubmed">16745441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez A, Castrillo A. Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. Biochim. Biophys. Acta. 2011;1812:982&#x2013;994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21193033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Im SS, Osborne TF. Liver x receptors in atherosclerosis and inflammation. Circ. Res. 2011;108:996&#x2013;1001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3082200</ArticleId>
            <ArticleId IdType="pubmed">21493922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bories G, et al. Liver X receptor activation stimulates iron export in human alternative macrophages. Circ. Res. 2013;113:1196&#x2013;1205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3989231</ArticleId>
            <ArticleId IdType="pubmed">24036496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korf H, et al. Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. J. Clin. Invest. 2009;119:1626&#x2013;1637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2689129</ArticleId>
            <ArticleId IdType="pubmed">19436111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barish GD, Evans RM. A nuclear strike against Listeria&#x2013;the evolving life of LXR. Cell. 2004;119:149&#x2013;151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15479632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olivier M, Van Den Ham K, Shio MT, Kassa FA, Fougeray S. Malarial pigment hemozoin and the innate inflammatory response. Front. Immunol. 2014;5:25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3913902</ArticleId>
            <ArticleId IdType="pubmed">24550911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amodu OK, Adeyemo AA, Olumese PE, Gbadegesin RA. Intraleucocytic malaria pigment and clinical severity of malaria in children. Trans. R. Soc. Trop. Med. Hyg. 1998;92:54&#x2013;56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9692152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arese P, Schwarzer E. Malarial pigment (haemozoin): a very active &#x2018;inert&#x2019; substance. Ann. Trop. Med. Parasitol. 1997;91:501&#x2013;516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9329987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sherry BA, et al. Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF, MIP-1 alpha, and MIP-1 beta) in vitro, and altered thermoregulation in vivo. J. Inflamm. 1995;45:85&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7583361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jablonski KA, et al. Novel markers to delineate murine M1 and M2 macrophages. PloS ONE. 2015;10:e0145342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4689374</ArticleId>
            <ArticleId IdType="pubmed">26699615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long, S. S., Prober, C. G &amp; Fischer, M. Principles and Practice of Pediatric Infectious Diseases Vol. 20 (Elsevier, 2003).</Citation>
        </Reference>
        <Reference>
          <Citation>Barton JC, Acton RT. Hepcidin, iron, and bacterial infection. Vitam. Horm. 2019;110:223&#x2013;242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30798814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cairo G, Recalcati S, Mantovani A, Locati M. Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol. 2011;32:241&#x2013;247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21514223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroncke KD, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin. Exp. Immunol. 1998;113:147&#x2013;156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1905037</ArticleId>
            <ArticleId IdType="pubmed">9717962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardbower DM, et al. Arginase 2 deletion leads to enhanced M1 macrophage activation and upregulated polyamine metabolism in response to Helicobacter pylori infection. Amino Acids. 2016;48:2375&#x2013;2388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5042810</ArticleId>
            <ArticleId IdType="pubmed">27074721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valledor AF, et al. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc. Natl Acad. Sci. USA. 2004;101:17813&#x2013;17818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC539759</ArticleId>
            <ArticleId IdType="pubmed">15601766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barton JC, Edwards CQ, Acton RT. HFE gene: Structure, function, mutations, and associated iron abnormalities. Gene. 2015;574:179&#x2013;192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6660136</ArticleId>
            <ArticleId IdType="pubmed">26456104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordeuk VR, et al. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol. Dis. 2003;31:299&#x2013;304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14636642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barton JC, et al. HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants. Am. J. Hematol. 2009;84:710&#x2013;714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19787796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison-Findik DD. Gender-related variations in iron metabolism and liver diseases. World J. Hepatol. 2010;2:302&#x2013;310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2999297</ArticleId>
            <ArticleId IdType="pubmed">21161013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Douglass AN, et al. Host-based prophylaxis successfully targets liver stage malaria parasites. Mol. Ther. 2015;23:857&#x2013;865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4427874</ArticleId>
            <ArticleId IdType="pubmed">25648263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaushansky A, et al. Suppression of host p53 is critical for Plasmodium liver-stage infection. Cell Rep. 2013;3:630&#x2013;637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3619000</ArticleId>
            <ArticleId IdType="pubmed">23478020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wozencraft AO, Croft SL, Sayers G. Oxygen radical release by adherent cell populations during the initial stages of a lethal rodent malarial infection. Immunology. 1985;56:523&#x2013;531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1453744</ArticleId>
            <ArticleId IdType="pubmed">3000927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dockrell HM, Alavi A, Playfair JH. Changes in oxidative burst capacity during murine malaria and the effect of vaccination. Clin. Exp. Immunol. 1986;66:37&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1542660</ArticleId>
            <ArticleId IdType="pubmed">3026701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martiney JA, et al. Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia. Infect. Immun. 2000;68:2259&#x2013;2267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC97412</ArticleId>
            <ArticleId IdType="pubmed">10722628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jakobsen PH, et al. Tumour necrosis factor and interleukin-6 production induced by components associated with merozoite proteins of Plasmodium falciparum. Parasite Immunol. 1993;15:229&#x2013;237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8506119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azcarate IG, et al. Iron supplementation in mouse expands cellular innate defences in spleen and defers lethal malaria infection. Biochim. Biophys. Acta Mol. Basis Dis. 2017;1863:3049&#x2013;3059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28965885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang DL, et al. Erythrocytic ferroportin reduces intracellular iron accumulation, hemolysis, and malaria risk. Science. 2018;359:1520&#x2013;1523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29599243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leitner DF, Stoute JA, Landmesser M, Neely E, Connor JR. The HFE genotype and a formulated diet controlling for iron status attenuate experimental cerebral malaria in mice. Int J. Parasitol. 2015;45:797&#x2013;808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26296689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hay SI, Rogers DJ, Toomer JF, Snow RW. Annual Plasmodium falciparum entomological inoculation rates (EIR) across Africa: literature survey, Internet access and review. Trans. R. Soc. Trop. Med. Hyg. 2000;94:113&#x2013;127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3204456</ArticleId>
            <ArticleId IdType="pubmed">10897348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walch M, et al. Cytotoxic cells kill intracellular bacteria through granulysin-mediated delivery of granzymes. Cell. 2014;157:1309&#x2013;1323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4090916</ArticleId>
            <ArticleId IdType="pubmed">24906149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox J, et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteom. 2014;13:2513&#x2013;2526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4159666</ArticleId>
            <ArticleId IdType="pubmed">24942700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc. Natl Acad. Sci. USA. 2003;100:9440&#x2013;9445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC170937</ArticleId>
            <ArticleId IdType="pubmed">12883005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36:3943&#x2013;3956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5511239</ArticleId>
            <ArticleId IdType="pubmed">28288132</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31775041</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2211-1247</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Nov</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell reports</Title>
          <ISOAbbreviation>Cell Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>B1 and Marginal Zone B Cells but Not Follicular B2 Cells Require Gpx4 to Prevent Lipid Peroxidation and Ferroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>2731</StartPage>
          <EndPage>2744.e4</EndPage>
          <MedlinePgn>2731-2744.e4</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2019.10.070</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2211-1247(19)31392-0</ELocationID>
        <Abstract>
          <AbstractText>Aerobic organisms need to maintain cellular redox homeostasis. Glutathione peroxidase-4 (Gpx4) has the unique ability to protect cells against lipid peroxidation. Here, we show that Gpx4 is absolutely required to prevent ferroptosis during development, maintenance, and responses of innate-like B cells, namely, the B1 and marginal zone (MZ) B cells. In contrast, Gpx4 is dispensable for the development, germinal center reactions, and antibody responses of follicular B2 cells. Mechanistically, we show increased lipid metabolism and sensitivity to lipid peroxidation and ferroptosis in B1 and MZ B cells compared to follicular B2 cells, consistent with the requirement of Gpx4 in innate-like B cells. This high sensitivity to ferroptosis of innate-like B cells may be used to therapeutically target Gpx4 in certain forms of B cell malignancies involving B1 cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Muri</LastName>
            <ForeName>Jonathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Health Sciences, ETH Zurich, 8093 Zürich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thut</LastName>
            <ForeName>Helen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Health Sciences, ETH Zurich, 8093 Zürich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bornkamm</LastName>
            <ForeName>Georg W</ForeName>
            <Initials>GW</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Clinical Molecular Biology and Tumor Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kopf</LastName>
            <ForeName>Manfred</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Health Sciences, ETH Zurich, 8093 Zürich, Switzerland. Electronic address: manfred.kopf@ethz.ch.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Rep</MedlineTA>
        <NlmUniqueID>101573691</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C472639">BBS9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.9</RegistryNumber>
          <NameOfSubstance UI="D005979">Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005979" MajorTopicYN="N">Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">B cell immunometabolism</Keyword>
        <Keyword MajorTopicYN="N">B1 cells</Keyword>
        <Keyword MajorTopicYN="N">Gpx4</Keyword>
        <Keyword MajorTopicYN="N">fatty-acid metabolism</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">glutathione</Keyword>
        <Keyword MajorTopicYN="N">lipid ROS</Keyword>
        <Keyword MajorTopicYN="N">marginal zone B cells</Keyword>
        <Keyword MajorTopicYN="N">redox system</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31775041</ArticleId>
        <ArticleId IdType="doi">10.1016/j.celrep.2019.10.070</ArticleId>
        <ArticleId IdType="pii">S2211-1247(19)31392-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31554642</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>08</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2159-8290</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer discovery</Title>
          <ISOAbbreviation>Cancer Discov</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11.</ArticleTitle>
        <Pagination>
          <StartPage>1673</StartPage>
          <EndPage>1685</EndPage>
          <MedlinePgn>1673-1685</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-19-0338</ELocationID>
        <Abstract>
          <AbstractText>A challenge in oncology is to rationally and effectively integrate immunotherapy with traditional modalities, including radiotherapy. Here, we demonstrate that radiotherapy induces tumor-cell ferroptosis. Ferroptosis agonists augment and ferroptosis antagonists limit radiotherapy efficacy in tumor models. Immunotherapy sensitizes tumors to radiotherapy by promoting tumor-cell ferroptosis. Mechanistically, IFNγ derived from immunotherapy-activated CD8[+] T cells and radiotherapy-activated ATM independently, yet synergistically, suppresses SLC7A11, a unit of the glutamate-cystine antiporter xc[-], resulting in reduced cystine uptake, enhanced tumor lipid oxidation and ferroptosis, and improved tumor control. Thus, ferroptosis is an unappreciated mechanism and focus for the development of effective combinatorial cancer therapy. SIGNIFICANCE: This article describes ferroptosis as a previously unappreciated mechanism of action for radiotherapy. Further, it shows that ferroptosis is a novel point of synergy between immunotherapy and radiotherapy. Finally, it nominates SLC7A11, a critical regulator of ferroptosis, as a mechanistic determinant of synergy between radiotherapy and immunotherapy.This article is highlighted in the In This Issue feature, p. 1631.</AbstractText>
          <CopyrightInformation>&#xa9;2019 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Lang</LastName>
            <ForeName>Xueting</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Green</LastName>
            <ForeName>Michael D</ForeName>
            <Initials>MD</Initials>
            <Identifier Source="ORCID">0000-0003-4951-7118</Identifier>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Weimin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Jiali</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Jae Eun</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Michigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Long</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-8409-5574</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Jiajia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Qiang</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dow</LastName>
            <ForeName>Ania</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saripalli</LastName>
            <ForeName>Anjali L</ForeName>
            <Initials>AL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Education, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kryczek</LastName>
            <ForeName>Ilona</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-3130-2533</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Shuang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Szeliga</LastName>
            <ForeName>Wojciech</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vatan</LastName>
            <ForeName>Linda</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stone</LastName>
            <ForeName>Everett M</ForeName>
            <Initials>EM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Georgiou</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cieslik</LastName>
            <ForeName>Marcin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Computational Medicine and Bioinformatics, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Howard Hughes Medical Institute, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wahl</LastName>
            <ForeName>Daniel R</ForeName>
            <Initials>DR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morgan</LastName>
            <ForeName>Meredith A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chinnaiyan</LastName>
            <ForeName>Arul M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Michigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Computational Medicine and Bioinformatics, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Howard Hughes Medical Institute, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lawrence</LastName>
            <ForeName>Theodore S</ForeName>
            <Initials>TS</Initials>
            <Identifier Source="ORCID">0000-0002-4186-8821</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Weiping</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan. wzou@umich.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Graduate Program in Immunology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Graduate Program in Cancer Biology, University of Michigan School of Medicine, Ann Arbor, Michigan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>UM1 HG006508</GrantID>
            <Acronym>HG</Acronym>
            <Agency>NHGRI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>S10 OD025046</GrantID>
            <Acronym>OD</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 CA216449</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA193136</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA046592</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA189623</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA217510</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA152470</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA240515</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA211016</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA123088</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA190176</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA214911</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA099985</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K08 CA234416</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>09</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Discov</MedlineTA>
        <NlmUniqueID>101561693</NlmUniqueID>
        <ISSNLinking>2159-8274</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027182">Amino Acid Transport System y+</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C573415">IFNG protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C118895">SLC7A11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3XC8GUZ6CB</RegistryNumber>
          <NameOfSubstance UI="D012460">Sulfasalazine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D027182" MajorTopicYN="N">Amino Acid Transport System y+</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="N">Melanoma, Experimental</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012460" MajorTopicYN="N">Sulfasalazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflict of Interest: The authors declare no competing financial interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31554642</ArticleId>
        <ArticleId IdType="mid">NIHMS1053458</ArticleId>
        <ArticleId IdType="pmc">PMC6891128</ArticleId>
        <ArticleId IdType="doi">10.1158/2159-8290.CD-19-0338</ArticleId>
        <ArticleId IdType="pii">2159-8290.CD-19-0338</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations. Science translational medicine 2016;8(328):328rv4&#x2013;rv4 doi 10.1126/scitranslmed.aad7118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aad7118</ArticleId>
            <ArticleId IdType="pmc">PMC4859220</ArticleId>
            <ArticleId IdType="pubmed">26936508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. Journal for immunotherapy of cancer 2016;4:51 doi 10.1186/s40425-016-0156-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-016-0156-7</ArticleId>
            <ArticleId IdType="pmc">PMC5028964</ArticleId>
            <ArticleId IdType="pubmed">27660705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 2017;548:466 doi 10.1038/nature23470</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature23470</ArticleId>
            <ArticleId IdType="pmc">PMC5857357</ArticleId>
            <ArticleId IdType="pubmed">28759889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 2017;8:15618 doi 10.1038/ncomms15618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms15618</ArticleId>
            <ArticleId IdType="pmc">PMC5472757</ArticleId>
            <ArticleId IdType="pubmed">28598415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakhoum SF, Kabeche L, Wood MD, Laucius CD, Qu D, Laughney AM, et al. Numerical chromosomal instability mediates susceptibility to radiation treatment. Nature Communications 2015;6:5990 doi 10.1038/ncomms6990</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms6990</ArticleId>
            <ArticleId IdType="pmc">PMC4516720</ArticleId>
            <ArticleId IdType="pubmed">25606712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan MA, Lawrence TS. Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21(13):2898&#x2013;904 doi 10.1158/1078-0432.CCR-13-3229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-3229</ArticleId>
            <ArticleId IdType="pmc">PMC4494107</ArticleId>
            <ArticleId IdType="pubmed">26133775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3&#x3c3; is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616 doi 10.1038/44188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/44188</ArticleId>
            <ArticleId IdType="pubmed">10524633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H-H, Wu Z-Q, Qian D, Zaorsky NG, Qiu M-H, Cheng J-J, et al. Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis In Vitro and In Vivo. International Journal of Radiation Oncology*Biology*Physics 2018;101(1):49&#x2013;62 doi: 10.1016/j.ijrobp.2018.01.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijrobp.2018.01.036</ArticleId>
            <ArticleId IdType="pubmed">29619976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nature Reviews Cancer 2004;4:592 doi 10.1038/nrc1412...</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1412</ArticleId>
            <ArticleId IdType="pubmed">15286739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gebicki JM, Du J, Collins J, Tweeddale H. Peroxidation of proteins and lipids in suspensions of liposomes, in blood serum, and in mouse myeloma cells. Acta Biochim Pol. 2000;47:901&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11996113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spitz DR, Azzam EI, Li JJ, Gius D. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology Cancer Metastasis Rev. Springer; 2004;23:311&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15197331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149(5): 1060&#x2013;72 doi 10.1016/j.cell.2012.03.042..</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z, et al.
Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med. jem.rupress.org; 1994;180:525&#x2013;35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2191598</ArticleId>
            <ArticleId IdType="pubmed">8046331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity 2014;41(5):843&#x2013;52 doi 10.1016/j.immuni.2014.10.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.10.019</ArticleId>
            <ArticleId IdType="pmc">PMC5155593</ArticleId>
            <ArticleId IdType="pubmed">25517616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. The Journal of Clinical Investigation 2014; 124(2):687&#x2013;95 doi 10.1172/jci67313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci67313</ArticleId>
            <ArticleId IdType="pmc">PMC3904601</ArticleId>
            <ArticleId IdType="pubmed">24382348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Green M, Choi JE, Gij&#xf3;n M, Kennedy PD, Johnson JK, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 2019;569(7755):270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, Stockwell BR. Ferroptosis: Death by lipid peroxidation. Trends in Cell Biology. 2015;26(3):165&#x2013;176 doi 10.1016/j.tcb.2015.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2015.10.014</ArticleId>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cramer SL, Saha A, Liu J, Tadi S, Tiziani S, Yan W, et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nature Medicine 2016;23:120 doi 10.1038/nm.4232</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4232</ArticleId>
            <ArticleId IdType="pmc">PMC5218918</ArticleId>
            <ArticleId IdType="pubmed">27869804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magtanong L, Ko PJ, To M, Cao JY, Forcina GC, Tarangelo A, et al. Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State. Cell chemical biology 2019;26(3):420&#x2013;32.e9 doi 10.1016/j.chembiol.2018.11.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2018.11.016</ArticleId>
            <ArticleId IdType="pmc">PMC6430697</ArticleId>
            <ArticleId IdType="pubmed">30686757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nature chemical biology 2016;13:91 doi 10.1038/nchembio.2239</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2239</ArticleId>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009;114(3):589&#x2013;95 doi 10.1182/blood-2009-02-206870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2009-02-206870</ArticleId>
            <ArticleId IdType="pmc">PMC2713472</ArticleId>
            <ArticleId IdType="pubmed">19349616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minn AJ, Wherry EJ. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell 2016;165(2):272&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27058661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poli G, Schaur RJ, Siems Wa, Leonarduzzi G. 4-Hydroxynonenal: A membrane lipid oxidation product of medicinal interest. Medicinal research reviews 2008;28(4):569&#x2013;631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18058921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 2015;527(7577):249&#x2013;53 doi 10.1038/nature15520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature15520</ArticleId>
            <ArticleId IdType="pmc">PMC4779053</ArticleId>
            <ArticleId IdType="pubmed">26503055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkata Narayanan I, Paulsen MT, Bedi K, Berg N, Ljungman EA, Francia S, et al. Transcriptional and post-transcriptional regulation of the ionizing radiation response by ATM and p53. Sci Rep 2017;7:43598 doi 10.1038/srep43598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep43598</ArticleId>
            <ArticleId IdType="pmc">PMC5335570</ArticleId>
            <ArticleId IdType="pubmed">28256581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 2014;3:e02523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of Ferroptotic Cancer Cell Death by GPX4. Cell 2014; 156(0):317&#x2013;31 doi 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Purbey PK, Scumpia PO, Kim PJ, Tong A-J, Iwamoto KS, McBride WH, et al. Defined Sensing Mechanisms and Signaling Pathways Contribute to the Global Inflammatory Gene Expression Output Elicited by Ionizing Radiation. Immunity 2017;47(3):421&#x2013;34.e3 doi 10.1016/j.immuni.2017.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2017.08.017</ArticleId>
            <ArticleId IdType="pmc">PMC5661954</ArticleId>
            <ArticleId IdType="pubmed">28930658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen P-H, Wu J, Ding C-KC, Lin C-C, Pan S, Bossa N, et al. Kinome screen of ferroptosis reveals a novel role of ATM in regulating iron metabolism. Cell Death &amp; Differentiation 2019. doi 10.1038/S41418-019-0393-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/S41418-019-0393-7</ArticleId>
            <ArticleId IdType="pmc">PMC7206124</ArticleId>
            <ArticleId IdType="pubmed">31320750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banin S, Moyal L, Shieh S-Y, Taya Y, Anderson C, Chessa L, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281(5383):1674&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9733514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Kryczek I, Dost&#xe1;l L, Lin H, Tan L, Zhao L, et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell 2016; 165(5):1092&#x2013;105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4874853</ArticleId>
            <ArticleId IdType="pubmed">27133165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clinical cancer research : an official journal of the American Association for Cancer Research 2009; 15(17):5379&#x2013;88 doi 10.1158/1078-0432.Ccr-09-0265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.Ccr-09-0265</ArticleId>
            <ArticleId IdType="pmc">PMC2746048</ArticleId>
            <ArticleId IdType="pubmed">19706802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520(7547):373&#x2013;7 doi 10.1038/nature14292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14292</ArticleId>
            <ArticleId IdType="pmc">PMC4401634</ArticleId>
            <ArticleId IdType="pubmed">25754329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 2017;171(2):273&#x2013;85 doi 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruiswijk F, Labuschagne C, Vousden K, p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nature Reviews Molecular Cell Biology 2015; 16(7):393&#x2013;405. doi: 10.1038/nrm4007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm4007</ArticleId>
            <ArticleId IdType="pubmed">26122615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Science advances 2018;4(6):eaat1719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6010333</ArticleId>
            <ArticleId IdType="pubmed">29938225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252&#x2013;64 doi 10.1038/nrc3239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3239</ArticleId>
            <ArticleId IdType="pmc">PMC4856023</ArticleId>
            <ArticleId IdType="pubmed">22437870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer discovery 2015;5(9):915&#x2013;9 doi 10.1158/2159-8290.cd-15-0563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.cd-15-0563</ArticleId>
            <ArticleId IdType="pmc">PMC4560619</ArticleId>
            <ArticleId IdType="pubmed">26272491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell&#x2013;mediated antitumor immunity. Nature Medicine 2003;9(5):562&#x2013;7 doi 10.1038/nm863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm863</ArticleId>
            <ArticleId IdType="pubmed">12704383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade&#x2013;mediated tumor regression. The Journal of Clinical Investigation 2018;128(2):805&#x2013;15 doi 10.1172/JCI96113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI96113</ArticleId>
            <ArticleId IdType="pmc">PMC5785251</ArticleId>
            <ArticleId IdType="pubmed">29337305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 2004;10(9):942&#x2013;9 doi 10.1038/nm1093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1093</ArticleId>
            <ArticleId IdType="pubmed">15322536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, et al. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2014;20):5085&#x2013;96 doi 10.1158/1078-0432.ccr-14-1038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.ccr-14-1038</ArticleId>
            <ArticleId IdType="pmc">PMC4184968</ArticleId>
            <ArticleId IdType="pubmed">25117293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (Oxford, England) 2010;26(1): 139&#x2013;40 doi 10.1093/bioinformatics/btp616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId>
            <ArticleId IdType="pmc">PMC2796818</ArticleId>
            <ArticleId IdType="pubmed">19910308</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31509699</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>06</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-4804</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <Issue>19</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Oct</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of medicinal chemistry</Title>
          <ISOAbbreviation>J Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Natural Product Albiziabioside A Conjugated with Pyruvate Dehydrogenase Kinase Inhibitor Dichloroacetate To Induce Apoptosis-Ferroptosis-M2-TAMs Polarization for Combined Cancer Therapy.</ArticleTitle>
        <Pagination>
          <StartPage>8760</StartPage>
          <EndPage>8772</EndPage>
          <MedlinePgn>8760-8772</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.9b00644</ELocationID>
        <Abstract>
          <AbstractText>The reprogramming of energy metabolism is considered to be one of the main characteristics of cancer. The development of therapeutic agents targeting glycolysis to alter aberrant glucose metabolism and restore oxidative phosphorylation has emerged as an effective approach for cancer therapy. In this way, we have developed a conjugate AlbA-DCA, which can induce a marked increase in intracellular ROS and alleviate the accumulation of lactic acid in TME. Meanwhile, AlbA-DCA selectively kills cancer cells and exhibits an excellent synergistic effect. Mechanism studies confirm that AlbA-DCA can induce apoptosis and ferroptosis. We also confirm that AlbA-DCA can remold the tumor immunosuppression microenvironment via eliminating M2-TAMs to inhibit both primary and distal tumor progression in a dual-4T1 tumor model in female BALB/c mice. As a result, rational design of natural saponin and PDK inhibitor to induce apoptosis-ferroptosis-M2-TAMs polarization for enhanced cancer therapy is a promising strategy, thus providing a new idea for cancer therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Gaofei</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery of Ministry of Education , Shenyang Pharmaceutical University , Shenyang 110016 , China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Research , Northwestern Polytechnical University , Xi'an 710072 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Jiahong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biopharmaceutical Science, School of Pharmacy and Health Sciences , Keck Graduate Institute , Claremont , California 91711 , United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luan</LastName>
            <ForeName>Weijing</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery of Ministry of Education , Shenyang Pharmaceutical University , Shenyang 110016 , China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Yantai Branch, Shanghai Institute of Materia Medica , Chinese Academy of Sciences (CAS) , Yantai 264000 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Zhuang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery of Ministry of Education , Shenyang Pharmaceutical University , Shenyang 110016 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Shuai</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery of Ministry of Education , Shenyang Pharmaceutical University , Shenyang 110016 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Shanshan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery of Ministry of Education , Shenyang Pharmaceutical University , Shenyang 110016 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Maosheng</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery of Ministry of Education , Shenyang Pharmaceutical University , Shenyang 110016 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-9284-1944</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Structure-Based Drug Design &amp; Discovery of Ministry of Education , Shenyang Pharmaceutical University , Shenyang 110016 , China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>09</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Med Chem</MedlineTA>
        <NlmUniqueID>9716531</NlmUniqueID>
        <ISSNLinking>0022-2623</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001688">Biological Products</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081382">Pyruvate Dehydrogenase Acetyl-Transferring Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012503">Saponins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000597544">albiziabioside A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9LSH52S3LQ</RegistryNumber>
          <NameOfSubstance UI="D003999">Dichloroacetic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003999" MajorTopicYN="N">Dichloroacetic Acid</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081382" MajorTopicYN="N">Pyruvate Dehydrogenase Acetyl-Transferring Kinase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012503" MajorTopicYN="N">Saponins</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31509699</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.jmedchem.9b00644</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31043744</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-4687</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>569</Volume>
            <Issue>7755</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature</Title>
          <ISOAbbreviation>Nature</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CD8[+] T cells regulate tumour ferroptosis during cancer immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>270</StartPage>
          <EndPage>274</EndPage>
          <MedlinePgn>270-274</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-1170-y</ELocationID>
        <Abstract>
          <AbstractText>Cancer immunotherapy restores or enhances the effector function of CD8[+] T cells in the tumour microenvironment[1,2]. CD8[+] T cells activated by cancer immunotherapy clear tumours mainly by inducing cell death through perforin-granzyme and Fas-Fas ligand pathways[3,4]. Ferroptosis is a form of cell death that differs from apoptosis and results from iron-dependent accumulation of lipid peroxide[5,6]. Although it has been investigated in vitro[7,8], there is emerging evidence that ferroptosis might be implicated in a variety of pathological scenarios[9,10]. It is unclear whether, and how, ferroptosis is involved in T cell immunity and cancer immunotherapy. Here we show that immunotherapy-activated CD8[+] T cells enhance ferroptosis-specific lipid peroxidation in tumour cells, and that increased ferroptosis contributes to the anti-tumour efficacy of immunotherapy. Mechanistically, interferon gamma (IFNγ) released from CD8[+] T cells downregulates the expression of SLC3A2 and SLC7A11, two subunits of the glutamate-cystine antiporter system xc[-], impairs the uptake of cystine by tumour cells, and as a consequence, promotes tumour cell lipid peroxidation and ferroptosis. In mouse models, depletion of cystine or cysteine by cyst(e)inase (an engineered enzyme that degrades both cystine and cysteine) in combination with checkpoint blockade synergistically enhanced T cell-mediated anti-tumour immunity and induced ferroptosis in tumour cells. Expression of system xc[-] was negatively associated, in cancer patients, with CD8[+] T cell signature, IFNγ expression, and patient outcome. Analyses of human transcriptomes before and during nivolumab therapy revealed that clinical benefits correlate with reduced expression of SLC3A2 and increased IFNγ and CD8. Thus, T cell-promoted tumour ferroptosis is an anti-tumour mechanism, and targeting this pathway in combination with checkpoint blockade is a potential therapeutic approach.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Weimin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Green</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Jae Eun</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Michigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gijón</LastName>
            <ForeName>Miguel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cayman Chemical Company, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kennedy</LastName>
            <ForeName>Paul D</ForeName>
            <Initials>PD</Initials>
            <AffiliationInfo>
              <Affiliation>Cayman Chemical Company, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Jeffrey K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Cayman Chemical Company, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lang</LastName>
            <ForeName>Xueting</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kryczek</LastName>
            <ForeName>Ilona</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sell</LastName>
            <ForeName>Amanda</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Houjun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Jiajia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Gaopeng</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Shuang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vatan</LastName>
            <ForeName>Linda</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hongjuan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Szeliga</LastName>
            <ForeName>Wojciech</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Cancer Genetics, Department of Pathology and Cell Biology, and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Rebecca</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lawrence</LastName>
            <ForeName>Theodore S</ForeName>
            <Initials>TS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lamb</LastName>
            <ForeName>Candice</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanno</LastName>
            <ForeName>Yuri</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cieslik</LastName>
            <ForeName>Marcin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Computational Medicine &amp; Bioinformatics, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stone</LastName>
            <ForeName>Everett</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Georgiou</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>Timothy A</ForeName>
            <Initials>TA</Initials>
            <AffiliationInfo>
              <Affiliation>Immunogenomics and Precision Oncology Platform, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chinnaiyan</LastName>
            <ForeName>Arul</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Michigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Howard Hughes Medical Institute, University of Michigan School of Medicine, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Weiping</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA. wzou@med.umich.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI, USA. wzou@med.umich.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA. wzou@med.umich.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Graduate Program in Immunology, University of Michigan School of Medicine, Ann Arbor, MI, USA. wzou@med.umich.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Graduate Program in Cancer Biology, University of Michigan School of Medicine, Ann Arbor, MI, USA. wzou@med.umich.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA046592</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA189623</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA152470</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA008748</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA193136</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA189623</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA123088</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA217510</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA205426</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA190176</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA214911</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA127648</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 CA232097</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA099985</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA211016</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>05</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nature</MedlineTA>
        <NlmUniqueID>0410462</NlmUniqueID>
        <ISSNLinking>0028-0836</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027182">Amino Acid Transport System y+</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027282">Fusion Regulatory Protein 1, Heavy Chain</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C573415">IFNG protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C545989">SLC3A2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C118895">SLC7A11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31YO63LBSN</RegistryNumber>
          <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>K848JZ4886</RegistryNumber>
          <NameOfSubstance UI="D003545">Cysteine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Cancer Discov. 2019 Jul;9(7):OF2</RefSource>
          <PMID Version="1">31113802</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Cell Res. 2019 Sep;29(9):692-693</RefSource>
          <PMID Version="1">31160718</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Cell Metab. 2019 Jul 2;30(1):14-15</RefSource>
          <PMID Version="1">31269423</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D027182" MajorTopicYN="N">Amino Acid Transport System y+</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003545" MajorTopicYN="N">Cysteine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027282" MajorTopicYN="N">Fusion Regulatory Protein 1, Heavy Chain</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Competing interests GG and ES are inventors on intellectual property related to cyst(e)inase and hold equity interest in Aeglea Biotherapeutics Inc. TAC is a co-founder of Gritstone Oncology and holds equity. TAC holds equity in An2H. TAC acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai. TAC has served as a paid advisor for Bristol-Myers Squibb, Illumina, Eisai, and An2H. MSK has licensed the use of TMB for the identification of patients that benefit from immune checkpoint therapy to PGDx. MSK and TAC receives royalties as part of this licensing agreement. WZ has served as a consultant or advisor for Lycera, NGM, Synlogic, and Henlix.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31043744</ArticleId>
        <ArticleId IdType="mid">NIHMS1525540</ArticleId>
        <ArticleId IdType="pmc">PMC6533917</ArticleId>
        <ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s41586-019-1170-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zou W, Wolchok JD &amp; Chen L PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations. Sci Transl Med 8, 328rv324 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4859220</ArticleId>
            <ArticleId IdType="pubmed">26936508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khalil DN, Smith EL, Brentjens RJ &amp; Wolchok JD The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature reviews. Clinical oncology 13, 394, (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5558237</ArticleId>
            <ArticleId IdType="pubmed">27118494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barry M &amp; Bleackley RC Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2, 401&#x2013;409 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12093006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golstein P &amp; Griffiths GM An early history of T cell-mediated cytotoxicity. Nat Rev Immunol, 18, 527&#x2013;535 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29662120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060&#x2013;1072 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317&#x2013;331, (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol 13, 81&#x2013;90 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13, 91&#x2013;98 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M, Angeli JP, Vandenabeele P &amp; Stockwell BR Regulated necrosis: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 15, 348&#x2013;366 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6531857</ArticleId>
            <ArticleId IdType="pubmed">26775689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linkermann A et al. Synchronized renal tubular cell death involves ferroptosis. Proceedings of the National Academy of Sciences of the United States of America 111, 16836&#x2013;16841 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4250130</ArticleId>
            <ArticleId IdType="pubmed">25385600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS &amp; Stockwell BR Ferroptosis: Death by Lipid Peroxidation. Trends in cell biology 26, 165&#x2013;176 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4764384</ArticleId>
            <ArticleId IdType="pubmed">26653790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SE et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nature nanotechnology 11, 977&#x2013;985 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5108575</ArticleId>
            <ArticleId IdType="pubmed">27668796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braumuller H et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361&#x2013;365 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23376950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamanaka K et al. A novel fluorescent probe with high sensitivity and selective detection of lipid hydroperoxides in cells. RSC Advances 2, 7894&#x2013;7900 (2012).</Citation>
        </Reference>
        <Reference>
          <Citation>Tsoi J et al. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer cell 33, 890&#x2013;904 e895 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5953834</ArticleId>
            <ArticleId IdType="pubmed">29657129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rees MG et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol 12, 109&#x2013;116 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4718762</ArticleId>
            <ArticleId IdType="pubmed">26656090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishimoto T et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(&#x2212;) and thereby promotes tumor growth. Cancer cell 19, 387&#x2013;400 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21397861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroder K, Hertzog PJ, Ravasi T &amp; Hume DA Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75, 163&#x2013;189 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14525967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W et al. Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell 165, 1092&#x2013;1105 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4874853</ArticleId>
            <ArticleId IdType="pubmed">27133165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linher-Melville K, Haftchenary S, Gunning P &amp; Singh G Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells. Molecular and cellular biochemistry 405, 205&#x2013;221 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25896132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cramer SL et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nature medicine 23, 120&#x2013;127 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5218918</ArticleId>
            <ArticleId IdType="pubmed">27869804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvarez SW et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. Nature 551, 639&#x2013;643 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5808442</ArticleId>
            <ArticleId IdType="pubmed">29168506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riaz N et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell 171, 934&#x2013;949 e915 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685550</ArticleId>
            <ArticleId IdType="pubmed">29033130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buck MD, Sowell RT, Kaech SM &amp; Pearce EL Metabolic Instruction of Immunity. Cell 169, 570&#x2013;586 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5648021</ArticleId>
            <ArticleId IdType="pubmed">28475890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O&#x2019;Neill LA, Kishton RJ &amp; Rathmell J A guide to immunometabolism for immunologists. Nat Rev Immunol 16, 553&#x2013;565 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5001910</ArticleId>
            <ArticleId IdType="pubmed">27396447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bligh EG &amp; Dyer WJ A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37, 911&#x2013;917 (1959).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13671378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg JE et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909&#x2013;1920 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5480242</ArticleId>
            <ArticleId IdType="pubmed">26952546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 3, e02523 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4054777</ArticleId>
            <ArticleId IdType="pubmed">24844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu YM et al. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173, 1770&#x2013;1782 e1714 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6084431</ArticleId>
            <ArticleId IdType="pubmed">29906450</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30830879</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1558-8238</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>129</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Feb</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical investigation</Title>
          <ISOAbbreviation>J Clin Invest</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation.</ArticleTitle>
        <Pagination>
          <StartPage>2293</StartPage>
          <EndPage>2304</EndPage>
          <MedlinePgn>2293-2304</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI126428</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">126428</ELocationID>
        <Abstract>
          <AbstractText>Non-apoptotic forms of cell death can trigger sterile inflammation through the release of danger-associated molecular patterns, which are recognized by innate immune receptors. However, despite years of investigation the mechanisms which initiate inflammatory responses after heart transplantation remain elusive. Here, we demonstrate that ferrostatin-1 (Fer-1), a specific inhibitor of ferroptosis, decreases the level of pro-ferroptotic hydroperoxy-arachidonoyl-phosphatidylethanolamine, reduces cardiomyocyte cell death and blocks neutrophil recruitment following heart transplantation. Inhibition of necroptosis had no effect on neutrophil trafficking in cardiac grafts. We extend these observations to a model of coronary artery ligation-induced myocardial ischemia reperfusion injury where inhibition of ferroptosis resulted in reduced infarct size, improved left ventricular systolic function, and reduced left ventricular remodeling. Using intravital imaging of cardiac transplants, we uncover that ferroptosis orchestrates neutrophil recruitment to injured myocardium by promoting adhesion of neutrophils to coronary vascular endothelial cells through a TLR4/TRIF/type I IFN signaling pathway. Thus, we have discovered that inflammatory responses after cardiac transplantation are initiated through ferroptotic cell death and TLR4/Trif-dependent signaling in graft endothelial cells. These findings provide a platform for the development of therapeutic strategies for heart transplant recipients and patients, who are vulnerable to ischemia reperfusion injury following restoration of coronary blood flow.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Wenjun</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Guoshuai</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gauthier</LastName>
            <ForeName>Jason M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lokshina</LastName>
            <ForeName>Inessa</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Higashikubo</LastName>
            <ForeName>Ryuji</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Evans</LastName>
            <ForeName>Sarah</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xinping</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hassan</LastName>
            <ForeName>Adil</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanaka</LastName>
            <ForeName>Satona</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cicka</LastName>
            <ForeName>Markus</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsiao</LastName>
            <ForeName>Hsi-Min</ForeName>
            <Initials>HM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruiz-Perez</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bredemeyer</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gross</LastName>
            <ForeName>Richard W</ForeName>
            <Initials>RW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mann</LastName>
            <ForeName>Douglas L</ForeName>
            <Initials>DL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tyurina</LastName>
            <ForeName>Yulia Y</ForeName>
            <Initials>YY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gelman</LastName>
            <ForeName>Andrew E</ForeName>
            <Initials>AE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Immunology, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kagan</LastName>
            <ForeName>Valerian E</ForeName>
            <Initials>VE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Navigational Redox Lipidomics, I.M. Sechenov Moscow State Medical University, Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Linkermann</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine III, Division of Nephrology, University Hospital Carl Gustav Carus at Technische Universität Dresden, Dresden, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lavine</LastName>
            <ForeName>Kory J</ForeName>
            <Initials>KJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Immunology, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Developmental Biology, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kreisel</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery and.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Immunology, Washington University, Saint Louis, Missouri, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 HL123519</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL139714</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 AI116501</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL094601</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL138466</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 DK052574</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>I01 BX002730</GrantID>
            <Acronym>BX</Acronym>
            <Agency>BLRD VA</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>02</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Invest</MedlineTA>
        <NlmUniqueID>7802877</NlmUniqueID>
        <ISSNLinking>0021-9738</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033942">Adaptor Proteins, Vesicular Transport</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003514">Cyclohexylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010655">Phenylenediamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C476286">TICAM-1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C493487">Tlr4 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C573944">ferrostatin-1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D033942" MajorTopicYN="N">Adaptor Proteins, Vesicular Transport</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003514" MajorTopicYN="N">Cyclohexylamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016027" MajorTopicYN="Y">Heart Transplantation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015428" MajorTopicYN="N">Myocardial Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020556" MajorTopicYN="Y">Neutrophil Infiltration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010655" MajorTopicYN="N">Phenylenediamines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Inflammation</Keyword>
        <Keyword MajorTopicYN="N">Neutrophils</Keyword>
        <Keyword MajorTopicYN="N">Organ transplantation</Keyword>
        <Keyword MajorTopicYN="N">Transplantation</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of interest: DK serves on The Scientific Advisory Board of and receives research support from Compass Therapeutics. DK and KJL have a pending patent entitled &#x201c;Compositions and methods for detecting CCR2 receptors&#x201d; (US patent application no. 15/611,577).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30830879</ArticleId>
        <ArticleId IdType="pmc">PMC6546457</ArticleId>
        <ArticleId IdType="doi">10.1172/JCI126428</ArticleId>
        <ArticleId IdType="pii">126428</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kobashigawa J, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant. 2014;33(4):327&#x2013;340. doi: 10.1016/j.healun.2014.02.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.healun.2014.02.027</ArticleId>
            <ArticleId IdType="pubmed">24661451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicoara A, et al. Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors. Am J Transplant. 2018;18(6):1461&#x2013;1470. doi: 10.1111/ajt.14588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ajt.14588</ArticleId>
            <ArticleId IdType="pubmed">29136325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreisel D, et al. Bcl3 prevents acute inflammatory lung injury in mice by restraining emergency granulopoiesis. J Clin Invest. 2011;121(1):265&#x2013;276. doi: 10.1172/JCI42596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI42596</ArticleId>
            <ArticleId IdType="pmc">PMC3007142</ArticleId>
            <ArticleId IdType="pubmed">21157041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest. 1991;88(4):1237&#x2013;1243. doi: 10.1172/JCI115427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI115427</ArticleId>
            <ArticleId IdType="pmc">PMC295592</ArticleId>
            <ArticleId IdType="pubmed">1680879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald B, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science. 2010;330(6002):362&#x2013;366. doi: 10.1126/science.1195491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1195491</ArticleId>
            <ArticleId IdType="pubmed">20947763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu MY, et al. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. 2018;46(4):1650&#x2013;1667. doi: 10.1159/000489241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000489241</ArticleId>
            <ArticleId IdType="pubmed">29694958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarhan M, Land WG, Tonnus W, Hugo CP, Linkermann A. Origin and Consequences of Necroinflammation. Physiol Rev. 2018;98(2):727&#x2013;780. doi: 10.1152/physrev.00041.2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.00041.2016</ArticleId>
            <ArticleId IdType="pubmed">29465288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159&#x2013;175. doi: 10.1038/nri3399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3399</ArticleId>
            <ArticleId IdType="pubmed">23435331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, et al. Intravital 2-photon imaging of leukocyte trafficking in beating heart. J Clin Invest. 2012;122(7):2499&#x2013;2508. doi: 10.1172/JCI62970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI62970</ArticleId>
            <ArticleId IdType="pmc">PMC3386827</ArticleId>
            <ArticleId IdType="pubmed">22706307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, et al. Heart-resident CCR2. JCI Insight. 2016;1(12):87315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4985028</ArticleId>
            <ArticleId IdType="pubmed">27536731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanou T, et al. Inhibition of regulated necrosis attenuates receptor-interacting protein kinase 1-mediated ischemia-reperfusion injury after lung transplantation. J Heart Lung Transplant. 2018;37(10):1261&#x2013;1270. doi: 10.1016/j.healun.2018.04.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.healun.2018.04.005</ArticleId>
            <ArticleId IdType="pubmed">29907500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luedde M, et al. RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc Res. 2014;103(2):206&#x2013;216. doi: 10.1093/cvr/cvu146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cvr/cvu146</ArticleId>
            <ArticleId IdType="pubmed">24920296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann Angeli JP, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180&#x2013;1191. doi: 10.1038/ncb3064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3064</ArticleId>
            <ArticleId IdType="pmc">PMC4894846</ArticleId>
            <ArticleId IdType="pubmed">25402683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka O, et al. On the Mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Cent Sci. 2017;3(3):232&#x2013;243. doi: 10.1021/acscentsci.7b00028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acscentsci.7b00028</ArticleId>
            <ArticleId IdType="pmc">PMC5364454</ArticleId>
            <ArticleId IdType="pubmed">28386601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81&#x2013;90. doi: 10.1038/nchembio.2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2238</ArticleId>
            <ArticleId IdType="pmc">PMC5506843</ArticleId>
            <ArticleId IdType="pubmed">27842066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaschler MM, Stockwell BR. Lipid peroxidation in cell death. Biochem Biophys Res Commun. 2017;482(3):419&#x2013;425. doi: 10.1016/j.bbrc.2016.10.086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2016.10.086</ArticleId>
            <ArticleId IdType="pmc">PMC5319403</ArticleId>
            <ArticleId IdType="pubmed">28212725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skouta R, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc. 2014;136(12):4551&#x2013;4556. doi: 10.1021/ja411006a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ja411006a</ArticleId>
            <ArticleId IdType="pmc">PMC3985476</ArticleId>
            <ArticleId IdType="pubmed">24592866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dewald O, et al. Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation. 2005;112(3):407&#x2013;415. doi: 10.1161/CIRCULATIONAHA.105.536318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.536318</ArticleId>
            <ArticleId IdType="pubmed">16009788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. Transplantation and Damage-Associated Molecular Patterns (DAMPs) Am J Transplant. 2016;16(12):3338&#x2013;3361. doi: 10.1111/ajt.13963.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ajt.13963</ArticleId>
            <ArticleId IdType="pubmed">27421829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, et al. Myocardial ischemia activates an injurious innate immune signaling via cardiac heat shock protein 60 and Toll-like receptor 4. J Biol Chem. 2011;286(36):31308&#x2013;31319. doi: 10.1074/jbc.M111.246124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.246124</ArticleId>
            <ArticleId IdType="pmc">PMC3173057</ArticleId>
            <ArticleId IdType="pubmed">21775438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanoni I, et al. CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell. 2011;147(4):868&#x2013;880. doi: 10.1016/j.cell.2011.09.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.09.051</ArticleId>
            <ArticleId IdType="pmc">PMC3217211</ArticleId>
            <ArticleId IdType="pubmed">22078883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lazear HM, et al. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog. 2013;9(1):e1003118. doi: 10.1371/journal.ppat.1003118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1003118</ArticleId>
            <ArticleId IdType="pmc">PMC3536698</ArticleId>
            <ArticleId IdType="pubmed">23300459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freitas MC, Uchida Y, Lassman C, Danovitch GM, Busuttil RW, Kupiec-Weglinski JW. Type I interferon pathway mediates renal ischemia/reperfusion injury. Transplantation. 2011;92(2):131&#x2013;138. doi: 10.1097/TP.0b013e318220586e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/TP.0b013e318220586e</ArticleId>
            <ArticleId IdType="pmc">PMC4240623</ArticleId>
            <ArticleId IdType="pubmed">21577179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaczorowski DJ, et al. Toll-like receptor 4 mediates the early inflammatory response after cold ischemia/reperfusion. Transplantation. 2007;84(10):1279&#x2013;1287. doi: 10.1097/01.tp.0000287597.87571.17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.tp.0000287597.87571.17</ArticleId>
            <ArticleId IdType="pubmed">18049113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaczorowski DJ, et al. Mechanisms of Toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart. Transplantation. 2009;87(10):1455&#x2013;1463. doi: 10.1097/TP.0b013e3181a36e5e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/TP.0b013e3181a36e5e</ArticleId>
            <ArticleId IdType="pmc">PMC2766805</ArticleId>
            <ArticleId IdType="pubmed">19461481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding HS, et al. High mobility group [corrected] box 1 mediates neutrophil recruitment in myocardial ischemia-reperfusion injury through toll like receptor 4-related pathway. Gene. 2012;509(1):149&#x2013;153. doi: 10.1016/j.gene.2012.07.072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2012.07.072</ArticleId>
            <ArticleId IdType="pubmed">22890140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu H, Li J, Wang S, Liu K, Wang L, Huang L. Hmgb1-TLR4-IL-23-IL-17A axis promote ischemia-reperfusion injury in a cardiac transplantation model. Transplantation. 2013;95(12):1448&#x2013;1454. doi: 10.1097/TP.0b013e318293b7e1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/TP.0b013e318293b7e1</ArticleId>
            <ArticleId IdType="pubmed">23677049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsung A, et al. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol. 2005;175(11):7661&#x2013;7668. doi: 10.4049/jimmunol.175.11.7661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.175.11.7661</ArticleId>
            <ArticleId IdType="pubmed">16301676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhai Y, et al. Type I, but not type II, interferon is critical in liver injury induced after ischemia and reperfusion. Hepatology. 2008;47(1):199&#x2013;206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17935177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhai Y, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol. 2004;173(12):7115&#x2013;7119. doi: 10.4049/jimmunol.173.12.7115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.173.12.7115</ArticleId>
            <ArticleId IdType="pubmed">15585830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou H, Andonegui G, Wong CH, Kubes P. Role of endothelial TLR4 for neutrophil recruitment into central nervous system microvessels in systemic inflammation. J Immunol. 2009;183(8):5244&#x2013;5250. doi: 10.4049/jimmunol.0901309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0901309</ArticleId>
            <ArticleId IdType="pubmed">19786543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andonegui G, Goyert SM, Kubes P. Lipopolysaccharide-induced leukocyte-endothelial cell interactions: a role for CD14 versus toll-like receptor 4 within microvessels. J Immunol. 2002;169(4):2111&#x2013;2119. doi: 10.4049/jimmunol.169.4.2111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.169.4.2111</ArticleId>
            <ArticleId IdType="pubmed">12165539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McAvoy EF, McDonald B, Parsons SA, Wong CH, Landmann R, Kubes P. The role of CD14 in neutrophil recruitment within the liver microcirculation during endotoxemia. J Immunol. 2011;186(4):2592&#x2013;2601. doi: 10.4049/jimmunol.1002248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1002248</ArticleId>
            <ArticleId IdType="pubmed">21217012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andonegui G, et al. Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs. J Clin Invest. 2003;111(7):1011&#x2013;1020. doi: 10.1172/JCI16510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI16510</ArticleId>
            <ArticleId IdType="pmc">PMC152584</ArticleId>
            <ArticleId IdType="pubmed">12671050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature. 2015;517(7534):311&#x2013;320. doi: 10.1038/nature14191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14191</ArticleId>
            <ArticleId IdType="pubmed">25592536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell. 2015;59(2):298&#x2013;308. doi: 10.1016/j.molcel.2015.06.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2015.06.011</ArticleId>
            <ArticleId IdType="pmc">PMC4506736</ArticleId>
            <ArticleId IdType="pubmed">26166707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060&#x2013;1072. doi: 10.1016/j.cell.2012.03.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linkermann A, et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci USA. 2014;111(47):16836&#x2013;16841. doi: 10.1073/pnas.1415518111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1415518111</ArticleId>
            <ArticleId IdType="pmc">PMC4250130</ArticleId>
            <ArticleId IdType="pubmed">25385600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Sanchez D, et al. Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI. J Am Soc Nephrol. 2017;28(1):218&#x2013;229. doi: 10.1681/ASN.2015121376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2015121376</ArticleId>
            <ArticleId IdType="pmc">PMC5198282</ArticleId>
            <ArticleId IdType="pubmed">27352622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, et al. Inhibition of neuronal ferroptosis protects hemorrhagic brain. JCI Insight. 2017;2(7):e90777. doi: 10.1172/jci.insight.90777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.90777</ArticleId>
            <ArticleId IdType="pmc">PMC5374066</ArticleId>
            <ArticleId IdType="pubmed">28405617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57&#x2013;62. doi: 10.1038/nature14344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14344</ArticleId>
            <ArticleId IdType="pmc">PMC4455927</ArticleId>
            <ArticleId IdType="pubmed">25799988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10(1):9&#x2013;17. doi: 10.1038/nchembio.1416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.1416</ArticleId>
            <ArticleId IdType="pubmed">24346035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doll S, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91&#x2013;98. doi: 10.1038/nchembio.2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.2239</ArticleId>
            <ArticleId IdType="pmc">PMC5610546</ArticleId>
            <ArticleId IdType="pubmed">27842070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1-2):317&#x2013;331. doi: 10.1016/j.cell.2013.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC4076414</ArticleId>
            <ArticleId IdType="pubmed">24439385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhalla NS, Elmoselhi AB, Hata T, Makino N. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res. 2000;47(3):446&#x2013;456. doi: 10.1016/S0008-6363(00)00078-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0008-6363(00)00078-X</ArticleId>
            <ArticleId IdType="pubmed">10963718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lejay A, et al. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J Mol Cell Cardiol. 2016;91:11&#x2013;22. doi: 10.1016/j.yjmcc.2015.12.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yjmcc.2015.12.020</ArticleId>
            <ArticleId IdType="pubmed">26718721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu B, Zhao C, Li H, Chen X, Ding Y, Xu S. Puerarin protects against heart failure induced by pressure overload through mitigation of ferroptosis. Biochem Biophys Res Commun. 2018;497(1):233&#x2013;240. doi: 10.1016/j.bbrc.2018.02.061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2018.02.061</ArticleId>
            <ArticleId IdType="pubmed">29427658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koudstaal S, et al. Necrostatin-1 alleviates reperfusion injury following acute myocardial infarction in pigs. Eur J Clin Invest. 2015;45(2):150&#x2013;159. doi: 10.1111/eci.12391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/eci.12391</ArticleId>
            <ArticleId IdType="pubmed">25496079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavlosky A, et al. RIPK3-mediated necroptosis regulates cardiac allograft rejection. Am J Transplant. 2014;14(8):1778&#x2013;1790. doi: 10.1111/ajt.12779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ajt.12779</ArticleId>
            <ArticleId IdType="pubmed">24984764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Sanchez D, et al. TWEAK and RIPK1 mediate a second wave of cell death during AKI. Proc Natl Acad Sci USA. 2018;115(16):4182&#x2013;4187. doi: 10.1073/pnas.1716578115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1716578115</ArticleId>
            <ArticleId IdType="pmc">PMC5910825</ArticleId>
            <ArticleId IdType="pubmed">29588419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Sawy T, Belperio JA, Strieter RM, Remick DG, Fairchild RL. Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation. 2005;112(3):320&#x2013;331. doi: 10.1161/CIRCULATIONAHA.104.516708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.104.516708</ArticleId>
            <ArticleId IdType="pubmed">15998678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su CA, Iida S, Abe T, Fairchild RL. Endogenous memory CD8 T cells directly mediate cardiac allograft rejection. Am J Transplant. 2014;14(3):568&#x2013;579. doi: 10.1111/ajt.12605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ajt.12605</ArticleId>
            <ArticleId IdType="pmc">PMC3947453</ArticleId>
            <ArticleId IdType="pubmed">24502272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ardehali A, et al. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. Lancet. 2015;385(9987):2577&#x2013;2584. doi: 10.1016/S0140-6736(15)60261-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(15)60261-6</ArticleId>
            <ArticleId IdType="pubmed">25888086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreisel D, et al. Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med. 2002;8(3):233&#x2013;239. doi: 10.1038/nm0302-233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0302-233</ArticleId>
            <ArticleId IdType="pubmed">11875493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinto AR, et al. Revisiting cardiac cellular composition. Circ Res. 2016;118(3):400&#x2013;409. doi: 10.1161/CIRCRESAHA.115.307778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.115.307778</ArticleId>
            <ArticleId IdType="pmc">PMC4744092</ArticleId>
            <ArticleId IdType="pubmed">26635390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497&#x2013;509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13428781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, et al. Oxidized fatty acid analysis by charge-switch derivatization, selected reaction monitoring, and accurate mass quantitation. Anal Biochem. 2013;442(1):40&#x2013;50. doi: 10.1016/j.ab.2013.06.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ab.2013.06.014</ArticleId>
            <ArticleId IdType="pmc">PMC3823533</ArticleId>
            <ArticleId IdType="pubmed">23850559</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30787033</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1540-9538</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>216</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Mar</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of experimental medicine</Title>
          <ISOAbbreviation>J Exp Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A major role for ferroptosis in Mycobacterium tuberculosis-induced cell death and tissue necrosis.</ArticleTitle>
        <Pagination>
          <StartPage>556</StartPage>
          <EndPage>570</EndPage>
          <MedlinePgn>556-570</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20181776</ELocationID>
        <Abstract>
          <AbstractText>Necrotic cell death during Mycobacterium tuberculosis (Mtb) infection is considered host detrimental since it facilitates mycobacterial spread. Ferroptosis is a type of regulated necrosis induced by accumulation of free iron and toxic lipid peroxides. We observed that Mtb-induced macrophage necrosis is associated with reduced levels of glutathione and glutathione peroxidase-4 (Gpx4), along with increased free iron, mitochondrial superoxide, and lipid peroxidation, all of which are important hallmarks of ferroptosis. Moreover, necrotic cell death in Mtb-infected macrophage cultures was suppressed by ferrostatin-1 (Fer-1), a well-characterized ferroptosis inhibitor, as well as by iron chelation. Additional experiments in vivo revealed that pulmonary necrosis in acutely infected mice is associated with reduced Gpx4 expression as well as increased lipid peroxidation and is likewise suppressed by Fer-1 treatment. Importantly, Fer-1-treated infected animals also exhibited marked reductions in bacterial load. Together, these findings implicate ferroptosis as a major mechanism of necrosis in Mtb infection and as a target for host-directed therapy of tuberculosis.</AbstractText>
          <CopyrightInformation>This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Amaral</LastName>
            <ForeName>Eduardo P</ForeName>
            <Initials>EP</Initials>
            <Identifier Source="ORCID">0000-0001-5465-8113</Identifier>
            <AffiliationInfo>
              <Affiliation>Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD eduardo.amaral@nih.gov.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Costa</LastName>
            <ForeName>Diego L</ForeName>
            <Initials>DL</Initials>
            <Identifier Source="ORCID">0000-0002-9440-2814</Identifier>
            <AffiliationInfo>
              <Affiliation>Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Namasivayam</LastName>
            <ForeName>Sivaranjani</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Riteau</LastName>
            <ForeName>Nicolas</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University of Orleans and CNRS, UMR7355, Orleans, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kamenyeva</LastName>
            <ForeName>Olena</ForeName>
            <Initials>O</Initials>
            <Identifier Source="ORCID">0000-0002-6541-5616</Identifier>
            <AffiliationInfo>
              <Affiliation>Research Technology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mittereder</LastName>
            <ForeName>Lara</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mayer-Barber</LastName>
            <ForeName>Katrin D</ForeName>
            <Initials>KD</Initials>
            <AffiliationInfo>
              <Affiliation>Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andrade</LastName>
            <ForeName>Bruno B</ForeName>
            <Initials>BB</Initials>
            <Identifier Source="ORCID">0000-0001-6833-3811</Identifier>
            <AffiliationInfo>
              <Affiliation>Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, José Silveira Foundation, Salvador, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Wellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Universidade Salvador, Laureate University, Salvador, Bahia, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sher</LastName>
            <ForeName>Alan</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-7053-2895</Identifier>
            <AffiliationInfo>
              <Affiliation>Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD asher@nih.gov.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>02</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Exp Med</MedlineTA>
        <NlmUniqueID>2985109R</NlmUniqueID>
        <ISSNLinking>0022-1007</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007502">Iron Chelating Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.12</RegistryNumber>
          <NameOfSubstance UI="D000080662">Phospholipid Hydroperoxide Glutathione Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.9</RegistryNumber>
          <NameOfSubstance UI="C000611332">glutathione peroxidase 4, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Exp Med. 2019 Mar 4;216(3):471-473</RefSource>
          <PMID Version="1">30787032</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007502" MajorTopicYN="N">Iron Chelating Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015227" MajorTopicYN="N">Lipid Peroxidation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009169" MajorTopicYN="N">Mycobacterium tuberculosis</DescriptorName>
          <QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080662" MajorTopicYN="N">Phospholipid Hydroperoxide Glutathione Peroxidase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30787033</ArticleId>
        <ArticleId IdType="pmc">PMC6400546</ArticleId>
        <ArticleId IdType="doi">10.1084/jem.20181776</ArticleId>
        <ArticleId IdType="pii">jem.20181776</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Amaral E.P., Concei&#xe7;&#xe3;o E.L., Costa D.L., Rocha M.S., Marinho J.M., Cordeiro-Santos M., D&#x2019;Imp&#xe9;rio-Lima M.R., Barbosa T., Sher A., and Andrade B.B.. 2016b N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions. BMC Microbiol. 16:251 10.1186/s12866-016-0872-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12866-016-0872-7</ArticleId>
            <ArticleId IdType="pmc">PMC5084440</ArticleId>
            <ArticleId IdType="pubmed">27793104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amaral E.P., Lasunskaia E.B., and D&#x2019;Imp&#xe9;rio-Lima M.R.. 2016a Innate immunity in tuberculosis: how the sensing of mycobacteria and tissue damage modulates macrophage death. Microbes Infect. 18:11&#x2013;20. 10.1016/j.micinf.2015.09.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.micinf.2015.09.005</ArticleId>
            <ArticleId IdType="pubmed">26369715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrade B.B., Pavan Kumar N., Mayer-Barber K.D., Barber D.L., Sridhar R., Rekha V.V., Jawahar M.S., Nutman T.B., Sher A., and Babu S.. 2013. Plasma heme oxygenase-1 levels distinguish latent or successfully treated human tuberculosis from active disease. PLoS One. 8:e62618 10.1371/journal.pone.0062618</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0062618</ArticleId>
            <ArticleId IdType="pmc">PMC3646008</ArticleId>
            <ArticleId IdType="pubmed">23671613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behar S.M., Divangahi M., and Remold H.G.. 2010. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat. Rev. Microbiol. 8:668&#x2013;674. 10.1038/nrmicro2387</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrmicro2387</ArticleId>
            <ArticleId IdType="pmc">PMC3221965</ArticleId>
            <ArticleId IdType="pubmed">20676146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boelaert J.R., Vandecasteele S.J., Appelberg R., and Gordeuk V.R.. 2007. The effect of the host&#x2019;s iron status on tuberculosis. J. Infect. Dis. 195:1745&#x2013;1753. 10.1086/518040</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/518040</ArticleId>
            <ArticleId IdType="pubmed">17492589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boradia V.M., Malhotra H., Thakkar J.S., Tillu V.A., Vuppala B., Patil P., Sheokand N., Sharma P., Chauhan A.S., Raje M., and Raje C.I.. 2014. Mycobacterium tuberculosis acquires iron by cell-surface sequestration and internalization of human holo-transferrin. Nat. Commun. 5:4730 10.1038/ncomms5730</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms5730</ArticleId>
            <ArticleId IdType="pubmed">25163484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castillo E.F., Dekonenko A., Arko-Mensah J., Mandell M.A., Dupont N., Jiang S., Delgado-Vargas M., Timmins G.S., Bhattacharya D., Yang H., et al. . 2012. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc. Natl. Acad. Sci. USA. 109:E3168&#x2013;E3176. 10.1073/pnas.1210500109</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1210500109</ArticleId>
            <ArticleId IdType="pmc">PMC3503152</ArticleId>
            <ArticleId IdType="pubmed">23093667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y.L., Kong X., Xie Y., and Hider R.C.. 2018. The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron. J. Inorg. Biochem. 180:194&#x2013;203. 10.1016/j.jinorgbio.2017.12.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jinorgbio.2017.12.007</ArticleId>
            <ArticleId IdType="pubmed">29329026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conrad M., Kagan V.E., Bayir H., Pagnussat G.C., Head B., Traber M.G., and Stockwell B.R.. 2018. Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev. 32:602&#x2013;619. 10.1101/gad.314674.118</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.314674.118</ArticleId>
            <ArticleId IdType="pmc">PMC6004068</ArticleId>
            <ArticleId IdType="pubmed">29802123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa D.L., Namasivayam S., Amaral E.P., Arora K., Chao A., Mittereder L.R., Maiga M., Boshoff H.I., Barry C.E. III, Goulding C.W., et al. . 2016. Pharmacological inhibition of host heme oxygenase-1 suppresses Mycobacterium tuberculosis infection in vivo by a mechanism dependent on T lymphocytes. MBio. 7:e01675-16 10.1128/mBio.01675-16</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mBio.01675-16</ArticleId>
            <ArticleId IdType="pmc">PMC5080384</ArticleId>
            <ArticleId IdType="pubmed">27795400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deshmukh P., Unni S., Krishnappa G., and Padmanabhan B.. 2017. The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys. Rev. 9:41&#x2013;56. 10.1007/s12551-016-0244-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12551-016-0244-4</ArticleId>
            <ArticleId IdType="pmc">PMC5425799</ArticleId>
            <ArticleId IdType="pubmed">28510041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Divangahi M., Chen M., Gan H., Desjardins D., Hickman T.T., Lee D.M., Fortune S., Behar S.M., and Remold H.G.. 2009. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat. Immunol. 10:899&#x2013;906. 10.1038/ni.1758</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1758</ArticleId>
            <ArticleId IdType="pmc">PMC2730354</ArticleId>
            <ArticleId IdType="pubmed">19561612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Divangahi M., Behar S.M., and Remold H.. 2013. Dying to live: how the death modality of the infected macrophage affects immunity to tuberculosis. Adv. Exp. Med. Biol. 783:103&#x2013;120. 10.1007/978-1-4614-6111-1_6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4614-6111-1_6</ArticleId>
            <ArticleId IdType="pmc">PMC4678885</ArticleId>
            <ArticleId IdType="pubmed">23468106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon S.J., and Stockwell B.R.. 2014. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10:9&#x2013;17. 10.1038/nchembio.1416</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.1416</ArticleId>
            <ArticleId IdType="pubmed">24346035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., et al. . 2012. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 149:1060&#x2013;1072. 10.1016/j.cell.2012.03.042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.042</ArticleId>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorhoi A., and Kaufmann S.H.. 2016. Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis. Semin. Immunopathol. 38:153&#x2013;166. 10.1007/s00281-015-0531-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-015-0531-3</ArticleId>
            <ArticleId IdType="pubmed">26438324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Downey J., Pernet E., Coulombe F., Allard B., Meunier I., Jaworska J., Qureshi S., Vinh D.C., Martin J.G., Joubert P., and Divangahi M.. 2017. RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection. PLoS Pathog. 13:e1006326 10.1371/journal.ppat.1006326</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1006326</ArticleId>
            <ArticleId IdType="pmc">PMC5406035</ArticleId>
            <ArticleId IdType="pubmed">28410401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dragset M.S., Poce G., Alfonso S., Padilla-Benavides T., Ioerger T.R., Kaneko T., Sacchettini J.C., Biava M., Parish T., Arg&#xfc;ello J.M., et al. . 2015. A novel antimycobacterial compound acts as an intracellular iron chelator. Antimicrob. Agents Chemother. 59:2256&#x2013;2264. 10.1128/AAC.05114-14</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.05114-14</ArticleId>
            <ArticleId IdType="pmc">PMC4356758</ArticleId>
            <ArticleId IdType="pubmed">25645825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elkington P.T., D&#x2019;Armiento J.M., and Friedland J.S.. 2011. Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci. Transl. Med. 3:71ps6 10.1126/scitranslmed.3001847</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3001847</ArticleId>
            <ArticleId IdType="pmc">PMC3717269</ArticleId>
            <ArticleId IdType="pubmed">21346167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gangaidzo I.T., Moyo V.M., Mvundura E., Aggrey G., Murphree N.L., Khumalo H., Saungweme T., Kasvosve I., Gomo Z.A., Rouault T., et al. . 2001. Association of pulmonary tuberculosis with increased dietary iron. J. Infect. Dis. 184:936&#x2013;939. 10.1086/323203</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/323203</ArticleId>
            <ArticleId IdType="pubmed">11528590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordeuk V.R., McLaren C.E., MacPhail A.P., Deichsel G., and Bothwell T.H.. 1996. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan&#x2019;s 1929 thesis revisited. Blood. 87:3470&#x2013;3476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8605366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutierrez M.G., Master S.S., Singh S.B., Taylor G.A., Colombo M.I., and Deretic V.. 2004. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell. 119:753&#x2013;766. 10.1016/j.cell.2004.11.038</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2004.11.038</ArticleId>
            <ArticleId IdType="pubmed">15607973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey C.J., Thimmulappa R.K., Singh A., Blake D.J., Ling G., Wakabayashi N., Fujii J., Myers A., and Biswal S.. 2009. Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic. Biol. Med. 46:443&#x2013;453. 10.1016/j.freeradbiomed.2008.10.040</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2008.10.040</ArticleId>
            <ArticleId IdType="pmc">PMC2634824</ArticleId>
            <ArticleId IdType="pubmed">19028565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hermes-Lima M., Santos N.C., Yan J., Andrews M., Schulman H.M., and Ponka P.. 1999. EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on *OH formation by the Fenton reaction. Biochim. Biophys. Acta. 1426:475&#x2013;482. 10.1016/S0304-4165(98)00167-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0304-4165(98)00167-6</ArticleId>
            <ArticleId IdType="pubmed">10076064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hermes-Lima M., Ponka P., and Schulman H.M.. 2000. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate. Biochim. Biophys. Acta. 1523:154&#x2013;160. 10.1016/S0304-4165(00)00115-X</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0304-4165(00)00115-X</ArticleId>
            <ArticleId IdType="pubmed">11042379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hern&#xe1;ndez J., Garibay-Escobar A., Mendoza-Mendoza A., Pinelli-Saavedra A., and Valenzuela O.. 2008. Effect of exogenous vitamin E on proliferation and cytokine production in peripheral blood mononuclear cells from patients with tuberculosis. Br. J. Nutr. 99:224&#x2013;229. 10.1017/S0007114507795302</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S0007114507795302</ArticleId>
            <ArticleId IdType="pubmed">18290270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou W., Xie Y., Song X., Sun X., Lotze M.T., Zeh H.J. III, Kang R., and Tang D.. 2016. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 12:1425&#x2013;1428. 10.1080/15548627.2016.1187366</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2016.1187366</ArticleId>
            <ArticleId IdType="pmc">PMC4968231</ArticleId>
            <ArticleId IdType="pubmed">27245739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ingold I., Berndt C., Schmitt S., Doll S., Poschmann G., Buday K., Roveri A., Peng X., Porto Freitas F., Seibt T., et al. . 2018. Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis. Cell. 172:409&#x2013;422.e21. 10.1016/j.cell.2017.11.048</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.11.048</ArticleId>
            <ArticleId IdType="pubmed">29290465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jorgensen I., Rayamajhi M., and Miao E.A.. 2017. Programmed cell death as a defence against infection. Nat. Rev. Immunol. 17:151&#x2013;164. 10.1038/nri.2016.147</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2016.147</ArticleId>
            <ArticleId IdType="pmc">PMC5328506</ArticleId>
            <ArticleId IdType="pubmed">28138137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang R., Zeng L., Zhu S., Xie Y., Liu J., Wen Q., Cao L., Xie M., Ran Q., Kroemer G., et al. . 2018. Lipid Peroxidation Drives Gasdermin D-Mediated Pyroptosis in Lethal Polymicrobial Sepsis. Cell Host Microbe. 24:97&#x2013;108.e4. 10.1016/j.chom.2018.05.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2018.05.009</ArticleId>
            <ArticleId IdType="pmc">PMC6043361</ArticleId>
            <ArticleId IdType="pubmed">29937272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan G., Post F.A., Moreira A.L., Wainwright H., Kreiswirth B.N., Tanverdi M., Mathema B., Ramaswamy S.V., Walther G., Steyn L.M., et al. . 2003. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 71:7099&#x2013;7108. 10.1128/IAI.71.12.7099-7108.2003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.71.12.7099-7108.2003</ArticleId>
            <ArticleId IdType="pmc">PMC308931</ArticleId>
            <ArticleId IdType="pubmed">14638800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiran D., Podell B.K., Chambers M., and Basaraba R.J.. 2016. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Semin. Immunopathol. 38:167&#x2013;183. 10.1007/s00281-015-0537-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-015-0537-x</ArticleId>
            <ArticleId IdType="pmc">PMC4779125</ArticleId>
            <ArticleId IdType="pubmed">26510950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J., Repasy T., Papavinasasundaram K., Sassetti C., and Kornfeld H.. 2011. Mycobacterium tuberculosis induces an atypical cell death mode to escape from infected macrophages. PLoS One. 6:e18367 10.1371/journal.pone.0018367</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0018367</ArticleId>
            <ArticleId IdType="pmc">PMC3069075</ArticleId>
            <ArticleId IdType="pubmed">21483832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemire J.A., Harrison J.J., and Turner R.J.. 2013. Antimicrobial activity of metals: mechanisms, molecular targets and applications. Nat. Rev. Microbiol. 11:371&#x2013;384. 10.1038/nrmicro3028</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrmicro3028</ArticleId>
            <ArticleId IdType="pubmed">23669886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lerner T.R., Borel S., Greenwood D.J., Repnik U., Russell M.R., Herbst S., Jones M.L., Collinson L.M., Griffiths G., and Gutierrez M.G.. 2017. Mycobacterium tuberculosis replicates within necrotic human macrophages. J. Cell Biol. 216:583&#x2013;594. 10.1083/jcb.201603040</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201603040</ArticleId>
            <ArticleId IdType="pmc">PMC5350509</ArticleId>
            <ArticleId IdType="pubmed">28242744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linkermann A., Skouta R., Himmerkus N., Mulay S.R., Dewitz C., De Zen F., Prokai A., Zuchtriegel G., Krombach F., Welz P.S., et al. . 2014a Synchronized renal tubular cell death involves ferroptosis. Proc. Natl. Acad. Sci. USA. 111:16836&#x2013;16841. 10.1073/pnas.1415518111</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1415518111</ArticleId>
            <ArticleId IdType="pmc">PMC4250130</ArticleId>
            <ArticleId IdType="pubmed">25385600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linkermann A., Stockwell B.R., Krautwald S., and Anders H.J.. 2014b Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat. Rev. Immunol. 14:759&#x2013;767. 10.1038/nri3743</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3743</ArticleId>
            <ArticleId IdType="pubmed">25324125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lounis N., Maslo C., Boelaert J.R., Bonnafous P., Trnffot-Pernot C., Baohong J., and Grosset J.. 1999. Impact of iron loading and iron chelation on murine tuberculosis. Clin. Microbiol. Infect. 5:687&#x2013;692. 10.1111/j.1469-0691.1999.tb00514.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1469-0691.1999.tb00514.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lounis N., Truffot-Pernot C., Grosset J., Gordeuk V.R., and Boelaert J.R.. 2001. Iron and Mycobacterium tuberculosis infection. J. Clin. Virol. 20:123&#x2013;126. 10.1016/S1386-6532(00)00136-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1386-6532(00)00136-0</ArticleId>
            <ArticleId IdType="pubmed">11166659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mancias J.D., Wang X., Gygi S.P., Harper J.W., and Kimmelman A.C.. 2014. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 509:105&#x2013;109. 10.1038/nature13148</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13148</ArticleId>
            <ArticleId IdType="pmc">PMC4180099</ArticleId>
            <ArticleId IdType="pubmed">24695223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marques P.E., Antunes M.M., David B.A., Pereira R.V., Teixeira M.M., and Menezes G.B.. 2015a Imaging liver biology in vivo using conventional confocal microscopy. Nat. Protoc. 10:258&#x2013;268. 10.1038/nprot.2015.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nprot.2015.006</ArticleId>
            <ArticleId IdType="pubmed">25569332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marques P.E., Oliveira A.G., Pereira R.V., David B.A., Gomides L.F., Saraiva A.M., Pires D.A., Novaes J.T., Patricio D.O., Cisalpino D., et al. . 2015b Hepatic DNA deposition drives drug-induced liver injury and inflammation in mice. Hepatology. 61:348&#x2013;360. 10.1002/hep.27216</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.27216</ArticleId>
            <ArticleId IdType="pubmed">24824608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin C.J., Booty M.G., Rosebrock T.R., Nunes-Alves C., Desjardins D.M., Keren I., Fortune S.M., Remold H.G., and Behar S.M.. 2012. Efferocytosis is an innate antibacterial mechanism. Cell Host Microbe. 12:289&#x2013;300. 10.1016/j.chom.2012.06.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2012.06.010</ArticleId>
            <ArticleId IdType="pmc">PMC3517204</ArticleId>
            <ArticleId IdType="pubmed">22980326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayer-Barber K.D., Andrade B.B., Barber D.L., Hieny S., Feng C.G., Caspar P., Oland S., Gordon S., and Sher A.. 2011. Innate and adaptive interferons suppress IL-1&#x3b1; and IL-1&#x3b2; production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity. 35:1023&#x2013;1034. 10.1016/j.immuni.2011.12.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2011.12.002</ArticleId>
            <ArticleId IdType="pmc">PMC3246221</ArticleId>
            <ArticleId IdType="pubmed">22195750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer D. 2006. Iron chelation as therapy for HIV and Mycobacterium tuberculosis co-infection under conditions of iron overload. Curr. Pharm. Des. 12:1943&#x2013;1947. 10.2174/138161206777442164</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138161206777442164</ArticleId>
            <ArticleId IdType="pubmed">16787239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molloy A., Laochumroonvorapong P., and Kaplan G.. 1994. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Gu&#xe9;rin. J. Exp. Med. 180:1499&#x2013;1509. 10.1084/jem.180.4.1499</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.180.4.1499</ArticleId>
            <ArticleId IdType="pmc">PMC2191680</ArticleId>
            <ArticleId IdType="pubmed">7931080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moraco A.H., and Kornfeld H.. 2014. Cell death and autophagy in tuberculosis. Semin. Immunol. 26:497&#x2013;511. 10.1016/j.smim.2014.10.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.smim.2014.10.001</ArticleId>
            <ArticleId IdType="pmc">PMC4314446</ArticleId>
            <ArticleId IdType="pubmed">25453227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newton K., Dugger D.L., Wickliffe K.E., Kapoor N., de Almagro M.C., Vucic D., Komuves L., Ferrando R.E., French D.M., Webster J., et al. . 2014. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science. 343:1357&#x2013;1360. 10.1126/science.1249361</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1249361</ArticleId>
            <ArticleId IdType="pubmed">24557836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oddo M., Renno T., Attinger A., Bakker T., MacDonald H.R., and Meylan P.R.. 1998. Fas ligand-induced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis. J. Immunol. 160:5448&#x2013;5454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9605147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owens C.P., Chim N., and Goulding C.W.. 2013. Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target. Future Med. Chem. 5:1391&#x2013;1403. 10.4155/fmc.13.109</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4155/fmc.13.109</ArticleId>
            <ArticleId IdType="pmc">PMC3838433</ArticleId>
            <ArticleId IdType="pubmed">23919550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajuelo D., Gonzalez-Juarbe N., Tak U., Sun J., Orihuela C.J., and Niederweis M.. 2018. NAD+ Depletion Triggers Macrophage Necroptosis, a Cell Death Pathway Exploited by Mycobacterium tuberculosis. Cell Reports. 24:429&#x2013;440. 10.1016/j.celrep.2018.06.042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.06.042</ArticleId>
            <ArticleId IdType="pmc">PMC6136256</ArticleId>
            <ArticleId IdType="pubmed">29996103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan H., Yan B.S., Rojas M., Shebzukhov Y.V., Zhou H., Kobzik L., Higgins D.E., Daly M.J., Bloom B.R., and Kramnik I.. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature. 434:767&#x2013;772. 10.1038/nature03419</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature03419</ArticleId>
            <ArticleId IdType="pmc">PMC1388092</ArticleId>
            <ArticleId IdType="pubmed">15815631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasparakis M., and Vandenabeele P.. 2015. Necroptosis and its role in inflammation. Nature. 517:311&#x2013;320. 10.1038/nature14191</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14191</ArticleId>
            <ArticleId IdType="pubmed">25592536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picard V., Epsztejn S., Santambrogio P., Cabantchik Z.I., and Beaumont C.. 1998. Role of ferritin in the control of the labile iron pool in murine erythroleukemia cells. J. Biol. Chem. 273:15382&#x2013;15386. 10.1074/jbc.273.25.15382</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.273.25.15382</ArticleId>
            <ArticleId IdType="pubmed">9624120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy V.P., Chinta K.C., Saini V., Glasgow J.N., Hull T.D., Traylor A., Rey-Stolle F., Soares M.P., Madansein R., Rahman M.A., et al. . 2018. Ferritin H deficiency in myeloid compartments dysregulates host energy metabolism and increases susceptibility to Mycobacterium tuberculosis infection. Front. Immunol. 9:860 10.3389/fimmu.2018.00860</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.00860</ArticleId>
            <ArticleId IdType="pmc">PMC5943674</ArticleId>
            <ArticleId IdType="pubmed">29774023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riendeau C.J., and Kornfeld H.. 2003. THP-1 cell apoptosis in response to Mycobacterial infection. Infect. Immun. 71:254&#x2013;259. 10.1128/IAI.71.1.254-259.2003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.71.1.254-259.2003</ArticleId>
            <ArticleId IdType="pmc">PMC143334</ArticleId>
            <ArticleId IdType="pubmed">12496173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaible U.E., Collins H.L., Priem F., and Kaufmann S.H.. 2002. Correction of the iron overload defect in beta-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J. Exp. Med. 196:1507&#x2013;1513. 10.1084/jem.20020897</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20020897</ArticleId>
            <ArticleId IdType="pmc">PMC2194267</ArticleId>
            <ArticleId IdType="pubmed">12461085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seyedrezazadeh E., Ostadrahimi A., Mahboob S., Assadi Y., Ghaemmagami J., and Pourmogaddam M.. 2008. Effect of vitamin E and selenium supplementation on oxidative stress status in pulmonary tuberculosis patients. Respirology. 13:294&#x2013;298. 10.1111/j.1440-1843.2007.01200.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1843.2007.01200.x</ArticleId>
            <ArticleId IdType="pubmed">18339032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiloh M.U., Manzanillo P., and Cox J.S.. 2008. Mycobacterium tuberculosis senses host-derived carbon monoxide during macrophage infection. Cell Host Microbe. 3:323&#x2013;330. 10.1016/j.chom.2008.03.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2008.03.007</ArticleId>
            <ArticleId IdType="pmc">PMC2873178</ArticleId>
            <ArticleId IdType="pubmed">18474359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silva-Gomes S., Vale-Costa S., Appelberg R., and Gomes M.S.. 2013. Iron in intracellular infection: to provide or to deprive? Front. Cell. Infect. Microbiol. 3:96 10.3389/fcimb.2013.00096</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2013.00096</ArticleId>
            <ArticleId IdType="pmc">PMC3856365</ArticleId>
            <ArticleId IdType="pubmed">24367768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skouta R., Dixon S.J., Wang J., Dunn D.E., Orman M., Shimada K., Rosenberg P.A., Lo D.C., Weinberg J.M., Linkermann A., and Stockwell B.R.. 2014. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136:4551&#x2013;4556. 10.1021/ja411006a</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ja411006a</ArticleId>
            <ArticleId IdType="pmc">PMC3985476</ArticleId>
            <ArticleId IdType="pubmed">24592866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell B.R., Friedmann Angeli J.P., Bayir H., Bush A.I., Conrad M., Dixon S.J., Fulda S., Gasc&#xf3;n S., Hatzios S.K., Kagan V.E., et al. . 2017. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 171:273&#x2013;285. 10.1016/j.cell.2017.09.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stutz M.D., Ojaimi S., Allison C., Preston S., Arandjelovic P., Hildebrand J.M., Sandow J.J., Webb A.I., Silke J., Alexander W.S., and Pellegrini M.. 2018a Necroptotic signaling is primed in Mycobacterium tuberculosis-infected macrophages, but its pathophysiological consequence in disease is restricted. Cell Death Differ. 25:951&#x2013;965. 10.1038/s41418-017-0031-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-017-0031-1</ArticleId>
            <ArticleId IdType="pmc">PMC5943269</ArticleId>
            <ArticleId IdType="pubmed">29229989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stutz M.D., Ojaimi S., Ebert G., and Pellegrini M.. 2018b Is receptor-interacting protein kinase 3 a viable therapeutic target for Mycobacterium tuberculosis infection? Front. Immunol. 9:1178 10.3389/fimmu.2018.01178</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01178</ArticleId>
            <ArticleId IdType="pmc">PMC5985376</ArticleId>
            <ArticleId IdType="pubmed">29892302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su L., Quade B., Wang H., Sun L., Wang X., and Rizo J.. 2014. A plug release mechanism for membrane permeation by MLKL. Structure. 22:1489&#x2013;1500. 10.1016/j.str.2014.07.014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.str.2014.07.014</ArticleId>
            <ArticleId IdType="pmc">PMC4192069</ArticleId>
            <ArticleId IdType="pubmed">25220470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanzer M.C., Tripaydonis A., Webb A.I., Young S.N., Varghese L.N., Hall C., Alexander W.S., Hildebrand J.M., Silke J., and Murphy J.M.. 2015. Necroptosis signalling is tuned by phosphorylation of MLKL residues outside the pseudokinase domain activation loop. Biochem. J. 471:255&#x2013;265. 10.1042/BJ20150678</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20150678</ArticleId>
            <ArticleId IdType="pubmed">26283547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas F., Serratrice G., B&#xe9;guin C., Aman E.S., Pierre J.L., Fontecave M., and Laulh&#xe8;re J.P.. 1999. Calcein as a fluorescent probe for ferric iron. Application to iron nutrition in plant cells. J. Biol. Chem. 274:13375&#x2013;13383. 10.1074/jbc.274.19.13375</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.274.19.13375</ArticleId>
            <ArticleId IdType="pubmed">10224100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyokuni S., Ito F., Yamashita K., Okazaki Y., and Akatsuka S.. 2017. Iron and thiol redox signaling in cancer: An exquisite balance to escape ferroptosis. Free Radic. Biol. Med. 108:610&#x2013;626. 10.1016/j.freeradbiomed.2017.04.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2017.04.024</ArticleId>
            <ArticleId IdType="pubmed">28433662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trousseau A. 1872. True, false chlorosis. In Lectures on clinical medicine. The New Sydenham Society, London: pp. 95&#x2013;117.</Citation>
        </Reference>
        <Reference>
          <Citation>Venketaraman V., Millman A., Salman M., Swaminathan S., Goetz M., Lardizabal A., David Hom, and Connell N.D.. 2008. Glutathione levels and immune responses in tuberculosis patients. Microb. Pathog. 44:255&#x2013;261. 10.1016/j.micpath.2007.09.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.micpath.2007.09.002</ArticleId>
            <ArticleId IdType="pubmed">17959342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vilch&#xe8;ze C., Hartman T., Weinrick B., and Jacobs W.R. Jr. 2013. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction. Nat. Commun. 4:1881 10.1038/ncomms2898</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms2898</ArticleId>
            <ArticleId IdType="pmc">PMC3698613</ArticleId>
            <ArticleId IdType="pubmed">23695675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallis R.S., and Hafner R.. 2015. Advancing host-directed therapy for tuberculosis. Nat. Rev. Immunol. 15:255&#x2013;263. 10.1038/nri3813</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3813</ArticleId>
            <ArticleId IdType="pubmed">25765201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinlich R., Oberst A., Beere H.M., and Green D.R.. 2017. Necroptosis in development, inflammation and disease. Nat. Rev. Mol. Cell Biol. 18:127&#x2013;136. 10.1038/nrm.2016.149</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm.2016.149</ArticleId>
            <ArticleId IdType="pubmed">27999438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welin A., Eklund D., Stendahl O., and Lerm M.. 2011. Human macrophages infected with a high burden of ESAT-6-expressing M. tuberculosis undergo caspase-1- and cathepsin B-independent necrosis. PLoS One. 6:e20302 10.1371/journal.pone.0020302</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0020302</ArticleId>
            <ArticleId IdType="pmc">PMC3102687</ArticleId>
            <ArticleId IdType="pubmed">21637850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong K.W., and Jacobs W.R. Jr. 2011. Critical role for NLRP3 in necrotic death triggered by Mycobacterium tuberculosis. Cell. Microbiol. 13:1371&#x2013;1384. 10.1111/j.1462-5822.2011.01625.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1462-5822.2011.01625.x</ArticleId>
            <ArticleId IdType="pmc">PMC3257557</ArticleId>
            <ArticleId IdType="pubmed">21740493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization 2017. World Health Organization. Tuberculosis Fact Sheet. Number 104. World Health Organization, Geneva.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao X., Khan N., Gan H., Tzelepis F., Nishimura T., Park S.Y., Divangahi M., and Remold H.G.. 2017. Bcl-xL mediates RIPK3-dependent necrosis in M. tuberculosis-infected macrophages. Mucosal Immunol. 10:1553&#x2013;1568. 10.1038/mi.2017.12</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2017.12</ArticleId>
            <ArticleId IdType="pmc">PMC5638669</ArticleId>
            <ArticleId IdType="pubmed">28401933</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
